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Abbreviat ions 
AUG - area under the plasma concentration versus time curve 
ARA-C - cytosine arabinoside 
CHO - Chinese hamster ovary cells 
CL-j, - creatinine clearance 
CL™ - non-renal clearance 
CLp - renal clearance 
С - steady state concentration 
D - dose 
dSm - deshydroxy-sparsomycin 
EdSm - ethyl-deshydroxy-sparsomycin 
5-FU - 5-fluorouracil 
i.d. - internal diameter 
i.p. - intraperitoneal 
i.v. - intravenous 
LD10 - dose lethal to 10% of the animal population 
LD50 - dose lethal to 50% of the animal population 
MEM - minimal essential medium 
MTX - methotrexate 
n.s. - not significant 
PSI(s) - protein synthesis inhibitor(s) 
PSm - n-pentyl-sparsomycin 
PQP - renal glomerular filtration 
RPE - retinal pigment epythelium 
s.c. - subcutaneous 
SD - standard deviation 
SEM - standard error of the mean 
Sm - sparsomycin 
T/C - treatment to control ratio of respective median survival 
times 
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CHAPTER 1 
OUTLINE OP INVESTIGATIONS AND OBJECTIVES IN THIS THESIS 
9 
In 1981 Ottenheijm and co-workers from our university succeeded in the 
synthesis of an antitumor antibiotic Sparsomycm (Sm). Sm was already dis-
covered m 1962 as a natural product of Streptomyces sparsogenes and 
Streptomyces cuspidosporus. It appeared that Sm is a potent inhibitor of 
nbosomal protein synthesis. The drug showed attractive antitumor activity 
in several rodent tumor models. In 1964 Sm entered a phase I clinical trial. 
This study was discontinued because of probable drug-induced retinotoxicity 
observed m two patients. 
The chemical synthesis and preparation of new Sm analogues by the group 
from Nijmegen initiated a new phase in Sm research. Highly purified Sm as 
well as its analogues have become available In quantities sufficient for 
preclinical and clinical investigations. 
Because its mechanism of action is completely different from that of the 
cytotoxic drugs in common use, we were very pleased to become involved in 
the research and to study the innovative possibilities of these compounds 
especially in combination chemotherapy. 
All synthetic derivatives were primarily tested for their inhibitory 
activity in cell free protein synthesizing systems, and parallelly in the 
L1210 murine leukemia clonogenic assay. Compounds with the highest inhibi-
tory activity were subjected to preclinical studies. The results of these 
studies are reported in this thesis. 
The introductory chapter gives a detailed history of Sm and reviews its 
chemistry, biological properties and pharmacology as well as selection 
procedures for new analogues (Chapter 2). 
The analogues were analyzed and their physicochemical properties studied 
in relation to their m vitro and in vivo activity (Chapter 3). Subsequent-
ly, Sm and selected analogues were tested for m vivo antitumor activity in 
eight murine tumor models (Chapter 4) . Because the mechanism of action of Sm 
is different from that of other cytotoxic drugs, its use m combination 
chemotherapy was evaluated. It appeared that Sm is a potent modulator of the 
cytotoxic effect of cisplatin m vitro (Chapter 5) and in vivo (Chapter 6). 
Later, it was found that cisplatin is not the only compound of which the 
activity can be modified by Sm. Modification of in vitro cytotoxicity of 
several other cytotoxic drugs has been described (Chapter 7). 
In order to understand the relationships between compounds m terms of 
activity and toxicity, preclinical pharmacokinetic studies with the three 
most promising analogues i.e. deshydroxy-Sm, ethyl-deshydroxy-Sm and n-
pentyl-Sm were performed in mice. The compounds were compared with each 
other at equitoxic doses (Chapter 8). These studies were followed by pharma-
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cokinetic and toxicological studies of Sm in beagle dogs (Chapter 9 ) . The 
pharmacokinetics of the three most promising analogues in beagle dogs are 
presented in Chapters 10, 11 and 12. 
Finally, attention was paid to the possible mechanisms underlying Sm-
induced retinal toxicity that was described first in 1964. Much effort was 
spent on reproducing this toxicity in animals (Chapter 13). 
The thesis is completed by a general discussion and summary. (Chapter 
14). 
11 

CHAPTER 2 
SPARSOMYCIN 
A review of preclinical and clinical studies 
13 
2.1 Introduction 
Mankind's encounter with protein synthesis inhibitors (PSI) dates from his 
earliest existence. Many bacterial toxins and plant products act by inhibi-
ting protein synthesis. Through the millenia, man has learned to use these 
toxins as medicine. PSI agents were used with success to induce vomiting and 
to treat various protozoal diseases (1,2,3), and leukemia (4,5). Several 
potential antitumor agents like homoharrlngtonine (6), bruceantin (7) and 
emetine (4,8) have been derived from these traditional drugs. Until now all 
of the compounds studied were very toxic to humans, and not one compound 
from this group appeared to be active on solid tumors. Most of these 
compounds possess a very complicated structure, which is difficult for the 
organic chemist to modify. 
Sparsomycin (Sm) is one of the first PSI agents that has been made 
accessible by chemical synthesis and on which systematic studies on the 
relationship between structure and activity have been performed. From these 
studies it appeared that small changes in the structure of Sm result in 
significant changes in its biological activity and toxicity. For this reason 
Sm is an attractive candidate for further preclinical evaluation. This 
chapter reviews the data available on Sm and introduces the reader to pre-
clinical studies on Sm and its analogues as reported in this thesis. 
2.2 Discovery and initial studies 
Sm was detected initially in beers and was isolated subsequently in 1962 
from a Streptomyces sparsogenes fermentation broth (9,10). A few years 
later, the antibiotic was also isolated from a culture filtrate of Strepto-
myces cuspidosporus (11,12). Owen et al. found that this newly isolated 
antibiotic was active in vitro on KB human epidermoid carcinoma cells and on 
11 out of 20 rodent tumor models tested in vivo (9). These data prompted 
further development of the drug and lead to its introduction in a clinical 
setting just two years after its discovery. 
2.3 Phase I clinical trial 
In 1964, five patients suffering from far advanced cancer took part in this 
study (13). The patients were treated with increasing daily doses of the 
drug. The initial doses (0.0016-0.016 mg/kg/day) were based on toxicological 
studies in animals. In general, the patients tolerated Sm without abnormal 
side effects. In four patients a rise in SCOT was noticed after therapy, but 
two of them had liver metastases. For details see Table 1. 
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Table 1. Data on five patients treated with Sm (13) 
Patient nr Total dose Treat-
and diagno- (mg) (mg/kg) ment 
sis (days) 
1. Carcinoma 5.5 0.085 10 
of cecum with 
liver meta-
stasis 
2. Carcinoma 12.0 0.24 13 
of the colon 
with lung 
and liver 
metastasis 
3. Carcinoma 7.5 0.15 15 
of the lung 
4. Carcinoma 7.7 0.136 10 
of the lung 
5. Osteogenic 14.1 0.154 17 
sarcoma 
Level of Level of Observa-
alkaline SCOT tions at 
phosphatase necropsy 
Increased be- Increased Liver 
fore therapy; after meta-
no further therapy stasis 
change 
No change No change Eye 
changes ; 
no meta-
stasis 
Increased one Increased Eye chan-
week after one week ges; no 
therapy; re- after the- liver 
mained eleva- rapy; normal metasta-
ted. 3 weeks sis 
later. 
Increased be- Increased Liver 
fore therapy; before meta-
continued to therapy; stasis 
rise. continued 
to rise 
Increased be- Normal be- Fatty 
fore therapy; fore changes 
continued to therapy; in liver 
rise increased 
one week 
after 
therapy. 
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2.4 Eye toxicity in humans 
Two patients, nr 2 and 3, reported blurred vision, one after 13 days of 
therapy (total dose 0.24 mg/kg) and one after 15 days of therapy (total dose 
0.15 mg/kg) (13). The postmortem investigations were performed 2 and 2.5 
months, respectively, after Sm therapy and showed widespread degeneration 
of the retinal pigment epithelium which was particularly marked in the 
posterior temporal areas. The impaired vision, the progressive objective 
changes noted during ocular examination in the form of ring scotomata, and 
the histologic evidences of retinal pigment epithelium degeneration at 
necropsy were suggestive for ocular toxicity. The study was discontinued. 
It is interesting to discuss these data in retrospect. Nowadays the use 
of incremental daily doses of cytotoxic drugs in phase I studies has been 
abandoned because of the high risk of accumulation and toxicity (14). The 
two patients, both males, that developed retinopathy had very low initial 
body weights- both 50 kg - suggesting poor general condition. Although 
patient 5 received a similar total dose of 0.15 mg/kg over 17 days, in 
contrast to patients 2 and 3, he did not develop retinopathy. The initial 
body weight of this patient was 92 kg. On the basis of these observations 
one might speculate that the eye toxicity of Sm may be related to previous 
treatment, poor general condition, and cachexia. Under normal conditions, 
the blood retina barrier should be impermeable to the hydrophilic Sm (15). 
This hypothesis will be discussed in detail in chapter 13. 
Additionally, patient 2 was treated with thioridazine concomitantly with 
Sm. This drug appeared to possess its own retinotoxic potential probably 
also related to the inhibition of protein synthesis (8). Thus, retinopathy 
in this patient might be attributed to a synergism between this drug and 
thioridazine. This deserves further studies. 
After discontinuation of this phase I study, intensive research was 
initiated in order to elucidate the mechanism of eye toxicity (17). Electro-
retinographic and histopathologic investigations in healthy rats and monkeys 
treated with Sm did not show any abnormality of the retina. The only finding 
was that some electroretinographic abnormalities in sick and moribund 
animals were probably related to their poor general condition. Further 
clinical studies were not undertaken. 
2.5 Elucidation of the chemical structure 
The structure of Sm remained unresolved until 1970, when Wiley and MacKellar 
reported the results of synthetic, spectroscopic, and degradation studies 
(18). The complete structure of Sm is presented in Fig. 1. 
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H 
Fig.1 Structure of Sm 
The molecular structure of Sm consists of a C(б)-methylated uracil 
moiety, and a cysteine derived amino acid fragment. The configuration of the 
chiral carbon atom was shown to be S, correlating with D-cysteine. Some 
years later, Ottenheijm and co-workers showed that the sulphoxide function 
of Sm possesses the R configuration (19). 
2.6 Biological activity and mechanism of action 
Studies initiated in the late sixties on the mechanism of action and bio­
logical activity showed that Sm possesses antiviral activity (20), inhibi­
tory activity on Gram-positive and Gram-negative bacteria as well as on a 
number of fungi (9) and parasites (21). 
The different metabolic parameters altered by Sm for E. coli were studied 
by Slechta et al. (22). Protein synthesis was affected at a drug concen­
tration lower than that affecting the synthesis of DNA and RNA. Cell growth 
and DNA synthesis were inhibited in parallel in the presence of the drug, 
whereas RNA accumulated as tRNA. The release of amino acids into the growth 
medium due to growth inhibition was also reported. These results were con­
firmed later by others, and the isolation of a Sm-resistant strain of E. 
coli was reported (23). 
Preferential inhibition by Sm of protein synthesis rather than DNA of RNA 
synthesis has also been reported in growing L cells (24) and in mouse livers 
(25). Sm does not, however, inhibit protein synthesis in intact reticulo­
cytes (26). In reticulocyte lysates (27), as well as in mouse livers (25), 
yeast (27), plasma cell tumors (28), and E. coli systems (29), Sm prevented 
the run-off of polysomes freezing them on the mRNA. 
2.7 Synthesis of Sparsomycin and its anlogues 
The synthesis of Sm was investigated concurrently by the research groups 
lead by Ottenheijm and Helquist. Both groups succeeded in synthesizing Sm, 
but used different approaches. The synthetic endeavours of both research 
O^N^-CH, 
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groups are described in recent review articles (30,31). 
After the total synthesis of Sm was accomplished, Ottenheijm's group 
prepared a large number of structural analogues of the drug (30,31). Most of 
the derivatives possessed only one, and some only two modifications of the 
original structure. The analogues were tested for their inhibitory activity 
in cell free protein synthesizing systems as well as in the L1210 murine 
leukemia clonogenic assay. The structures of those analogues selected for 
preclinical investigations are presented in Table 2. 
Table 2. Structures of Sm analogues selected for preclinical investigations. 
0 0 R1 0 
Nr name RI R2 
I 
I I 
I I I 
IV 
V 
VI 
V I I 
VIII 
IX 
Sparsomycin (Sm) 
n-butyl-Sm 
n-pentyl-Sm 
benzyl-Sm 
n-octyl-Sm 
deshydroxy-Sm 
ethyl-deshydroxy-Sm 
n-butyl-deshydroxy-
n-octyl-deshydroxy-
•Sm 
•Sm 
сн2он 
сн2он 
сн2он 
сн2он 
сн2он 
C H 3 
C H 3 
C H 3 
CH3 
2.8 Activity of the novel Sparsomycin analogues 
In the cell free protein synthesis systems, ribosomes from both E. coli and 
S. cerevisiae were used. The Sm analogues were investigated using the 
following tests: 
1. Polyphenylalanine (PolyPhe) synthesis assay. This test uses synthetic 
mRNAs, thus it does not require a physiological initiation. Sm pre­
ferentially inhibits the polymerization of amino acids encoded by poly-
uridylic, polyadenylic, and polycytidylic acids (24,29). The inhibition 
of peptide bond formation observed in this system suggests that Sm does 
not act as an inhibitor of initiation, but that it may be an inhibitor of 
CH-j 
(сн2)3сн3 
(сн2)4снз 
C H2 C6 H5 
(СН2)7СНз 
сн3 
CH2CH3 
(сн2)3сн3 
(сн2)7сн3 
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the elongation step m protein synthesis. 
2. Puromycin reaction. The antibiotic puromycin, functioning as an analogue 
of the 3' end of the aminoacyl-tRNA, is used extensively as an acceptor 
in model assays for peptide bond formation (32). N-blocked aminoacyl-
tRNAs bound to the peptidyl transferase P-site on the ribosome react with 
puromycin, forming N-acetylaminoacyl-puromycin. This reaction is also 
sensitive to Sm (32,33,34). 
3. Fragment reaction. Monro and Marcker (35) tested peptide bond formation 
using N-acetylaminoacylpentanucleotide and puromycin as donor and ac-
ceptor substrates, respectively. The reaction requires only the presence 
of the large ribosomal subunit and an alcohol to increase the affinity of 
the ribosome for the 3'-terminal oligonucleotide. This assay, termed 
"fragment reaction", eliminates the requirements for natural substrates. 
All the available data indicate that this process takes place at the 
peptidyl transferase centre, which is in agreement with the normal mech-
anism of peptide bond formation (35). The reaction is sensitive to Sm 
(36) and this sensitivity was the definite proof that the action of Sm 
occurs at the peptidyl transferase centre. Similar inhibitory results 
were obtained with nbosomes from human tonsils (37), yeast (38), wheat 
germ (39), and mammalian cells (40). 
The investigations on the analogues of Sm in cell free protein synthesizing 
systems were completed by studies using the L1210 clonogenic assay. L1210 is 
a murine lymphatic leukemia cell line used frequently to screen antitumor 
activity. 
In Table 3. the inhibitory activity of the selected Sm analogues in cell 
free systems as well as m the L1210 leukemia clonogenic assay are presented 
as ED50 or ID50 values representing the 50% effective or inhibitory dose, 
respectively. For the sake of brevity only data concerning analogues chosen 
for further investigation are presented. The results of other analogues pre-
pared are reported in references 30 and 31. 
2.9 Structure activity relationships 
From structure activity relationship studies (of which part of the results 
are presented in Table 3. and depicted in Fig. 2) the following conclusions 
can be drawn: 
1. The presence of two chiral centres in the molecule accounts for the 
existence of four stereoisomers, all of which have been synthesized (33). 
Of these stereoisomers only that compounds with S-R- configuration is a 
strong inhibitor of protein synthesis and of L1210 colony formation. 
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Table 3. Biological activity of sparsomycin analogues. The results are 
expressed as ED50 (cell free systems) and ID50 values (L1210). These values 
represent the median effective or inhibitory dose (in uM). 
compound 
E 
I Sm 
II n-butyl-Sm 
III n-pentyl-Sm 
IV benzyl-Sm 
V n-octyl-Sm 
VI deshydroxy-Sm 
VII ethyl-des-
Cell 
PolyPhe* 
synthesis 
• coll 
8.5 
1.Θ 
1.0 
0.6 
1.6 
14.6 
12.0 
S.cerev. 
5.2 
1.0 
0.17 
6.0 
1.3 
50.0 
11.1 
*** 
free systems 
Puromycin 
reaction 
E.coli 
0.10 
0.06 
0.03 
0.13 
0.25 
0.25 
0.07 
fra gment 
reaction 
E.coli 
3.2 
5.1 
2.6 
7.6 
60.0 
18.0 
10.3 
S.cerev. 
2.8 
4.8 
2.7 
2.6 
300.0 
39.0 
10.4 
L1210 
clonogenic 
assay 
0.48 
0.10 
0.06 
0.11 
0.11 
0.07 
0.15 
hydroxy-Sm 
VIII n-butyl-des- 3.0 
hydroxy-Sm 
IX n-octyl-des- 8.5 
hydroxy-Sm 
1.9 
1.4 
0.05 
0.46 
12. 1 
46.0 
15.0 
60.0 
0.05 
0.03 
* polyphenylalanine synthesis test (see text) 
** Escherichia coli 
*** Sacharomyces cerevisiae 
2. The presence and position of the sulphoxide moiety in the cysteinol side 
chain is of importance. When the positions of the sulphoxide function (S 
alpha) and the sulphur (S beta) atom are reversed, the biological ac­
tivity is reduced markedly. 
3. The hydrophobic sulphinyl side chain is of great importance for the 
activity. An increase in the length of this side chain (compounds II-V) 
markedly enhances the activity of the analogues in all the in vitro 
assays. An optimum was observed for a side chain with 5-6 carbon atoms 
attached to the bivalent sulphur atom (42). These results seem to indi­
cate that the hydrophobic group introduced in the molecule interacts with 
a ribosomal region that forms part of the peptidyl transferase centre. 
This hydrophobic group is also partially involved in the binding of the 
aminoacyl-tRNA molecule, but is not implicated in the puromycin binding 
site. It can be speculated, that physiologically, this binding site could 
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be used for binding of lipophilic amino acids· The effect of the hydro­
phobic side of Sm chain on its biological activity will be discussed in 
detail in chapter 3. 
4. The hydroxyl function of Sm was blocked by acetylatlon (35). The re­
sulting O-acetylated compound shows activity similar to that of Sm it­
self, indicating that the hydroxyl group is not essential for the ac­
tivity. Further, some deshydroxy compounds were prepared (compounds VI-
IX) in which the hydroxymethyl group is substituted by a methyl group. 
These drugs showed some surprising physicochemical properties and high 
biological activity in the in vitro and in vivo assays. The significance 
of structural modification of Sm's hydroxymethyl function for the ac­
tivity will be discussed in chapter 3. 
5. The C(6)- methyl group on the uracil ring and the trans geometry of the 
alkene function of Sm are important for the activity. The analogue which 
lacks the C(6)-methyl group shows low activity, whereas the compound with 
a cis-alkene function is inactive. 
The structure activity relationship studies are summarized in Fig. 2. 
Η I 
Η 
Fig. 2. Importance for activity of different functional groups. 
- unimportant, + important, ++ essential. 
2.10 A mechanistic rationale for Sparsomycins' activity as an inhibitor of 
peptidyl transferase 
Sm has structural similarities with the 3' end of the acceptor tRNA mole­
cule (Fig. 3). The binding of Sm to a site on the peptidyl transferase 
centre that partially overlaps the interaction site for the aminoacyladenine 
moiety of the aminoacyl-tRNA, thereby blocking peptide synthesis, is the 
most acceptable mechanism to explain Sm's activity. This may disturb also 
the correct positioning of the 3' end of the large aminoacyl-tRNA molecule. 
In both cases the formation of the peptide bond will be inhibited. The 
mechanistic rationale for Sm's interaction with the peptidyl transferase 
centre is outlined in Fig. 4. 
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F i g . 3 . Sparsomycin 11) Benzylsparsomycin |1β) L-Phenylalanyl tF?NA Puromycin 
peptidyl transferase 
Fig. 4. Mechanism of action of Sm (44,45), 
2.11 Cytotoxicity. 
Sm, being an inhibitor of protein synthesis, must be intrinsically toxic to 
cells permeable to the drug. The cytotoxicity is probably related to the 
deficiency of proteins, especially those with a rapid biological turnover 
and of vital importance to the cell. It has been reported for E. coli (22) 
that the antibiotic is mainly bacteriostatic and not bactericidal. Similar­
ly, Chinese hamster fibroblasts incubated for 1 hour with Sm concentrations 
that inhibit 99% of their protein synthesis recover totally after removal of 
the drug (46). We obtained similar results with Chinese hamster ovary cells 
(47) (see chapter 4). CHO cells do not recover their synthetic capabilities 
after exposure periods exceeding four hours. Fibroblasts are sensitive to Sm 
only during the S phase of the cell cycle (46). This suggests that the 
synthesis inhibition of histones may be a critical factor for cell survival. 
The permeability of prokaryotic and eukaryotic cells to Sm is an impor-
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tant factor influencing cytotoxicity. Intact rabbit reticulocytes are im­
permeable to Sm (26). If the other bone marrow cells are also impermeable to 
Sm, than this may explain why Sm is not toxic to bone marrow in vitro (31) 
and in dogs (48). 
2.12 In v i tro antitumor activity 
The first in vitro antitumor activity testing of Sm was reported in 1962 
(Θ). Sm was found to be exceptionally active on KB human epidermoid carci­
noma cells. However, this activity was not confirmed by other investigators 
(49). 
Since 1964 several researchers have tried to prepare more active Sm 
analogues (49). The in vitro activity of Sm and several of its analogues on 
L1210 leukemia cells (43,50) and on Ehrlich ascites carcinoma cells (51,52) 
has been reported. These assays were used to select compounds with a higher 
antitumor activity than the unmodified drug. For the L1210 leukemia system, 
a good correlation was found between the in vitro and in vivo antitumor ac­
tivity of the tested drug (42). 
Recently, Sm wag tested for cytotoxicity against human and murine tumor 
cells and human bone marrow (31). Sm, at concentrations that were toxic to 
24% of the human tumors and 80% of the murine tumors, did not decrease the 
viability of human bone marrow cells (see Table 4 ) . However, this "se­
lective" cytotoxicity to the tumor cells but not to the bone marrow was only 
apparent, as bone marrow toxicity is not a dose limiting factor for this 
drug. 
2.13 Antitumor activity of Sparsomycin in vivo 
In 1962, Owen et al. reported a marked antitumor activity of Sm in 11 out of 
20 rodent tumor models (8). The data from this publication are, however, 
difficult to interpret. The activity criteria used are somewhat different 
than those used nowadays, and it seems that in at least some cases activity 
was found with doses that were considerably toxic. The present general 
criterion for minimal activity in solid tumors is tumor volume reduction of 
_<_ 42% of the control without obvious toxicity. This criterion was not ful­
filled in any tumor system investigated by Owen et al. (8). Of the 20 tumor 
models tested, many have disappeared from the screening panel; and only one, 
the Lewis lung carcinoma, is still in use. Sm was then, as now, not active 
on this tumor. 
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Table 4. In vitro effect of Sm on murine tumors, human bone marrow and human 
tumor cells lines derived from xenografts in nude mice expressed as the 
number of responses / the number tested (31). 
t e s t system 
Murine tumors: P388, L1210, 
B16, LL, СоЗ 
Human bone marrow (CFU-C) 
0 . 0 3 
Sparsomycin 
0.1 
4/5 
0/4 
( цд/ті)* 
0 . 3 
5/5 
2/4 
1.0 
5/5 
4/4 
Human tumor cell lines: 
lung - non-smal l c e l l 
- smal l 
l a r g e bowel 
melanoma 
c e l l 
P l e u r a e p i t h e l i o m a 
stomach 
b r e a s t 
k idney 
t h y r o i d 
sarcomas 
t e s t i s 
0/7 
0/3 
0/5 
1/4 
0/2 
0/4 
1/2 
1/3 
0/10 
1/6 
1/7 
1/7 
2/2 
1/5 
2/3 
1/1 
1/1 
1/3 
0/1 
5/8 
3/6 
2/6 
5/7 
2/2 
5/5 
2/3 
1/1 
1/1 
3/3 
1/1 
8/8 
4/4 
2/2 
4/4 
1/1 
1/1 
1/1 
1/1 
1/1 
1/1 
Human tumor cells lines (total) 3/30 11/46 30/43 24/24 
10% 24% 70% 100% 
* continuous drug exposure. Tumors and bone marrow are considered to be 
responsive if the colony count is ^ 30% of the control. 
During the course of studies on the antitumor properties of Sm analogues, Sm 
was reinvestigated (49). Sm was thoroughly tested on four tumors. Cures were 
not observed in any case. In general, multiple dose schedules were more 
effective than single doses. Sm was moderately active on P388 leukemia (T/C 
156 +_ 8 %) and showed borderline activity on L1210 leukemia (T/C 125 +_ 9 % ) . 
There was no activity on B16 melanoma and there was only 50% reduction of 
tumor volume in Walker 256 carcinosarcoma. 
In our studies with synthetic Sm, activity was not observed in P388 
and/or in L1210 leukemias. The details on antitumor testing of the Sm ana­
logues are presented in Chapter 4. 
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2.14 Antitumor activity of Sparsomycin in combination with cisplatin 
There is sufficient evidence to indicate that protein synthesis inhibitors 
may potentiate the activity of other cytotoxic agents (53,54,55). This 
potentiating effect was also observed for Sm (47) in Chinese hamster ovary 
cells m vitro (see Chapter 5). Preincubation of the cells with a low Sm 
concentration that inhibits protein synthesis by only 20%, protected cells 
from cisplatin toxicity. Higher Sm concentrations, which inhibited protein 
synthesis by 92%, rendered cells more sensitive to cisplatin. Similar exper-
iments were performed in vivo using L1210 leukemia bearing mice (56, Chapter 
6.1). Pretreatment with Sm for 3-6 hours before cisplatin administration in-
creased the number of cures from 0/6 for cisplatin alone to 4/6 for the 
optimal combinations. It is interesting to note, that Sm up to a certain 
level protected mice from weight loss induced by cisplatin. These data 
suggest that Sm may not only potentiate the antitumor activity of cisplatin, 
but also protect normal cells from its toxicity. 
2.15 Toxicity of Sparsomycin 
Of the animals studied, mice and rats are the most susceptible to Sm 
induced organ damage (57). Dogs and monkeys show hardly any gross or micro-
scopic pathology at toxic doses of Sm. Except for eye toxicity no organ 
pathology m humans has been observed. 
Sm induces emaciation and cachexia in mice and rats (57). The animals 
suffer from diarrhoea (sometimes bloody) and haematuria. Occasionally, mice 
develop orbital bleeding and eye degeneration (58,59,60). However, this 
pathology is not related to the retina toxicity seen in humans. It is 
probable that such haemorrhagic events are due to a deficiency in blood 
coagulation factors synthesized in the liver. 
Microscopic examination of rat organs, frequently disclosed abnorma-
lities of the pancreas and the male reproductive system (57). 
Sm induces emesis, bloody diarrhoea, petechias, dehydration, renal in-
sufficiency, and hypothermia in dogs (48,57). Haematological and biochemical 
studies reveal marked leukocytosis, mainly granulocytosis, elongation of 
prothrombine time, fibrinogen deficiency, and a decrease in plasma albumin. 
There is no evidence of bone marow depression. In contrast, mild erythroid 
and myeloid hyperplasia were observed in monkeys (17). The platelet count 
remains normal. Occasionally, the number of reticulocytes decreases (48). 
Emesis, diarrhoea, and anorexia are probably the cause of dehydration and 
renal insufficiency. There is no evidence that Sm damages the kidneys di-
rectly. All hematological and biochemical disturbances are reversible within 
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two weeks of discontinuing of the treatment (48). 
There were no observable pathological changes in the retinas of any 
animal treated with toxic doses of Sm (17,48). 
A marked increase in SCOT and SGPT, sometimes giving the impression of 
anicteric hepatitis, were observed (48,57). Typically, for dogs as for man, 
abnormalities in the liver function appear after discontinuation of the 
treatment (13,48). 
Sm particularly affects liver protein synthesis (25,61-63). The drug 
preferably interacts with membrane bound ribosomes producing export proteins 
(62). The liver polysomes affected by Sm disaggregate, thus making mRNA 
translation impossible. 
After treatment with Sm, plasma proteins, synthesized in the liver, 
disappear from plasma according to their biological half-lives. For example, 
blood coagulation factor VII has a biological half-life of 3.5 hours in 
humans. In dogs, it disappears nearly totally within 6-7 hours after a 
single dose of Sm suggesting a similar short biological half-life (48). 
Plasma albumin, which has a biological half-life of approximately 20 days, 
decreases by 30% after treatment with Sm for nine days (48). 
In some pathological situations, the rate of protein synthesis may in­
crease. This happens with inflammation or cancer cachexia (65) where the 
liver compensates for the losses to the tumor. In these situations Sm may 
inhibit this compensatory mechanism and be particularly toxic to the host. 
The toxicity studies on analogues of Sm fell beyond the scope of this 
thesis. 
2.16 Pharmacology of Sparsomycin 
Sm is a nonpolar small hydrophilic molecule (M.W. 361). After i.V. admin­
istration to the dog, approximately 10 % of the drug is bound to plasma 
proteins (Zylicz, unpublished). More than half of the drug dosis is excreted 
by the dog in the urine (48). Tubular excretion and absorption has been 
suggested. The drug is eliminated from plasma with a t 1 ,, В of 0.7 hours 
(48). There are sufficient data to propose that Sm's pharmacokinetics may be 
non-linear at higher doses, which could result from saturation of tubular 
secretion. When administered in daily sequential doses the drug clearly 
accumulates in plasma. Introduction of a more lipophilic analogue with a 
more rapid non-renal clearance would thus be an advantage. Details on the 
pharmacokinetics of Sm are given in Chapter 9. The pharmacokinetics of the 
most promising Sm analogues in mice and in beagle dogs are presented in 
Chapters 10, 11 and 12. 
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2.17 Conclusions 
Sm is a cytotoxic drug which acts according to a novel and unexplored 
principle. Sm itself is toxic and not active in the usual tumor models. 
However, it can act as a strong potentiator of the cytotoxicity of other 
anticancer agents and concomitantly may diminish their toxicity on normal 
cells. This could be an important application for this class of compounds in 
the future. Small modifications in the chemical structure of Sm may lead to 
the development of less toxic analogues showing even better effects in drug 
combination chemotherapy. 
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Abstract. The lipophilicity of 11 sparsomycin analogues was measured by determination of 
Rm, log k0 and log Ρ values. A linear correlation between these parameters was observed. Water 
solubility and drug toxicity in mice were found to be linearly correlated with lipophilicity. The 
deshydroxy-sparsomycin analogues (9-12) showed an interesting phenomenon: increase in 
hydrophobicity was accompanied by a considerable increase in water solubility. AU the 
derivatives studied are more lipophilic than sparsomycin (1) itself and all show higher biological 
activity than 1 in the in vitro and in vivo systems studied. Moreover, these analogues are 5-100 
times less toxic than 1. The sparsomycin analogues 4, 8 and 9 show the highest antitumor 
activity against L1210 leukemia in mice, their median T/C values are 386, 330 and 216%, 
respectively. Sparsomycin (1), showing a T/C value of 117%, is only marginally active against 
this tumor. 
Introduction 
Sparsomycin (I)1 is a broad spectrum antibiotic active against parasites,2 viruses,3,4 fungi,5" and 
bacteria.6·7 It is a potent inhibitor of protein biosynthesis, and there is ample evidence that its 
site of interaction is the large ribosomal subunit. The drug competes with the binding of the 
natural substrate, i.e. L-amino acyl-tRNA, thereby blocking the peptidyl transferase center.1 
Ever since the isolation of sparsomycin from Streptomyces sparsogenes in 1962, much attention 
was focused on its antitumor activity.1·5* In earlier reports8·9 on structure-activity relationships 
we described the synthesis of several analogues of sparsomycin which are more potent protein 
synthesis inhibitors than the natural product 1 itself. Subsequently, the influence of lipophilicity 
on the biological activity in cell-free (i.e. protein synthesis inhibition) and whole-cell systems 
(i.e. growth inhibition) was investigated systematically.9 Increase of the lipophilicity of the drug 
by substituting the SMe group by larger alkylthio groups (see structure of 1) causes an increase 
of the biological activity. 
Surprisingly, replacement of sparsomycin's hydroxymethyl group at the chira! carbon atom 
by more lipophilic substituents (alkyl or aralkyl groups) causes a decrease of the protein 
synthesis inhibitory capacity of these compounds.10 
The analogue having the hydroxymethyl group substituted by a methyl group (9)9 is five 
times more active than sparsomycin against LI 210 leukemia in vitro, whereas the activity of the 
compounds having the hydroxymethyl moiety substituted by larger alkyl or aralkyl groups10 is 
equal to or even slightly less than that of 1. Therefore, we felt the need to study systematically 
the relationship between physicochemical properties of sparsomycin analogues, i.e. their 
lipophilicity and water solubility, and their biological activity. A number of lipophilic 
sparsomycin analogues was selected (see Table I).9 The following biological activities were 
studied: the protein synthesis inhibition in a cell-free system, cytotoxicity in vitro, antitumor 
activity in vitro, toxicity in vivo, and antitumor activity in vivo. The results described in this 
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report are a firm basis for selection of the best drugs to be investigated in further 
pharmacological and toxicological studies. 
Results and Discussion 
The structure of the compounds studied in this report is shown in Table I. Their physicochemical 
properties, i.e. their lipophilicity and water solubility, are given in Table II. In Table ΙΠ the 
biological activity data of all drugs are presented. Regression equations describing the linear 
correlation between various physicochemical parameters studied and between lipophilicity and 
toxicity are shown in Table IV. 
Tabic L Sparsomycin and Analogues 
M e 0
 F/1 
C A A H 
о 
1 
\ R2 
H 
compd 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
R1 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
Me 
Me 
Me 
Me 
R2 
CH2SMe 
CH2S(CH2)2Me 
СН28(СН2)зМе 
CH2S(CH2)4Me 
CH2S(CH2)7Me 
CH2SCH2Ph 
(CH2)5Me 
(CH2)6Me 
CH2SMe 
CH2SEt 
СН28(СН2)зМе 
CH2S(CH2)7Me 
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On the basis of their structure the compounds studied (see Table I) can be devided into three 
classes, i.e. a series of sparsomycin analogues (1-2-3-4-5), two desthio analogues (7-8) and a 
group of deshydroxy-sparsomycin analogues (9-10-11-12). Compound 6 was included in order 
to study the influence of the presence of an aromatic ring in the side chain on the biological 
activity. One representative of each class, i.e. compounds 4, 8 and 9 have attracted our attention 
because these compounds in relation to sparsomycin, combine a high antitumor activity with a 
low toxicity in vivo. 
Compounds 7 and 8 are structurally related to compounds 3 and 4, respectively. In the 
former two compounds the bivalent sulfur atom has been replaced by a methylene group. 
Compounds 9, 11 and 12 carry identical side chains as compounds 1, 3 and 5, respectively. 
However, the hydroxymethyl group of the latter compounds has been replaced by a methyl 
group. 
Table II. Physicochemical Parameters 
compd Rm log k0 log Ρ water 
solubility 
(mg/mL) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
-0.638 
-0.261 
-0.028 
0.160 
0.895 
-0.042 
0.235 
0.560 
-0.404 
-0.190 
0.218 
1.151 
-0.676 
0.117 
0.777 
1.168 
3.333 
0.803 
1.111 
1.771 
-0.209 
0.079 
1.290 
3.533 
-1.713 
-0.665 
0.143 
0.600 
>2.424 
0.129 
0.410 
1.021 
-0.699 
-0.301 
0.819 
>2.424 
3.8 
1.5 
0.57 
0.28 
0.013 
0.76 
0.89 
0.22 
18.0 
8.8 
0.94 
0.015 
Physicochemical Properties. The lipophilicity of the sparsomycin compounds can be well 
characterized by the experimentally simple determination of Rm values (Table II). Excellent 
linear correlations were found (entries А, В and С of Table IV) between this parameter and the 
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other lipophüicity parameters measured, i.e. log k0 and log Ρ (Table II). The sparsomycin 
analogues 1, 3 and 5 have Rm, log k0 and log Ρ values that are lower than those of the 
corresponding deshydroxy-sparsomycin derivatives 9, 11 and 12, respectively (Table II). The 
linear coixelation calculated between the Rm values of the series 1-5 and 9-12 versus the number 
of carbon atoms attached to the bivalent sulfur atom is given in entries D and E, respectively, of 
Table IV. It can be seen that these linear regression lines have equal slopes. The difference in 
the Rm values of two corresponding structures in these series, e.g. 1 and 9, is equal to the effect 
of a single methylene group. 
Water solubility of the drugs (Table Π) correlates linearly with all lipophüicity parameters 
used; in entries F and G of Table IV only the correlation with log k0 is shown for the series 1-8 
and 9-12, respectively. Surprisingly, the deshydroxy-sparsomycin derivatives 9, 11 and 12 are 
better water soluble than the corresponding sparsomycin analogues 1, 3 and 5, respectively, 
despite their increased lipophüicity. E.g. compound 9 is five times more water soluble than 
sparsomycin 1 itself. We do not have an explanation for this interesting phenomenon. 
The pKa values of sparsomycin 1 (8.97 ± 0.02) and deshydroxy-sparsomycin 9 (9.02 ± 
0.02) were measured.5b From this we conclude that the hydroxy function of sparsomycin is 
poorly dissociated since the pKa values are virtually the same. 
Biological Activity In Vitro and In Vivo. The biological activity was studied in four in 
vitro assays and in one in vivo system; the results are given in Table ΙΠ. The following 
conclusions can be drawn. Of the hydroxy-containing sparsomycin analogues 1-8, the 5-oxo-
S-n-heptyl derivative 8 possesses the highest affinity for the ribosomal peptidyl transferase. The 
high activity in the phenylalanine polymerization (polyPhe) assay of analogues carrying a 
hydrophobic group attached to the sulfoxide function (e.g. 4 and 8) suggests that these 
compounds interact with a hydrophobic region on the peptidyl transferase. Probably this region 
functions as the recognition site for the lateral chains of hydrophobic amino acids during protein 
synthesis.1·8 
Comparison of the data obtained for compounds 1-5 in the polyPhe assay, in the L1210 
clonogenic assay and in the L1210 in vivo system shows that there is an optimum in activity for 
pentyl-sparsomycin 4. This optimum in activity is most pronounced in the in vivo L1210 
system. 
Substitution of the bivalent sulfur atom by a methylene group (compare the data of 
compound 7 vs. 3 and 8 vs. 4, respectively) has no serious effect on the in vitro and in vivo 
biological activity. The in vivo antitumor activity of compounds 7 and 8 is somewhat lower than 
that of compounds 3 and 4, respectively. In both cases a surprisingly better T/C ratio was 
obtained by extension of the side chain with a single methylene group. 
In the deshydroxy-sparsomycin series 9-12 an optimum in activity was observed for 
compound 11 in the protein synthesis inhibition assay and in the growth inhibition assays of T24 
and WiDr tumor cells. In this series compound 10 has the lowest activity in the L1210 
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clonogenic assay. 
Table ΠΙ. Biological Activity 
cell-free whole-cell in vivo 
polyPhe growth inhibition LD50 T/C 
synthesis 
compd E.coli T24 WiDr L1210 L1210 
Εϋ5ο(μΜ) Ι05ο(μΜ) (mg^g) (%) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
8.5 
3.0 
1.8 
1.0 
1.6 
0.6 
0.75 
0.46 
14.5 
12.0 
3.0 
8.5 
0.91 
0.65 
0.23 
0.28 
0.06 
0.34 
0.35 
0.16 
0.44 
0.34 
0.09 
0.14 
0.92 
0.89 
0.31 
0.40 
0.22 
0.51 
0.39 
0.28 
0.58 
0.48 
0.16 
0.28 
0.48 
0.14 
0.10 
0.06 
0.10 
0.11 
0.14 
0.15 
0.07 
0.15 
0.05 
0.03 
0.26 
NT 
2.33 
4.7 
29.5 
5.0 
1.6 
6.1 
2.33 
8.7 
16.5 
NT 
117 
NT 
156 
386 
151 
151 
135 
330 
216 
184 
164 
NT 
NT, not tested 
Despite the lower affinity for the ribosome of compounds 9 and 10 in companson with 
sparsomycin 1 itself, these analogues are more active than 1 in vivo against L1210 leukemia. 
Surprisingly, the antitumor activity of 11 is lower than that of 9, whereas the hydroxymethyl 
analogue of 11, i.e. 3, has a higher antitumor activity than 1. 
The benzyl derivative 6 is quite active in the in vitro assays and although more active than 
sparsomycin in vivo, this compound is one of the less active analogues as far as antitumor 
activity in tumor-bearing mice is concerned. 
Replacement of sparsomycin's methyl group at the bivalent sulfur atom by alkyl or aralkyl 
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groups (i.e. 2-6) and of its methylthio function by alkyl groups (i.e. 7 and 8), both leading to 
increased lipophilicity of the drug, results invariably in an increase of the biological activity in 
all assays tested. 
The activity of the sparsomycin analogues 1-8 against the two human tumor cell lines (T24 
bladder and WiDr colon carcinoma) is related to the lipophilicity of the compounds. In general, 
an increase of the lipophilicity results in an increase of the activity. 
Acute Toxicity. We observed a striking linear relationship between drug toxicity in mice 
and lipophilicity; an increase of the lipophilicity results in a decrease of the toxicity. The 
correlations found for the sparsomycin compounds 1, 3-8 and for the deshydroxy-sparsomycin 
compounds 9-11 are depicted in entries H and I, respectively, of Table IV. Removal of the 
hydroxy group decreases the drug's toxicity considerably; compare the data of compounds 9 vs. 
1 and 11 vs. 3, respectively (Tables II and III). Comparison of the LD50 values of compounds 7 
vs. 3 and 8 vs. 4, respectively, learns that substitution of the bivalent sulfur atom by a methylene 
group has a variable effect on in vivo toxicity. 
A rationale for the decreased toxicity of the more lipophilic analogues could be the 
following. Pentyl-sparsomycin 4 has a total body clearance in Beagle dogs that is twice that of 
sparsomycin I.11 A more rapid clearance permits on one hand the administration of higher doses 
of the drug, but on the other hand produces a lower AUC (area under the curve). In other words, 
the body is exposed less to more lipophilic analogues of sparsomycin, e.g. 4, resulting in a lower 
toxicity. The increased volume of distribution and increased protein binding of these lipophilic 
derivatives may explain further the increase of the LD50 value. 
The role of the substituent at the chiral carbon atom of sparsomycin on the biological 
activity in vitro has been investigated earlier.10 It was concluded that the affinity for the 
ribosome and the antitumor activity in vitro are hardly affected by replacement of this 
substituent by larger alkyl or aralkyl groups, or by its O-methylation or O-acylation. Some of 
these changes even cause a slight decrease in activity. Only when the hydroxymethyl group is 
replaced by a methyl group an increase in the in vitro activity in the L1210 clonogenic assay 
was observed. This study shows that also in vivo deshydroxy-sparsomycin 9 is a better 
antitumor drug than sparsomycin. Unfortunately, substitution of the methylthio group in 9 by 
larger alkylthio groups, as in compounds 10 and 11 does not give rise to an increase of the in 
vivo antitumor activity, as observed in the series 1-2-3-4. 
In conclusion: the therapeutic index of sparsomycin can be considerably improved by 
minor modification of the molecular structure. The drug with an n-pentyl side chain attached to 
the bivalent sulfur atom, i.e. 4, shows the highest antitumor activity in mice. 5-Oxo-S-n-heptyl-
sparsomycin 8 and deshydroxy-sparsomycin 9 also pair high antitumor activity with low toxicity 
in comparison with the unmodified antibiotic. Compound 9 shows the unique feature of 
combining an increased lipophilicity with a considerable increase in water solubility. 
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Table Г . Linear regression equations 
y = ax + b 
entry y χ b a r n compds 
A 
В 
С 
D 
E 
F 
G 
H 
I 
logk° 
logk" 
Rm 
Rm 
Rm 
logk» 
logk0 
logk0 
logk0 
log Ρ 
Rm 
log Ρ 
Cn 
Cn 
log Sol 
log Sol 
log LDso 
log LDJO 
-0.63 
-0.30 
0.07 
-0.90 
-0.64 
0.51 
1.28 
-0.06 
0.66 
0.92 
0.40 
2.28 
0.22 
0.22 
-1.55 
-1.23 
0.49 
0.47 
0.986 
0.989 
0.981 
0.998 
0.999 
-0.973 
-0.999 
0.937 
0.858 
12 
12 
12 
5 
4 
8 
4 
7 
3 
1-12 
1-12 
1-12 
1-5 
9-12 
1-8 
9-12 
1,3-8 
911 
abbreviations used: a, slope; b, intercept; г, correlation coefficient; η, 
number of compounds used in linear regression analysis; Cn, number of 
carbon atoms (see text); Sol, water solubility. 
Experimental Section 
Drugs. The syntheses of sparsomycin and analogues 2-12 have been described earlier.8·9·12,13 
The compounds used in this study are listed in Table I. 
Chromatography. Rf values were determined by high-performance thin-layer 
chromatography (hptlc) using Merck RP-8 F254
 s
 plates (eluent 60% methanol/water). Rm values 
were calculated from these Rf values by employment of the following formula: Rm = log (1/Rf -
1). 
Drug concentrations were determined using a semi-automated high-performance liquid 
chromatography (hplc) system from Kratos Analytical (Ramsey, New York, U.S.A.). This 
system consisted of two Spectroflow 400 pumps, Multiport Streamswitch with two six-way 
valves (Rheodyne, USA), a 757 UV-Vis Detector and a DS 610 Multi-range strip chart recorder. 
The connection of the sampling valves for the back flushing method has been described 
before.14 The whole system was operated by means of an hplc solvent programmer (9224, Kipp 
Analytical, The Netherlands) equipped with a digital time indicator. 
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The columns used are: a concentration column (5 cm χ 3 mm id) filled with LiChrosorb 
RP-8 (10 μπι particle size) and an analytical column (10 cm χ 4.6 mm id) filled with CP1"1 Spher 
C8 (8 μπι particle size); both packing materials were obtained from Chrompack B.V. 
(Middelburg, The Netherlands). 
Solvent A (flow 1.3 mL/min), used for sample concentration and cleaning of the columns 
consisted of filtered tap water. Solvent В (flow 1.0 mL/min), used to flush back the sample from 
the concentration column through the analytical column consisted of 0.1 M phosphoric acid 
buffer (pH 6.7) with different amounts of methanol (Fisons, England, hplc grade) added. 
Determination of log к values by HPLC. For each drug the retention time (tj) was 
determined on hplc for at least five methanol concentrations (see above). In general, the results 
for each drug could be described by the following equation:15 logk' = log k0 + bM, where k'= 
the capacity factor at a certain percentage of organic solvent in the eluent, k0 = the capacity 
factor obtained by extrapolation to 0% of organic solvent in the eluent, b = slope and M = 
percent of methanol in the eluent. The capacity factor k' is calculated from the difference 
between the retention time (t,) of the drug and the retention time (t,,) of the unretained substance: 
log k'= log (vto) - log t0. 
Octanol/water partition coefficient. The partition coefficients (P) of the drugs were 
measured by mixing 1 mL of a solution containing 12 μg/mL of a drug dissolved in 
demineralized water and 1 mL of 0.1 M phosphoric acid buffer (pH 7.4) saturated with 2 mL of 
1-octanol (Merck, Germany). After mixing for 1 min on a Vortex mixer and centrifugation at 
1400 g for 10 min, 1 mL of the water phase was analyzed by hplc (see above). Increasing the 
time of mixing did not change log P. Each test was repeated three times and each sample was 
determined in duplicate. The coefficient Ρ was calculated from the following formula: Ρ = (С -
C
w
)/C
w
, where С = total concentration of drug in both phases and C^ = concentration of drug in 
the water phase. 
Water solubility. An excessive amount of each drug was shaken overnight with 5 mL of 
demineralized water at room temperature (19.5 ± 0.3 0C). The drug suspension was filtered 
through a paper filter (Rundfilter, nr.595, Schleicher & Schuil, Germany). The last mL of the 
filtrate was collected and the concentration was determined by hplc (see above). Each 
experiment was performed twice. 
Dissociation constant pKa. The pKa values of 1 and 9 were determined following the 
method of Hurwitz and Liu.16 The UV absorption of several samples was measured at 328 nm 
(DU-7 UV-Vis Spectrofotometer, Beekman, USA). Samples with the same drug concentration 
dissolved in different borax and phosphate buffers (pH 3.5-12) were prepared and analyzed. The 
pKa value was calculated from the following formula: pKa = pH - log (A-Ag/A^A), where pH = 
pH of the buffer, A = absorbance at a specific pH, A
a
 = absorbance in acidic solution (pH 3.5) 
and Ab = absorbance in basic solution (pH 12). The pKa value is expressed as a mean of the 
results of each sample (n = 10) ± SD. 
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Inhibition of protein synthesis in a cell-free system. The protein synthesis was measured 
by the polyphenylalanine synthesis (polyPhe) assay. This assay has been described by us in 
detail elsewhere.8 Polymerization of phenylalanine using polyuridylic acid as template is 
generally accepted as a measure for the total polymerization capacity of cellular extracts. 
Ribosomes from Escherichia coli MRE 600 were used. ΕΌ^ represents the 50% effective dose. 
The values given are the average of three experiments and have an average error of 20%. 
In vitro cytotoxicity. The cytotoxicity against two human tumor cell lines was determined 
following a new automated technique for large-scale drug cytotoxicity testing, i.e. the PIT 
method.17 The 50% inhibitory dose (ID50) was calculated. In vitro antitumor activity was 
determined in the L1210 murine leukemia clonogenic assay in soft agar.13 The 50% inhibitory 
dose (ID50) was calculated. 
Toxicity in mice. The toxicity of each drug was determined following the NCI protocol.18 
The tests were done on male CDF, mice and each drug, suspended or dissolved in 0.9% NaCI, 
was injected ip daily χ 9. There were 5 dose levels and 10 mice per dose level. The LD^ values 
(mg/kg/inj) were calculated using Weils' tables.19 The 95% confidence interval was usually 
within 15-20% of the value shown. These data were reported elsewhere.20 
Antitumor activity in mice. The antitumor activity of the drugs against LI 210 leukemia 
was determined in male CDFj mice inoculated with 105 vital L1210 cells ip on day 0. Animals 
were treated with drugs dissolved or suspended in 0.9% NaCI ip on days 1-9. The median 
survival time of each treated group (T) was compared with that of the control group (C). The 
results are expressed as a T/C χ 100% ratio at the optimal dose (this dose is approximately equal 
to the LD 1 0 value). These data as well as the results of activity tests against other murine tumors 
(i.e. P388 leukemia, RC carcinoma and B16 melanoma) were reported elsewhere.20 
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SUMMARY 
Sparsomycin (Sm) is a known inhibitor of ribosomal protein synthesis with 
an attractive anticancer potential. Recently, several analogues of Sm which 
are more active than the parent drug were selected for further study on the 
basis of in vitro investigations. Six analogues as well as the parent drug 
were tested for their antitumor activity in eight in vivo murine tumor 
models: P388 and 1.1210 leukemiaS/ RC renal cell carcinoma, B16 melanoma, C38 
colon carcinoma, LL Lewis lung carcinoma, C22LR osteosarcoma and M5076 
sarcoma. Sm itself appeared to have only borderline activity on L1210 
leukemia. The analogues that were most active in vitro showed also the 
highest in vivo activity. The most sensitive tumors were RC, L1210 and P388. 
Minimal activity was found on B16 and no activity on C22LR, M5076, C38 and 
LL. The most active compounds are deshydroxy-Sm, ethyl-deshydroxy-Sm and n-
pentyl-Sm. There was a considerable loss of activity when L1210 leukemia was 
implanted s.c. while the drugs were administered i.v. Only one drug, ethyl-
deshydroxy-Sm appeared to be active in this assay. No single most effective 
compound could be found in this study. The overall activity of Sm and its 
analogues is moderate. The three analogues which show high activity in three 
ascitic tumors will be further investigated using human tumor xenograft 
models. 
INTRODUCTION 
Sparsomycin (Sm, NSC-059729) is a potent inhibitor of ribosomal protein 
synthesis (1). The natural product was isolated in the early sixties from a 
fermentation broth of Streptomyces sparsogenes (2). Sm was found to have 
antitumor activity against KB human epidermoid carcinoma cells m vitro and 
several rodent tumors in vivo (3). Based on these data, Sm entered a phase I 
clinical study in 1964. However it was withdrawn after the finding of an 
unusual retinal toxicity (ring scotomas) in two out of the five treated 
patients (4). Since then several investigators tried to synthesize more 
active and less toxic analogues; Sm was reinvestigated during these studies 
as a reference drug (5). Sm was found to be active against Ρ3Θ8 leukemia 
(T/C +_ 160%) and to have borderline activity against L1210 leukemia (T/C +_ 
125%). It was also moderately active on Walker 256 carcinosarcoma in rats, 
but it had no effect on B16 melanoma and C38 colon carcinoma. 
The revival of interest m this drug was stimulated by its present 
accessibility through a flexible total synthesis (6) and by the preparation 
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of more active and less toxic analogues (7,8). For the review on the total 
synthesis of Sm and the development of its structural analogues see 
references 9 and 10. 
Recently we found that pretreatment of in vitro growing CHO cells (11) or 
L1210 leukemia bearing animals (12) with Sm significantly enhance the cyto-
toxic effect of cisplatin. 
In this present study we report our findings on the dose-effect relation-
ship of several Sm analogues when tested against eight murine tumors in 
vivo. These analogues were selected from a larger pool on the basis of their 
activity in cell-free protein synthesizing systems and the L1210 clonogenic 
assay (7,8). The correlations between the in vitro and in vivo activity of 
analogues will be discussed. 
MATERIALS AND METHODS 
Drugs 
Sm and its analogues were synthesized as previously decribed (6,9). Drugs 
were acquired in a freeze dried form and dissolved or suspended in buffered 
physiological saline before use. For those drugs that do not dissolve in 
water 1% carboxy-methyl-cellulose was added. For i.v. studies, n-pentyl-Sra 
was formulated in 10% propylene glycol and 0.03 M phosphate buffer (pH = 7). 
In this formulation n-pentyl-Sm was stable even at 370c for 12 weeks (unpub-
lished). After dissolution (or after suspension), the drugs were stored for 
not longer than 10 days in the dark at +4° C. The concentration of the drug 
in the solution was regularly measured with HPLC (13). 
The structure of Sm and its analogues studied are listed in Table 1. 
LD50 tests 
The tests were performed and the LD50 values calculated according to the 
method of Weil (14). Four to five dose levels with 10 CD2F1 male mice per 
dose level were used. Drugs were injected i.p. for 9 days. For three 
compounds (I,VI and VII) single i.v. dose LD50 values were also determined. 
This was not possible for n-pentyl-Sm (III) as the maximal solubility of 
this compound in non toxic formulation was only 0.5 mg.ml" . 
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Table 1. Sparsomyrin and analogues 
0 0 R1 0 
H f f 
H 
H 
Nr name RI R2 
I 
II 
III 
IV 
V 
VI 
VII 
Sparsomycin 
n-butyl-Sm 
n-pentyl-Sm 
benzyl-Sm 
n-octyl-Sm 
(Sm) 
deshydroxy-Sm 
ethyl-deshydroxy-Sm 
сн2он 
сн2он 
сн2он 
сн2он 
сн2он 
CH3 
сн3 
Tumor models 
L1210 and P388 leukemias, and RC renal cell carcinoma tumor lines were 
kindly supplied by dr. G. Atassi (Inst. Jules Bordet, Lab. for Experimental 
Chemotherapy, Brussels, Belgium). Dr Atassi also performed control exper­
iments on L1210 leukemia as well as tests on the M5076 sarcoma. The B16 
melanoma, C38 colon carcinoma, C22LR osteosarcoma and LL Lewis lung carci­
noma tests were performed at the Radiobiological Institute TNO m Rijswijk 
(P.L.). After being thawed from liquid nitrogen, not more than three pass­
ages in vivo were used for the study. The protocol details are presented in 
the footnotes of tables 3-7. 
Animal survival (P388, LI210, RC, B16 and M5076 ) was recorded daily and 
the median survival time of each group (6 animals/group) was calculated. The 
final results for these tumors are presented as the treatment (T) to control 
(C) ratio of the respective median survival times. From each experiment, 
performed at 3 to 5 different dose levels (the increments were equal to a 
factor of 1.3 to 1.5), an optimal T/C was selected (see footnote Table 3). 
If more experiments were performed, the median optimal dose and the median 
T/C value at the optimal dose are given, as well as the ranges. Minimal 
activity criterion for these tumors was T/C >^  125%. The long term survivors 
(LTS) were defined as animals survival longer than 60 days without evidence 
of tumor growth. 
O ^ N ^ C H , 
сн 3 
(сн2)3сНз 
(сн2)4сНз 
сн 2с 6н 5 
\CHo)тСН^ 
сн 3 
сн,сн, 
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C38, C22LR and LL tumors were inoculated s.c, as a fragment or as 1-2 
.10 tumor cells in both flanks (for methodological details see ref.16). 
After randomization (5 mice per group = 10 tumors) animals were treated i.p. 
on days 2-10. The tumors were measured with calipers two to three times a 
week. The mean values were plotted on a semi-log graph (days vs tumor 
volume), and the volume doubling time was calculated as the time required to 
increase the tumor volume from 500 to 1000 mm . The growth delay factor 
(GDF) was calculated as follows : 
1000-
500-
tumor volume 
mm3 
/ b 
/ 
/ \ / \ / \ 
control 
/ a 
/ 
/ 
,/ 
/ 
/ 
/ 
treatment 
days 
Fig. 1. Growth delay factor (GDF) 
GDF 
where : 
a - growth delay between control and treatment group at the level of 1000 
mm (days). 
b - volume doubling time of the control (days). 
The control doubling times (b) were 5.3, 2.3, and 3.3 days for СЗ , C22LR 
and LL, respectively. 
RESULTS 
LD50 values 
The LD50 values of the compounds studied after administration as a single 
dose as well as after nine daily doses are presented in Table 2. Five 
different Sm analogues that differed from each other by the length of the 
hydrophobic R2 side chain were investigated. There is a linear relation (r = 
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0.99Θ) between the number of the carbon atoms in the R2 chain (lipophili-
city) and log LD50 (for compounds 1,11,III and V) : the higher the lipophili-
city of the drug, the lower its toxicity. Both deshydroxy analogues (VI and 
VII) showed substantially higher LD50 values than their hydroxylated 
counterparts, e.g. compare the LD50 value for compounds I and VI. 
Table 2. LD50 values for sparsomycin and its analogues. 
Nr 
I 
II 
III 
IV 
V 
VI 
VII 
nd = 
drug 
Sm 
n-butyl-Sm 
n-pentyl-Sm 
benzyl-Sm 
n-octyl-Sm 
deshydroxy-Sm 
ethyl-deshydroxy-Sm 
not done 
L D50 
single dose 
i.v. (95%) 
(mg.kg-1 ) 
11.3 (8.B-
nd 
nd 
nd 
nd 
23.2 (18.1· 
82.3 (74 -
13.5) 
-29.8) 
91) 
L D50 
daily 
i.p. 
(mg.kg-1 
0.26 
2.33 
4.7 
5.0 
29.5 
2.33 
8.0 
χ 9 
, (95%) 
per inj.) 
(0.17-0.38) 
(1.8-3.2) 
(3.7-5.9) 
(4.0-6.3) 
(24.0-37.0) 
(1.8-3.2) 
(6.95-9.2) 
Antitumor activity 
The optimal treatment schedule was determined for n-pentyl-Sm (III) in L1210 
leukemia; this data are presented in Table 3. Optimal sehe dules were those 
with a daily drug administration for 7-14 days and a total dose of about 30 
mg.kg" . The LTS (2/24) were only observed during the 9 day daily schedule. 
Mice treated with a 14 day daily schedule showed slow growth of a solid 
intraperitoneal lymphoma probably due to selection of the tumor cells. On 
the basis of these data, a 9 day daily treatment schedule was chosen for all 
the other experiments. 
All compounds except Sm (I) appeared to be active on RC carcinoma, L1210 
leukemia and to a lesser extent on P388 leukemia (see Tables 4 - 6). An 
increase of the lipophilicity resulting from elongation of the R2 methyl 
side chain in Sm (series I, II, III and V) considerably increased the 
antitumor activity until the optimum was reached with n-pentyl-Sm (III). A 
further increase of the chain length (n-octyl-Sm, V) did not increase the 
activity. 
All the experiments reported here were performed with male animals. 
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Table 3. Schedule dependency of n-pentyl-Sm (III) on L1210 leukemia3 
treatment 
schedule 
dose optimal 
range dose 
-1 -1 
(mg.kg ) (mg.kg ) 
total 
dosec 
T/Ca 
at optimal 
LTS/total€ 
(mg.kg" ) dose (%) 
day 1 
day 1-5 
day 1-7 
day 1-9 
day 1-14 
day 1,3, 
day 1,4, 
day 1,5, 
i 
5, 
7, 
9 
,7,9 
.10 
10.0 
3.2 
3.2 
1.5 
1.4 
2.2 
5.0 
5.0 
-
-
-
-
-
-
-
-
38.3 
7.0 
7.0 
5.0 
3.2 
7.5 
17.0 
25.5 
15.0 
4.8 
4.8 
3.3 
2.1 
5.0 
11.3 
17.0 
15.0 
24.0 
33.6 
29.7 
29.4 
25.0 
45.2 
51.0 
128 
150 
206 
175 
206 
160 
165 
140 
0/18 
0/18 
0/18 
2/24 
0/18 
0/24 
0/24 
0/24 
a. 10 L1210 leukemia cells were inoculated i.p. on day 0 in CD2F1 male 
mice. Treatment i.p. was started on day 1. 
b. Optimal dose was selected from an experiment with 3-5 dose levels. For 
selection the following criteria were used: maximal T/C, no early toxic 
deaths before day 9, no weight loss (T - C) in the first 5 days exceeding 
4 g. 
c. Total dose required for optimal treatment. 
d. T/C is the ratio of the median survival time of the treatment group and 
that of the control. There were usually 10 animals/experiment as con-
trols. 
e. LTS/total - the ratio of the number of long term survivals to total 
number of animals used in experiment. 
Limited data from parallel experiments suggest that female mice were able to 
survive higher doses of the drugs and had relatively better treatment re-
sults (unpublished). 
A significant number of LTS were observed for mice bearing i.p. L1210 
leukemia and RC carcinoma. The drugs producing the highest number of LTS are 
n-pentyl-Sm (III) and deshydroxy-Sm (VI). LTS were also seen in animals 
bearing RC carcinoma treated with n-butyl-Sm (II). However these data wait 
further confirmation. The three most active compounds ( i.e. Ill, VI and 
VII) were administered i.v. to the animals bearing L1210 leukemia and RC 
renal cell carcinoma s.c. In L1210 leukemia (see Table 5 B) compound III 
and VI were inactive while compound VII showed some activity and a median 
T/C value of 139% (range 122-156). In RC carcinoma compounds III and VI 
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showed activity of about 150% (see Table 6 B ) , only compound VII showed a 
slightly lower T/C value (138%). 
Table 4. Antitumor activity of sparsomycin and its analogues on P388 
leukemia* 
drug 
I 
I I 
I I I 
IV 
V 
VI 
V I I 
dose 
range 
0 .063 
1 . 0 
2 . 0 
1 . 0 
10.0 
1 . 0 
3 . 2 
- 0 . 5 
- 3 . 4 
- 7 .0 
- 8 . 0 
- 3 3 . 8 
- 3 . 4 
- 8 . 0 
median 
opt imal 
dose 
(mg.kg" ) 
0 .125 
2 . 3 
5 . 0 
2 . 0 
2 2 . 5 
2 . 9 
6 . 2 
T/C range 
a t opt imal 
dose (%) 
(mg.kg" ) 
127 - 160 
146 - 175 
136 - 170 
medi 
T/C 
8 8 
144 
161 
133 
150 
153 
150 
a n 
(%) 
L T S / t o t a l 
0 /24 
0 /48 
0 /48 
0 /24 
0 /24 
0/48 
0 /24 
a. 10 P388 leukemia cells were inoculated i.p. in the CD2F1 male mice on 
day 0. Treatment i.p. on days 1 - 9 . 
For other explanations see footnotes of Table 3. 
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Table 5. Antitumor activity of sparsomycin and its analogues on L1210 
leukemia 
Exp. 
A 
В 
С 
drug 
I 
II 
III 
IV 
V 
VI 
VII 
III 
VI 
VII 
III 
VI 
VII 
do£ ¡e 
range 
(mg. 
0.25 
1.0 
1.5 
1.8 
9.0 
0.5 
3.0 
6.0 
4.0 
.kg"1) 
- 1.0 
- 3.4 
- Θ.0 
-20.0 
-30.0 
- 4.0 
- 12.0 
-
-
- 7.8 
- 5.0 
-
-
median 
optimal 
dose 
(mg.kg-1) 
0.25 
1.5 
5.4 
6.4 
15.0 
2.0 
6.1 
5.0 
2.0 
6.9 
4.5 
2.0 
6.0 
T/C range 
at optimal 
dose (%) 
154 - 175 
110 - 171 
120 - 152 
163 - 248 
158 - 185 
-
-
122 - 156 
111 - 125 
111 - 125 
-
median 
T/C (%) 
125 
145 
164 
141 
136 
206 
172 
111 
111 
139 
118 
118 
125 
LTS/total 
0/18 
0/24 
2/42 
0/96 
1/78 
5/84 
1/42 
0/20 
0/20 
0/40 
0/20 
0/20 
0/10 
A. 10 L1210 cells were inoculated i.p. on day 0 in CD2F1 male mice. Treat­
ment i.p. on days 1-9. 
B. 10 L1210 cells were inoculated s.c. in the right scapular region of 
CD2F1 male mice. Treatment was i.V. on days 1-7. 
4 
C. 10 L1210 cells were inoculated intracerebrally on day 0 in CD2F1 male 
mice. Treatment was i.v. on days 1 - 7 . 
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Table 6. Antitumor activity of sparsomycin and its analogues on RC carcinoma 
Exp. 
A 
В 
drug 
I 
II 
III 
IV 
V 
VI 
VII 
III 
VI 
VII 
1 
dose 
range 
[mg.kg" ) 
0.125 - 1.0 
0.7 
1.4 
1.0 
9.0 
0.5 
3.2 
5.0 
- 2.3 
- 4.θ 
- 8.0 
-33.θ 
- 2.5 
- Θ.Ο 
- 5.θ 
-
-
median 
optimal 
dose 
(mg.kg"1) 
0.125 
1.5 
3.9 
3.4 
17.5 
1.6 
4.1 
5.4 
2.0 
6.0 
T/C range 
at optimal 
dose (% ) 
227 
139 
161 
230 
156 
153 
134 
-
-
- 600 
- 158 
- 179 
- 304 
-
- 159 
- 154 
- 141 
median 
T/C (%) 
100 
600 
414 
149 
170 
277 
197 
158 
154 
138 
LTS/total 
0/24 
9/24 
8/48 
0/48 
0/4Θ 
5/54 
0/24 
0/20 
0/20 
0/20 
A. 10 RC renal carcinoma cells were inoculated i.p. on day 0 in CD2F1 male 
mice. Treatment was i.p. on days 1-9. 
B. 10 RC renal carcinoma cells were inoculated s.c. on day 0 in CD2F1 male 
mice. Treatment was i.v. on days 1-7. 
For other explanations see footnote of Table 3. 
All the drugs were rather ineffective on ВІ6 melanoma (Table 7). The minimal 
activity criterion of T/C = 125% was reached only by the three most active 
compounds (i.e. Ill/ VI, and VIII) and was not higher than 131%. No activity 
was observed on M5076 sarcoma. In three s.c. growing tumors, only n-pentyl-
Sm showed some activity on C38 colon carcinoma (see Table 8) but none of the 
compounds was active on C22LR osteosarcoma and LL Lewis lung carcinoma. The 
GDF for positive controls at optimal doses on C22LR and LL tumors were all 
significantly higher than the GDF obtained with Sm analogues. 
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Table 7. Antitumor activity of sparsomycin analogues on ВІ6 melanoma and 
M5076 sarcoma. 
Exp. drug dose 
range 
median 
optimal 
dose 
T/C range 
at optimal 
dose (%) 
median 
T/C (%) 
LTS/total 
(mg.kg" ) (mg.kg" ) 
I 
III 
IV 
V 
VI 
III 
VI 
VII 
0.2! 
1.4 
1.0 
5.0 
1.0 
4.0 
2.0 
6.0 
- 1.5 0.5 
- 6.0 4.0 
- Θ.0 2.0 
-20.0 20.0 
- 3.4 2.3 
90 
131 
108 
116 
131 
84 
82 
90 
0/24 
0/20 
0/24 
0/24 
0/20 
0/12 
0/12 
0/12 
- 8.0 4.0 
- 4.0 2.0 
-12.0 6.0 
A. 1:10 tumor brei from a solid B16 melanoma was inoculated i.p. on day 0 in 
C57BL male mice. Treatment was i.p. on days 1-9. 
B. 10 M5076 sarcoma cells were inoculated s.c. in the right flanks of 
B6C3F1 male mice on day 0. Treatment was i.p. on days 1-9. 
For other explanations see footnotes of Table 3. 
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Table 8. Antitumor activity of sparsomycin analogues on C38 colon carcinoma, 
C22LR osteosarcoma and LL Lewis lung carcinoma· 
Exp. drug dose median GDF LTS/total 
range optimal 
dose dose 
(mg.kg" ) (mg.kg" ) 
A III 1.4 - 6.0 6.0 1.Θ7 0/20 
VI 1.0-3.4 2.3 0.98 0/20 
В III 2.0 - 4.0 4.0 0.99 0/10 
VI 1.0 - 2.0 2.0 0.79 0/10 
VII 3.0 - 6.0 6.0 1.0 0/10 
С III 2.0 - 4.0 4.0 0.39 0/10 
VI 1.0 - 2.0 2.0 0.92 0/10 
VII 3.0 - 6.0 3.0 0.35 0/10 
A. C38 colon carcinoma tumor fragment of about 1 mm were implanted in both 
flanks of C57BL male mice on day 0. Treatment was i.p. on days 2 - 10. 
B. 10 C22LR osteosarcoma cells were inoculated in both flanks of male 
(C57BLxCBA)F1 mice on day 0. Treatment was on days 2-10. 
C. 2 χ 10 cells of LL Lewis lung carcinoma were inoculated in both flanks 
of C57BL male mice on day 0. Treatment was i.p. on days 2 - 10. 
d. GDF - growth delay factor is the ratio of the tumor growth delay between 
control and treatment groups and the volume doubling time of the control. 
For other explanations see footnotes of Table 3. 
DISCUSSION 
The LD50 value for Sm in a multiple schedule (daily χ 9) is 0.26 mg.kg 
per inj., this value is 44 times lower than Sm's single LD50. For 
deshydroxy-Sm (VI) and ethyl-deshydroxy-Sm (VII) this ratio is 1:10, thus 
close to the number of the doses administered. These differences suggest 
that in daily schedules Sm may be only administered in small doses because 
of cummulative toxicity. This may explain the low activity of Sm (I) in all 
the models tested. 
The difference in LD50 values between Sm ( I) and deshydroxy-Sm (VI) 
correlates well with pharmacokinetic studies performed in mice (un­
published). In that study, deshydroxy-Sm (VI) had a total body clearance 
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that was twice as high as that for Sm. Thus, it seems probable, that removal 
of the hydroxyl group improves membrane transport as well as excretion of 
the drug. This is the reason why deshydroxy-Sm (VI) in contrast to Sm (I) 
does not accumulate in plasma. 
The antitumor activity of synthetic Sm (I) on P388 leukemia (T/C - 88%) 
is much lower than previously reported for the natural product (T/C= 
160%)(5). For L1210, the activity is comparable with the older data (5). New 
Sm analogues, selected according to their in vitro activity in cell free 
systems and the L1210 clonogenic assay, appeared to be more active that the 
parent drug. The in vitro activity of the drugs increased with the length of 
the hydrophobic R2 side chain until the optimum was reached (7,8). 
In vivo, increase of drug lipophilicity correlates well with the increase 
in LD50. But the increase of antitumor activity is much smaller than would 
be expected from the increased LD50. This is in contrast to much higher in 
vitro activity of more lipophilic compounds (7,8). 
The divergence between the in vitro and in vivo results may be explained 
by the pharmacokinetic behaviour of the compounds. Two compounds found to be 
active when tested on i.p. growing carcinomas deshydroxy-Sm (VI) and n-
pentyl-Sm (III), were inactive when administered to animals bearing a 
sensitive tumor (L1210 leukemia) inoculated s.c. Only ethyl-deshydroxy-Sm 
(VII) was active in this setting. In the RC carcinoma s.c. model all three 
compounds were moderately active. 
Compounds III, VI and VII showed no effect on L1210 leukemia growing 
intracerebrally. 
The good activity of the three compounds (i.e. Ill, VI and VII) on RC 
renal cell carcinoma is of interest, because this tumor showed a good re-
sponsiveness to drugs that are clinically active but inactive on L1210 
leukemia (hexamethyl-melamine, bleomycin and busulphan) (17). 
In conclusion, Sm analogues appeared to be moderately active on two 
lymphocytic murine leukemias (L1210 and P388) and on RC renal cell carci-
noma. None of the drugs were active on solid tumors. The n-pentyl-Sm (III) 
and the deshydroxy compounds (VI and VII) showed the highest antitumor 
activity in the tumor models tested. Ethyl-deshydroxy-Sm (VII) differed from 
the other drugs by its outstanding high LD50 and its activity on L1210 
leukemia s.c. The three most active compounds will be further investigated 
using human tumor xenografts in nude mice. 
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In Vitro Modulation of Cisplatin Cytotoxicity by Sparsomycin 
Inhibition of Protein Synthesis12 
Zblgnlew Zyllcz,3 D. J. Theo Wagener,э Helga van Rennes,3 Johannes M. С. Wessels,4 
Ерро van der Kleljn,5 Willem J. de Grip,6 Leon A. G. M. van den Broek,7 
and Harry С J. Ottenheljm7 8 
ABSTRACT—Inhibition ol protein synthesis can alter cellular re­
sponsiveness to the classical anticancer drugs The in vitro 
response of Chinese hamster ovary (CHO) cells to cisplatin with or 
without sparsomycin (Sm) was studied with the use of [3H]leucine 
and [meffty/-3H]thymidine incorporation and clonogenic assay 
Pretreatment of exponentially growing CHO cells with 1 мд Sm/ml 
for 3 or 5 hours decreased [3H]leucine incorporation by 20% and 
resulted in significant resistance to cisplatin (P= 005) Sm in a 
concentration of 10 (ig/ml reduced [3H]leucine and [me/rty/-3H]-
thymidme incorporation after 3 hours by 92 and 84%, respectively, 
and resulted in potentiation of the cisplatin cytotoxicity (P= 004) 
This effect was the same in the case of nonprolilerating cells 
( P = 005), while protection due to Sm (1 μg/π\\) was seen only dur­
ing cell proliferation Simultaneous incubation and postmcubalion 
with Sm proved to have much less or no potentiating effect on 
cisplatin The mechanisms of both protection and potentiation are 
still not clear, but our data indicate that Sm is a promising drug for 
further studies on the modulation ol the cancer cell response to 
classical anticancer drugs —JNCI 1987, 78 701-705 
A body of information indicates that protein synthesis 
inhibitors can positively modulate the responsiveness of 
malignant and normal cells to classical anticancer drugs 
(1-4). Many normal tissues proliferate faster than most 
of the human tumors (5, 6). Preferential inhibition of 
protein synthesis and subsequent cell cycle arrest in 
normal, but not in malignant, cells would make the 
normal tissues insensitive to the S-phdse-specifi< cyto­
toxic agents, and larger doses of these drugs could be 
safely administered (7) In support of this concept, pro­
tection by cycloheximide of rat bone manow against 
cytarabine and mechlorelhamine (8) as well as of rat 
intestinal mucosa against cytarabine (9) has been de­
scribed. 
In contrast to the protective effect on normal cells, 
protein synthesis inhibitors can directly influence cancer 
cells, exerting a synergistic effect with classical anti­
cancer drugs. Corbett and Gris wold (/0) reported that 
anguidine in combination with 5-fluorouracil cured 80% 
of mice bearing the C38 colon carcinoma. However, a 
clinical trial in patients with colorectal cancels failed to 
prove this synergism (11). Hromas et al (7) reported 
that anguidine enhanced the in vitro cytotoxic effect of 
cisplatin on CHO cells. Recently, we have reported on 
the in vivo potentiation of cisplatin antitumoi activity 
on L1210 leukemia-bearing m u e (12). To produce an 
optimal effect, Sm should be administered 3-6 hours 
prior to cisplatin. In these experiments, subtoxic Sm 
doses induced 67% of cures (vs. 0% for cisplatin alone) 
and better toleration of cisplatin. 
For further evaluation of this concept, we have studied 
the effect of protein synthesis inhibition by Sm on 
cisplatin cytotoxicity to CHO cells. 
In contrast to anguidine, Sm is readily accessible 
through total synthesis (IB), and some more active ana­
logues have recently been developed (14, 15). Further­
more, a sensitive assay for detection of Sm has been 
developed with the use of high-performance liquid 
chromatography (16). Sm has its site of interaction in 
the large nbosomal subunit, where it prevents peptide 
transfer by interfering with the peptidyl transferase cen­
ter (17, 18). Many prokaryotic and eukaryotic cells 
proved to be sensitive to Sm (19). The antitumor activity 
of Sm has been confirmed for P388 leukemia and 
Walker 256 carcinosaicoma (20). Recently, Sm was 
found to be differentially cytotoxic against many in 
vitro growing human tumor cell lines, but not against 
human bone marrow (21 ). 
This report presents the results of in vitro experiments 
evaluating the effect of Sm on CHO cells and the syner­
gism of Sm with cisplatin in the same model. Depen­
dent on concentration, Sm can antagonize or potentiate 
cisplatin cytotoxicity Mechanisms that may explain 
these phenomena are briefly discussed. 
MATERIALS AND METHODS 
Cell line.—CHO cells were grown routinely as mono­
layer cultures in closed tissue culture flasks (Costar, 
Cambridge, MA) at 37°C m a humidified atmosphere 
(Heraeus incubator) of 5% CO2 in air. We used Eagle 
ABBRFMATIONS ι SFD CHO=Chi i ie sc hamster ovary, r R N A = n b o s o m a l 
RNA, Sm = spaisomycin 
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minimum essenual medium with Lailes salts (GIBCO, 
Grand Island, NY) supplemented IA uh 2Γ> mM HEPFS'1 
buffer, 10% heal inadivated fetal calf serum (GIBCO), 
2 mM glutamine (ВоеЬипцеі Vlannheim GmbH, Mann­
heim, Fedeial Republu of Germanv), and ^0 μg genta 
micm/ml (Boehrmçer Mannheim GmbH) Cells were 
harvested by ireatmenl wuh 0 025% trypsin (type III, 
Sigma Ghenural Co , bt Louis, MO) and 0 00% EDT Л 
for 3 minules at room lemperatim 
Drugs —Sm was synthesized as described before (1 J) 
Cisplatin was purchased from Bristol-Meyers C o , New 
York, NY 
Incorporation studies—[mc^yii-'HIlhymidine (sp 
act, 5 Gi/mmol) and [3II]leuiine (sp act, 130 Ci/mmol) 
were puichased from Amersham Iniernauonal Ltd , 
Amersham Fngland For incorporation studies, 0 2ЬУ. 
106 tells immtdiately after indibation with drugs were 
suspended m 0 5 ml medium and incubated for 1 hour 
at 37CC with 1 μ Ο [methyl 4l]ihvmidin( and [3Н]1еи-
cine Incorporation of the label wasarnsted by addition 
of 250 μΛί cold thymidine and leucine, respectively 
(both from ϊ Merck A G , Darmstadt, Federal Republic 
of Germany) Cells were cennifuged at 600Xg for 10 
minutes at 20C, and the supernatant was removed 1 he 
residue was incubated overnight at 0CG with 2 ml ice-
cold 1 Л' HCIO4, then harvested on a Millipore micro-
fiber glass filter (type AP, Millipore Coi ρ , Bedford, 
MA), and counted in a liquid scintillatoi (Beekman 
Instruments, Irvine, CA) I he studies were performed on 
duplicate samples 
Ъипп аі studies on cells in exponential growth and 
plateau phase —To assess cell survival, we used the col­
ony formation technique, with minor modifications (2, 
7) Exponentially growing cells and plateau phase cells 
were obtained after 24 and 72 hours of growth, respec­
tively The modification was that, after incubation with 
drugs, a constant number of 100 tells was added to each 
culture dish Clusters containing more than 30-50 cells 
were counted as colonics Cell survival and colony for­
mation after drug treatment were assessed aflei 5-6 days 
of incubation and were normali?ed with respect to those 
of untreated controls, which had a plating efficiency 
varying between 45 and 70% All experiments were 
repeated at least twite with the use of triplicate samples 
for eath drug toncentration The results are presented as 
means ± SF 
Flow cytometric studies —Cells for flow cytometry 
were harvested, fixed, and stained as described before 
(22) DNA histograms were analyzed with the use of a 
flow cvtofluorograph svslem ЗОН (Ortho Instruments, 
Westwood, MA) 
RESULTS 
Effect of Sm on CHO cells (text fig 1) —The effect of 
Sm on [ 3H]leuune and [meiAyi-'Hllhymidine incorpo­
ration by CHO tells was dose dependent and incubation 
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fìars represeiH means ± Sl· Cells svere inrubaied ssith Sm indifferent 
concentralions for I 2 % or 4 hr 
time dependent, with a plateau at the higher dose level 
(50 μg/ml) Profound changes in protein and DNA syn­
theses had relatively little impact on the eventual cell 
survival as deduced from clonogemcity, which proves 
that most cells recovered after termination of drug incu­
bation From the above experiments two concentrations 
(1 and 10 μg/ml) with widely divergent effects were 
selected for further studies 
DNA histograms (text-ftg 2) —Exponentially grow­
ing cells were incubated for 8 hours in the medium con­
taining 0, 1, 5, or 10 /ug Sm/ml The end-point control 
after 8 hours of incubation was identical to that at the 
start of the experiment Incubation with 1 μg Sm/ml did 
not change the DNA histogram However, intubation 
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ГЕХТ FIGURF 2 — Fife« of 8-hr incubdiion with Sm of exponentially 
growing CHO cells on the DNA hisiogram Note similariiy between 
1 /ig Sm/ml and control At higher Sm (oncenlrations, there is a 
clear delay ш the cell cycle progression (the G| peak is thinner than 
in the control) and (ells accumulate in the late S-phase Notr also 
increase ol debris before the C| peak at 10 /ig/ml, probably due to 
the direct loxiuty of Sm to the cells 
Pretreatment of exponentially growing CHO cells with 
Sm at a concentration of 10 μκ/mì for 3 hours reduced 
[3H]leucine to 8% and [methyl- H]lhymidinc incorpora-
tion to 16%. The [3H]leu(ine incorporation did not 
decrease further after addition of cisplalin. The survival 
curve showed strong potentiation of cisplalin cytotoxic-
ity (P = .0(M). 
Simultaneous incubation and postincubation with 10 
μ£ Sm/ml —Simultaneous incubation of exponentially 
growing CHO cells with cisplalin and Sm (10 Mg/ml for 
3 hr) and postincubation with Sm (10 Mg/ml for 3 hr) 
inhibited [3H]leucine and [meiAy/-9H]thymidine incor­
poration to the same extent (10 and 18%, respectively) as 
in the case of preincubation. However, simultaneous 
incubation of Sm with cisplatin did not have any effect 
on cell survival (F = .312). Postincubation, instead, re­
sulted in a significant but small reduction in cell sur­
vival (P = .028) However, the shape of the survival curve 
(parallel to that of the control) suggests an additive 
rather than a synergistic effect. 
Cells in plateau phase.—Preincubation of CHO cells 
in the plateau phase with Sm at a concentration of 
1 Mg/ml for 5 hours did not change incorporation of 
[sH]leucine or [mef/iyí-'HJthymidine as well as cell sur-
vival. However, preincubation with Sm at a concentra-
tion of 10 Mg/ml for 3 hours considerably reduced 
['Hlleucine (to 20%) and [meiAy/-3H]lhymidine incorpo-
ration (to 50%) and significantly potentiated cisplatin-
induced cytotoxicity (P = .005). 
with 5 and 10 Mg Sm/ml resulted in a Gi-S transfer 
delay and accumulation in the late S-phase. 
Preincubation with 1 μ§ Sm/ml (text-fig. 3).—The 
20% decrease m [3H]leucine incorporation after intuba­
tion with 1 Mg Sm/ml for 5 hours was accompanied by a 
decrease in [mei/iy(-3H]thymidine incorporation inhibi­
tion induced by cisplatin. The difference was significant 
after 5 hours of incubation at all ''isplatin concentra­
tions (Р<.05). The cells were apparently protected 
against cisplatin cytotoxicity (P = .0¡05). Table 1 gives 
further details. 
Preincubation with 10 μ§ Sm/ml (text-fig. ì).— 
DISCUSSION 
Our data show that Sm is a highly effettive inhibitor 
of protein synthesis, inducing profound but readily 
reversible biochemical perturbations. From the data 
available on Sm it is known that its interaction with the 
nbosome is irreversible (23). Upon inhibition of protein 
synthesis, the cell responds by temporaiily enhancing 
ihe biosynthesis of rRNA (24), providing new nbosomes 
that should replace those occupied by the drug. In the 
later stage the rRNA synthesis decreases and the capacity 
of the cell to restore its biosynthesis decreases as well. 
Sm at a low concentration (1 Mg/ml) is able to inhibit 
TABLE 1 —Effect of Sm on ciaplatm-induced cytotoricity Analysis of differences between control and test cunvs 
Experiment Sm incubation time, hr 
3 
5 
3 
3 
3 
5 
3 
Sm concentration 
»B/ml 
1 
1 
10 
10 
10 
1 
10 
D M 
difference" AUG ratio' 
Exponential growth 
Preincubation 
Simultaneous incubation 
Postincubation 
Plateau-phase cells 
Preincubation 
+ 0.8 
+3 9 
-2 .5 
0 0 
-2.3 
- 0 2 
-4.1 
.065 
.005* 
.004· 
.312 
028· 
.088 
.005· 
143 
158 
36 
95 
58 
98 
32 
" D50 is the concentration of the drug required for 50% reduction of cell survival, expressed as the difference between the treatment and 
control cell populations (Г-С) 
'' Significance level I' as calculated from the Wilcoxon two sample test comparing two survival curves at the level of 5 jig cisplatin/ml. 
Accepted significance level: Ж.05 (*) 
*• AUG = area under the curve expressed as treatment-to-control ratio {T/C X 100%). 
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1 FXT FIGI RF ì — Fffecl of Sm preincubation on cisplalin cytoloxicity 
to pxponcntially growing CHO cells Bars rcpresim means ± St 
Either the cells were tnctibjied wuh different concentrations of cis 
plann alone (control) or the incubation with cisplalin was preceded 
by incubation with Sm 
only up to 20% of [5H]leucine incorporation without 
cytotoxic consequenceb Sm at a high concentration (50 
fig/ml) dramamally decreases pHJleucine incorporation 
to 5% This residual '5% is apparently resistant to Sm 
Under these conditions, however, nbosomal protein syn-
thesis is completely inhibited The cells are rapidly 
depleted from the en/ymes with a high turnover, and 
cell death follows The biological effect of Sm at a con-
centration of 5 or 10 μ§/Γη1 is linearly dependent on the 
incubation time Up to a certain point, most of the cells 
survive and arc able to proliferate 
Sm at a low and nontoxic concenlrauon (1 μg/ml) 
actually protects the cells against cisplalin cytotoxicity 
At this (oncentration, Sm does not influente proiçres-
sion through the cell cycle Kishimoto and I lebtrman 
(25) and Veibin and barber (26) suggested that a tell 
cycle step in the S-Gj transit phase might be \ery sensi 
uve to the piotein synthesis inhibitors pu ronmm and 
cycloheximidi We have considered the possibility that 
Sm at a concentration of 1 μς ml can also inhibit this 
step and would subsequently synchronize cells in an 
S phase relatively insensime to cisplatm (18) Text 
figure 2 deaily demonstrates that sudi an effect does not 
occur at the level of 1 μg ml, but onh begins to app<ar 
at much highei contintrations and after a much longer 
incubation time However, even then, the synchroniza­
tion is not complete and should, therefore, have onl> a 
minor impact on cisplatin sensilmty I hits the observed 
protective effen is not due to changes in the cell tyde 
ЛпоіЫг explanation tould involve inhibition of the 
synthesis of an unknown cisplalin agonist I he exis­
tence of such a protein agonisi has been postulated (27, 
28), but never definitely proved Such a mechanism of 
protective action, however, seems unlikely, because Sm 
at higher concentrations is expected to inhibit the syn­
thesis of the agonisi as well, and this is not in agieement 
with the potentiation effect that we observed Λ further 
explanation might be that Sm at low conccntialions 
may selectively inhibit degradation of one or moie cis­
platin antagonists or enhance their synthesis due to 
increased RNA pioduction In that case the concentra­
tion of the antagonist should increase during preincuba­
tion, and more cisplatin molecules should be inacti­
vated I his in turn should result in decieased cisplalin 
interaction with DNA and does explain the reversal of 
the inhibition of [methyl sH]lhyinidiiie incorporation 
that we observed Sm at higher concentrations (i e , ^ 
and 10 μg/ml) will reduce protein synlhesis in a rather 
aselective way This may result in both a reduced turn­
over of cisplatin antagonist and/or a dramatic reduction 
in the de novo synlhesis The decreased capacity of the 
cell to pioduce antagonist during preincubation will 
increase its sensitivity to cisplatin 
The absence of cell protection in the case of the 
plateau phase cells could be due to the different cell 
densities and different cell number and drug relation­
ships that we used 
Prohferaling and nonproliferaling cells are equally 
sensitive to cisplalin (29) Sm ai higher concentrations 
potentiates cisplatin activity against both proliferating 
and nonproliferaling cells This reaction is similar to 
that described for anguidinc by Hromas el al (7) How­
ever, Sm acts differently from anguidinc The dominant 
effect of anguidme at low concentrations was a frozen 
cell cycle ' with virtually no cyloloxic expense ' Sm at a 
concentration up to 10 μg/ml, instead, does not induce 
ci ι cycle arrest but is already cytotoxic and does not 
r quire this mechanism to become able io potenliate 
cisplalin activity I his shows that cell cycle arrest is not 
a prerequisite for such an effect, as was suggested ear­
lier (7) 
Sm at a high concentration (10 μg/ml) inhibits 
[3H]lcucine and [me//iy/-sH]thymidine incorporation io 
the same extent in preincubauon, simultaneous incuba-
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tion, and postincubation setunsçs, but the biological 
effect of this inhibition is different Only cells preincu 
bated with Sm show strong potentiation of cisplalin 
cytotoxicity This implies that the reaction step inhib-
ited by Sm is localized close to the point of cisplatin 
addition Ί his could be explained if Sm would inhibit 
synthesis of cisplatin antagonists like glutathione (30) 
or metallothionein (31, 32) and/or would inhibit the 
synthesis of the DNA repairing enzymes induced by the 
action of cisplatin 
To address these questions, we are investigating the 
concentration of cisplatin-DNA adducls as well as their 
biological half life 
A similar concentration dependency of protection and 
potentiation was described by Pitillo el al (13) for the 
effect of Sm on irradiated Escherichia coli bacteria I ow 
Sm concentrations protected E coli against radiation, 
whereas high Sm concentrations potentiated radiation-
induced cytotoxicity 
In conclusion, the intensity and duration of the Sm-
induced inhibition of protein synthesis may become a 
useful and selective tool for manipulation of the cellular 
response to the cytotoxic effect of cisplatin Our in vivo 
observations on L1210 leukemia bearing mice (12) give 
a new dimension to this statement This may open new 
therapeulK prospects in the biochemical modification of 
normal and cancer cells 
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SUMMARY 
The influence of protein synthesis inhibition by sparsomycin (Sm) on in 
vivo cisplatin activity has been studied on BALBc X DBA2 : F, mice bearing 
L1210 leukemia i.p. Sm alone at the dose range from 0.5 to 3.0 mg/kg did 
not significantly improve animal survival. Sm potentiated cisplatin activity 
only when given 3 or 6 h prior to cisplatin (P < 0.001). Sm 0.5—1.5 mg/kg 
3 h prior to cisplatin resulted in a significant prolongation of animal survival 
(P < 0.001) and 66% cures in each group versus 0% due to cisplatin alone. 
Sm pretreatment decreased weight loss due to cisplatin suggesting that it 
probably is able to decrease cisplatin toxicity. 
INTRODUCTION 
Sm (NCS-059729) is known as an inhibitor of ribosomal protein synthesis 
[1] . Besides antibacterial, antiviral and antifungal activity the drug also 
appears to be active against several rodent tumors [ 2] . Sm is borderline active 
(T/C = 125%) against L1210 leukemia [3]. 
In 1980 the total synthesis of Sm was reported [4] and several more active 
and less toxic analogues have been prepared [5]. 
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Netherlands. 
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Recently, we have found that pretreatment of exponentially growing 
Chinese hamster ovary cells (CHO) with Sm in a concentration of 10 ßg/ml 
resulted in significant potentiation of the cisplatin cytotoxicity (unpublished 
data) This effect was the same in the case of non-proliferating cells. Simul-
taneous and postmcubation treatment with Sm proved to have much less 
or no potentiating effect on cisplatin. Surprisingly, pretreatment of exponen-
tially growing CHO cells with 1 ßg/mi Sm for 3 or 5 h resulted in significant 
resistance to cisplatin The mechanism of both protection and potentiation 
is still not elucidated, but our data indicate that Sm might influence the 
activity of cisplatin antagonists. 
This study was focused on 3 topics: confirmation of the Sm/cisplatin 
synergism in an in vivo model, search for the optimal doses and schedules of 
both drugs and orientative determination of the drug combination toxicity. 
MATERIALS AND METHODS 
Animals 
Female BALBc X DBA2 F, mice weighing 20—24 g were supplied by TNO 
Rijswijk, The Netherlands Animals were housed in plastic cages with wire 
bottoms. Drinking water, food, temperature, air humidity and light condi-
tions were provided according to the NCI standards [10]. The stock of L1210 
cells received from TNO Rijswijk, was stored frozen in liquid nitrogen. Cells 
went through 1 passage before every new experiment. Mice were injected 
i.p. on day 0 with IO5 L1210 cells suspended in 0 1 ml buffered saline and 
then randomized in the test and control groups. The tumor cell suspension 
was injected with a sterile 27 G needle (1 needle per mouse) to avoid forma-
tion of subcutaneous lymphomas. Each test group consisted of 6 mice. 
Experiments were repeated at least twice to achieve good reproducibility. 
Data presented m the figures are the means of those experiments. 
Drugs 
Sm was synthesized as described previously [4] and cisplatin (Platinol) 
was purchased m a freeze dried form from Bristol Meyers, USA. Cisplatin 
was dissolved in 0.9% NaCl The drugs were injected in a volume of 0.1 ml/ 
10 g of mouse. 
Treatment protocol 
Mice were injected on days 1, 5 and 9 i.p. according to the protocol in 
Fig 1. Animals were weighed on days 1 and 5. Good randomisation was 
ascertained if the weight of an individual animal varied less than 7.5% from 
the mean weight of all animals. Animals were weighed individually on days 
1 and 5. Weight loss was defined as the difference in mean group body weight 
on day 5 less that on day 1 ± S.D.). The significance of the difference in 
weight loss between the groups treated with cisplatin alone and Sm/cisplatin 
combination was determined using Wilcoxon test for unpaired samples;Ρ < 
69 
55 
τ 1 — ι — ι — ι 
-12 - 6 -3 0 +3 h o u r s 
E x p . l . 
Day 1. i and 9 I CDDP 2 mg/kg 
,t M l t -
S p a r a o o y c l n l . ! ) mg/kg 
Еяр.2. 
Day 1, % and 9 I CDDP } mg/kg 
Sin 0 . 2 5 , 0 . 5 , 1, 1.5, 2, 3 mg/kg 
Exp.3 . 
Day I, 5 and 9 I CDDP 1, 3, 5, 7.5, 10 «g/kg 
Sm I.5 mg/kg 
Fig. 1. Treatment protocol. 
0.05 was accepted as a significance level. The survival curves of animals 
treated either with cisplatin alone or with Sm and cisplatin at the same dose, 
were compared with each other using the Mantel-Haenszel procedure [10]. 
RESULTS 
The median survival time (MST) of the untreated controls ranged from 9 
to 10 days (Fig. 2, control a). Sm alone (1.5 mg/kg), given on days 1, 5 and 
9 showed no antitumor activity (Fig. 2, control b). Cisplatin alone at the 
doses used showed optimal activity at the level of 5.0 mg/kg (MST = 3 1 days, 
Fig. 3). 
Experiment 1 
In this experiment, drugs were combined with each other using about half 
the maximal tolerable doses, i.e. 1.5 mg/kg Sm and 2.0 mg/kg cisplatin. Sm 
was given 12, 6 and 3 h before, simultaneous to, or 3 h after the cisplatin 
(Fig. 2). When applied 12 h before, simultaneous to, or 3 h after the cisplatin, 
little effect of Sm over cisplatin alone was observed (MST = 17—19 days). 
However, when Sm was given 3 or 6 h before cisplatin the difference between 
the curves was highly significant (P < 0.001) and the MST were 26 and 27 
days, respectively. For practical reasons a 3-h pre-treatment with Sm has been 
selected and this schedule has been kept constant during the following exper­
iments. There were no significant differences in weight loss between the 
groups treated with cisplatin alone or Sm/cisplatin combination. 
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Fig. 2. Survival of animals treated with 2.0 mg/kg cisplatin alone ( ) or Sm 1 5 mg/kg 
prior to the same dose of cisplatin ( ). The time intervals between Sm and cisplatin 
injections and significance levels are indicated. Control a ( ) represents a group of un­
treated animals. Control Ь (· · · ) represents survival of animals treated with Sm 1.5 mg/ 
kg alone on days 1, 5 and 9. 
Experiment 2 
When Sm in escalating doses was combined with a fixed cisplatin dose (3.0 
mg/kg), a significant effect was already obtained with 0.5 mg/kg Sm (Fig. 3, 
Ρ < 0.05). Pretreatment with 0.5—1.5 mg/kg of Sm prior to cisplatin, signifi­
cantly prolonged animal survival and completely cured 4 out of 6 animals in 
% Sur-
50 
0-
too· 
0-
Sm QSmg/kg 
p<005 
Sm 1 mg/kg 
р<0£Ю1 
Sm 1 5mg/kg 
ρ < 0001 
Sm 2 mg/kg 
days 
20 60 0 20 L0 60 
Fig. 3. Survival of animals treated with 3 mg/kg cisplatin alone ( ) or Sm in variable 
doses injected 3 h prior to the same dose of cisplatin ( · · · ) · The effect of 0.25 mg/kg Sm 
and cisplatin was not significant and it is omitted in this figure. 
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each group. The deaths which were observed appeared during the late phase 
of the experiment and were certainly not due to toxic effect of the drug(s). 
At the higher dose level (> 2.0 mg/kg), Sm potentiated cisplatin toxicity. 
Experiment 3 
In the third experiment, Sm (1.5 mg/kg) was combined with escalating 
doses of cisplatin (Fig. 4). Sm improved animal survival considerably. The 
differences between the survival curves were significant at 3.0 mg/kg (P < 
0.001) and 7.5 mg/kg ( P < 0.05). At the level of 5.0 mg/kg the difference 
fell just below significance. However, again, in all 3 groups, 4 out of 6 mice 
were cured. Sm prevented early toxic death in the group treated with 7.5 mg/ 
kg cisplatin. This effect was seen in 2 independent experiments. Interestingly, 
Sm tended to limit the cisplatin induced weight loss (see Table 1) at the 
higher cisplatin doses. This effect was significant at the cisplatin dose of 
7.5 mg/kg (P < 0.01) and 10.0 mg/kg (P < 0.05). 
DISCUSSION 
The in vitro potentiation of cisplatin cytotoxicity recently found by us 
(unpublished data) has now been suggested in an in vivo model. Just as in 
%5urvival 
100· 
SO­
CI-
100-
50· 
0-
Ί 
CDDP 1 mg/kg" 
ns 
CDDP 5 mg/kg 
p<aooi 
"I CDDP75mg/kg ]' 
, I -- -, p<Q001 l 
CDDP 1Q mg/kg 
ns 
1 days 
20 40 60 0 20 60 
Fig. 4. Survival of animals treated with different cisplatin doses either alone ( ) or 
with Sm pretreatment of 1.5 mg/kg ( ). The effect of 3.C mg/kg cisplatin with or 
without Sm was omitted here and is to be found in Fig. 3. 
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TABLE 1 
MEAN BODY WEIGHT LOSS IN EXPT. 3 + S.D. 
Cisplatin 
dose ( 
0 
0 
0 
0 
0 
1.0 
3.0 
5.0 
7.5 
10.0 
1.0 
3.0 
5.0 
7.5 
10.0 
:mg/kg) 
Sm 
dose 
0 
0.5 
1.0 
1.5 
2.0 
0 
0 
0 
0 
0 
1.5 
1.5 
1.5 
1.5 
1.5 
(mg/kg) 
Weight 
loss (g) 
days 1—5 
+ 1.3 
- 1 . 1 
f0.4 
+ 0.1 
0.9 
+ 1.1 
1-1.6 
0.6 
- 3 . 1 
- 3.1 
+ 1.2 
+ 0.2 
- 0 . 1 
- 0 . 5 
- 1 . 8 
+ S.D., 
0.3 
0.3 
0.4 
0.2 
0.3 
0.3 
0.9 
Γι Λ 
υ.4 — 0.5 
0.5 
0.2 
0.4 
0.5 
0.5 
0.6 — 
Ρ 
Ι <ο.οι 
<0.05 ) 
1 
—1 —1 
—' 
~| | 
ns
a 
1 
J 
ns, not significant. 
vitro the pretreatment with Sm was essential for the enhancement effect. This 
suggests that the factor(s) involved in this reaction is (are) not present in the 
tumor cell at the moment of cisplatin administration and its induction is 
either blocked or delayed by Sm. Alternatively, the factor(s) may be present 
in the cell before cisplatin administration but have a short half-life. Inhibition 
of protein synthesis by Sm several hours before cisplatin injection decreases 
the activity of this hypothetical factor(s) and thereby blocks cellular defenses 
against cisplatin toxicity. 
In the dose range of 0.5—1.5 mg/kg Sm, given in combination with 3.0— 
7.5 mg/kg cisplatin, Sm does not increase the toxicity of the latter. Instead 
of this, combination of those drugs appears not only highly effective against 
the tumor cells but also less toxic than cisplatin alone suggesting that normal 
and malignant cells may have different susceptibility to the drug combination. 
The exact mechanism of this drug synergism is still unknown. Studies 
evaluating possible involvement of cisplatin antagonists [6—8] as Sm target 
are in progress. 
In conclusion, this study opens a new possibility of chemical modification 
of the cancer cell on the translational level which may have a profound 
influence on the therapeutic effect of cytotoxic drugs. However, the data 
reported here should be interpreted as preliminary. To confirm the hypothesis 
we are actually studying Sm/cisplatin activity against murine solid tumors. 
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CHAPTER 6.2 
IN VIVO POTENTIATION OF CISPLATIN ANTITUMOR ACTIVITY BY PRETREATMENT 
WITH DESHYDROXY-SPARSOMYCIN AND ETHYL-DESHYDROXY-SPARSOMYCIN 
(unpublished) 
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After completing the series of experiments on potentiating cisplatin ac-
tivity by pretreatment with sparsomycin (Sm) in L1210 leukemia i.p. (Chapter 
6) we performed two similar series of experiments using two promising des-
hydroxylated analogues: deshydroxy-Sm (dSm) and ethyl-deshydroxy-Sm (EdSm). 
The tumor model was modified, and L1210 leukemia cells were inoculated s.c. 
In the same model, EdSm but not dSm showed antitumor activity when adminis-
tered i.v. (see Chapter 4). We, then performed two experiments in order to 
further discriminate active and non-active analogues. 
CDJF-J male mice weighing 25 - 30 g, were inoculated s.c. with 10 vital 
L1210 cells and were treated with drugs i.p. on days 1, 5 and 9. dSm and 
EdSm were administered 3 hours prior to cisplatin. Animals were weighed on 
day 1 and 5 of the experiment. Other protocol details are the same as in 
chapter 4 and 6. The results are expressed as the T/C ratios of the median 
survival times of the treatment (T) and control (C) groups, respectively. 
RESULTS 
The weight loss (T-C) was less than 4 g in the groups of animals treated 
with doses less than 7.5 mg cisplatin/kg. Pretreatment with both dSm and 
EdSm, potentiated weight loss induced by cisplatin. dSm appeared to be 
ineffective in potentiation of cisplatin activity (Fig.1). The potentiation 
up to T/C = 188% seen at the level of 7.5 mg cisplatin/kg was accompanied by 
the weight loss of 4.0 - 5.8 g. EdSm showed significant potentiation of the 
antitumor effect of cisplatin at the dose of 10 and 15 mg EdSm/kg preceding 
5 mg cisplatin/kg (Fig.2). The maximal T/C value obtained at this level was 
313%. One of the six animals from this group survived longer than 60 days 
and was considered to be cured. The weight loss in animals treated with this 
combination of drugs was 1.8 to 3.2 g. 
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3
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Fig. 1. Potentiat ion of c i s p l a t i n antitumor a c t i v i t y by pretreatment with 
deshydroxy-Sm (dSm). The resu l ts are expressed as the T/C r a t i o . 
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ethyl deshydroxy - Sm. ( mg · kg - • ) 
cisplatin 
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Fig. 2. Potentiation of cisplatin antitumor activity by pretreatment with 
ethyl-deshydroxy-Sm (EdSm). The results are presented as the T/C 
ratio. 
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DISCUSSION 
Cisplatin alone was only moderately active on L1210 leukemia s.c, 
whereas EdSm showed only minor activity when administered alone. In combi-
nation/ EdSm appeared to potentiate antitumor activity of cisplatin. The 
effect was significantly higher than the sum of the effects of each drug 
alone. dSm appeared to be ineffective in this setting. EdSm potentiated 
also weight loss induced by cisplatin but in the groups showing maximal 
therapeutic effects the weight loss was still lower than 4 g. EdSm thus, did 
not protect animals from the weight loss induced by cisplatin as it was 
described for Sm in Chapter 6. 
The results of this study indicate, that EdSm might be a drug of choice 
for further preclinical studies on the synergism between sparsomycins and 
cisplatin. 
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CHAPTER 7 
MODULATION OF IN VITRO CYTOTOXICITY OF SEVEN ANTICANCER DRUGS BY 
PROTEIN SYNTHESIS INHIBITION USING SPARSOMYCIN 
Zbigniew Zylicz, D.J. Theo Wagener, Helga van Rennes, Paul A.J. Speth, 
Johannes M.C. Wessels, Leon A.G.M. van den Broek, Harry C.J. Ottenheijm 
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SUMMARY 
Inhibitors of protein synthesis may modify cell response to cytotoxic drugs. 
The influence of protein synthesis inhibition using sparsomycin (Sm) on the 
cytotoxicity of seven classical cytotoxic drugs: 5-FU, ARA-C, MTX, doxo-
rubicin, melphalan, bleomycin and vincristine was studied. Preincubations, 
simultaneous incubations and postincubations with Sm were investigated in 
vitro on CHO cells. Preincubation with Sm antagonized the activity of all S 
phase specific drugs 5-FU, ARA-C, MTX, and vincristin, while postincubation 
with Sm enhanced their efect. A similar pattern was observed with doxo-
rubicin. Preincubation with Sm potentiated non-S phase specific drugs like 
bleomycin and cisplatin, but not melphalan. Postincubation with Sm had a 
potentiating effect on bleomycin but had no effect on melphalan. These 
results indicate a strong, schedule dependent effect of Sm on various drugs 
and suggest some potentially useful combinations to test in vivo. 
INTRODUCTION 
A number of protein synthesis inhibitors (PSIs) have been shown to interact 
with anticancer drugs (1-9). PSI may either potentiate the activity of the 
classical cytotoxic agents on tumor cells (3,4,7) or protect normal cells 
from their toxicity (1,2,8). Both phenomena have been observed in vitro 
(6,8,10,11), in animal studies (1-4,9) and in the clinical therapy (12-14). 
There are sufficient data to suppose that PSIs may act differentially on 
transformed cells while normal cells will be protected (8-11). In patients 
with acute lymphocytic leukemia, inhibition of protein synthesis by L-
asparaginase after the administration of either MTX or ARA-C greatly in-
creases the therapeutic index (12,14). The fact that L-asparaginase is only 
active on human lymphocytic leukemia has hampered further development of 
this concept. Many other PSIs tested in the clinical setting were found to 
be too toxic in phase I studies, and none showed satisfactory single agent 
activity. However, all were natural products selected on P388 leukemia. None 
were available as a synthetic product for extensive toxicity and structure 
activity relationship studies. 
Sparsomycin (Sm) is the only PSI that is potentially modifiable through 
chemical synthesis, and development of less toxic analogues can be expected 
in future (15,16). Recently, we reported on the synergism between Sm and 
cisplatin on CHO cells in vitro (17) and L1210 leukemia in vivo (18). 
Preincubation with Sm appeared essential for the potentiating effect, and 
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this was dose dependent. Low Sm concentration (1 μ<3 Sm/ml for 5 hours) 
effectively protected CHO cells from cisplatin toxicity, while higher con­
centration (10 μg Sm/ml for 3 hours) greatly increased the cytotoxicity of 
cisplatin (17). Post and simultaneous incubations with Sm had less or even 
no effect. 
Here, we report on the Sm mediated modulation of the in vitro cyto­
toxicity on CHO cells of seven clinically important anticancer drugs. Com­
parison between the pre and post incubations with Sm gives valuable indi­
cations about the mechanism of these interactions. The results of this study 
can help in selecting the most interesting drug combination for further in 
vivo investigations. 
MATERIALS AND METHODS 
Cell line 
CHO cells were grown routinely as monolayer culture in MEM, in closed tissue 
culture flasks as previously described (17). 
Drugs 
Sm was synthesized as previously described (16). Melphalan was obtained from 
Wellcome, Great Britain; ARA-C, MTX and vincristine, from Bergel Manufac­
turing, Nijmegen, The Netherlands; Doxorubicine, from Farmitalia, Italy; 5-
FU from Hoffman-La Roche, Switzerland; and bleomycin from Lundbeck, F.R.G. 
The drugs were dissolved aseptically before each experiment. Incubation 
times were as follows: 5-FU and ARA-C, MTX and vincristine, 18 hours; doxo­
rubicine, 1 hour; melphalan, 1 hour, and bleomycine, 3 hours. 
Cell survival studies 
To assess cell survival the colony formation technique was used as pre­
viously described in detail (17). Cells in exponential growth were incubated 
in a medium containing Sm for 3 or 5 hours either before (preincubation) or 
after (postincubation) incubation with other cytotoxic drugs. Some exper­
iments were performed with simultaneous incubation. After incubation, the 
cells were gently trypsinized, counted and known aliquote of the cells were 
plated in culture dishes. The number of cells plated was adjusted to the 
expected effect of the treatment to provide 30 - 40 colonies per dish. Cell 
survival and colony formation after drug treatment were assessed after a 6 
day incubation in a drug free medium. A colony has been defined as an 
aggregate of more than 3 0-50 cells. The results were normalized with respect 
Θ1 
to untreated controls which had a plating efficiency varying between 45 and 
70%. The survival of the cells (clonogenicity) is expressed on a dose/log 
survival plot. The mean and SEM of two independent triplicate observations 
is provided for each point. The areas under the curves (AUC) were used to 
calculate the treatment/control ratios (cytotoxic drug with Sra over drug 
without Sm). Treatment/control (T/C) values higher than 1.50 and lower than 
0.50 were defined as significant· 
RESULTS 
The effect of Sm on CHO cells 
When administered as a single drug, Sm at concentrations of 1 or 5 pg/ml 
for 3 to 5 hours had no influence on cell survival. At 10 jig Sm/ml for 3 
hours, cell survival varied from 80 to 100%. 
Antimetabolites 5-FU, ARA-C and MTX 
Preincubation of exponentially growing CHO cells with Sm (10 ¿ig Sm/ml for 3 
hours) antagonized the cytotoxic effect of 5-FU, ARA-C, and MTX (see Fig.1-
3). In the case of 5-FU, a similar effect was obtained with 1 ^ ig Sm/ml for 3 
hours (see Table 1), suggesting a great sensitivity to protein synthesis 
inhibition. Simultaneous incubation of Sm and 5-FU during the first 3 hours 
of the experiment showed neither the inhibitory nor the enhancement effect 
(Table 1). Postincubation with the same Sm concentration (10 pg Sm/ml for 3 
hours) showed a marked increase in the cytotoxic effect of all the three 
antimetabolites. This enhancement in the cytotoxicity of ARA-C and MTX did 
not, however, change the pattern of the control curve. When CHO cells were 
resistant to high doses of ARA-C (see Fig.3), this resistance persisted 
after postincubation with Sm. Only in the case of 5-FU, did postincubâtion 
increase the slope of the exponential part of the curve (see Fig. 1). 
Doxorubicin 
Preincubation of CHO cells with 1, 5 and 10 jig Sm/ml showed significant 
antagonism at the two higher Sm concentrations (see Fig. 4 ) . The reaction 
was probably time dependent as 5 ug Sm/ml for 5 hours had a stronger effect 
than 10 jig Sm/ml for 3 hours (T/C ratios 2.2 and 1.7, respectively, see 
Table 1). At low concentrations no effect was seen after 3 nor after 5 hours 
of incubation. Postincubation with 10 pg Sm/ml showed no significant poten-
tiating effect (T/C ratio 0.8). 
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Pig.1. 
Survival (clonogenicity) of CHO 
cells treated for 18 hours with dif­
ferent concentrations of 5-FU ( · ). 
Preincubation of these cells with 10 
jigSm/ml for 3 hours ( о ) rendered 
cells insensitive to 5-FU. Postincu­
bation with 10 μg Sm/ml for 3 hours 
( • ) potentiated cytotoxic effect of 
5-FU. 
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Fig. 2. Cytotoxic effect of ARA-C incubation for 18 hours ( · ) on CHO 
cells. Pretreatment of the cells with 10 pq Sm/ml for 3 hours 
rendered cells resistant to ARA-C (О) (left panel). Postincubation 
of the cells with 10 μq Sm/ml for 3 hours potentiated cytotoxic 
effect of ARA-C (•) (right panel). 
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Fig. 3. Cytotoxic effect of ΚΓΧ on CHO cells after 16 hours of incubation 
with the drug ( · ). Preincubation with 10 pg Sm/ml for 3 hours ( O ) 
rendered cells resistant to MTX. Postincubation with 10 jjg Sm/ml for 
3 hours ( • ) potentiated the cytotoxic effect of MTX. 
% survival 
Fig. 4. 
Effect of doxorubicin in different 100-
concentrations on survival (clono-
genicity) of CHO cells incubated for 1 
hour with the drug ( · ). Preincu­
bation of these cells with 5 μq Sm/ml 
for 5 hours antagonized the cytotoxic 
effect ( о ). Post-incubâtions with 10 
μg Sm/ml for 3 hours slightly poten­
tiated cytotoxic effect of doxo­
rubicin ( • ). 
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Table 1. Modulation of cytotoxicity of the anticancer drugs by sparsomycin. 
Drug pre- simultaneous 
incubation incubation 
post- T/C 
incubation ratio 
pg Sm/ml(hours) 
5-FU 1.0 (3) 
10.0 (3) 
10.0 (3) 
10.0 (3) 
2.31 
2.10 
1.16 
0.36 
ARA-C 10.0 (3) 
10.0 (3) 
2.70 
0.21 
MTX 10.0 (3) 
10.0 (3) 
1.92 
0.26 
Doxorubicin 1.0 (3) 
1.0 (5) 
5.0 (5) 
10.0 (3) 
10.0 (3) 
1.10 
1.02 
2.23 
1.73 
0.75 
Melphalan 1.0 (5) 
10.0 (3) 
10.0 (3) 
1.91 
1.24 
0.75 
Bleomycin 10.0 (3) 
10.0 (3) 
0.34 
0.46 
Vincristine 10.0 (3) 
10.0 (3) 
1.57 
0.31 
Cisplatin 1.0 (5) 
10.0 (3) 
10.0 (3) 
10.0 (3) 
1.5Θ 
0.36 
0.95 
0.58 
* data from the reference 17. 
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Melphalan 
Preincubation with 1 jig Sm/ml for 5 hours showed a strong antagonistic 
effect (T/C ratio 1.9, see Fig. 6) while preincubation with 10 ug Sm/ml 
showed a much weaker and insignificant effect (T/C ratio 1.2, data not shown 
in Fig. 5). Postincubâtion showed an insignificant effect as well (T/C ratio 
0.8). 
1 2 3 4 
melphalan (j jg / ml ) 
Fig. 5. Cytotoxic effect of melphalan incubated for 1 hour on survival 
(clonogenicity) of CHO cells ( · ). Pretreatment with a low Sm 
concentration, 1^gSm/ml for 5 hours, ( о ) significantly decreased 
the cytotoxic effect. Post incubât ion with 10 ¿igSm/ml for 3 hours 
( • ) did not change the survival. 
Bleomycin 
Both, preincubation and postincubation with 10 ug Sm/ml for 3 hours showed 
significant potentiation of the cytotoxic effect (T/C ratios 0.3 and 0.5, 
respectively, see Fig. 6). 
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Fig. 6. Cytotoxic effect of bleomycin incubated for 3 hours on CHO cells 
( · ). Preincubation with 10 ugSm/ml for 3 hours (o) potentiated the 
cytotoxicity of bleomycin. Similar effect was observed in case of 
postincubation ( • ). 
Vincristine 
Preincubation with 10 pg Sm/ml for 3 hours showed an antagonistic effect 
(T/C ratio 1.6, see Fig. 7 ) , while postincubâtion with the same concen-
tration showed a significant potentiation effect (T/C ratio 0.3). The en-
hancement effect due to Sm postincubâtion did not result in a change of the 
pattern of the control curve. 
Fig. 7. 
Cytotoxic effect of Vincristine in-
cubated for 16 hours on CHO cells 
( · ). Preincubation with 10 ug 
Sm/ml for 3 hours ( о ) rendered the 
cells resistant to vincristine. 
Postincubation with 10 jig Sm/ml for 
3 hours potentiated the cytotoxic 
effect of Vincristine ( • ). 
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DISCUSSION 
Little is known about the interaction mechanisms of PSI with other drugs· In 
general PSI may inhibit synthesis of proteins involved m 1. membrane 
transport, 2. intracellular activation, 3. intracellular inactivation, 4. 
interaction with DNA, and 5. DNA repair. The effect will be inversely 
related to the biological half-lives of the proteins involved. The site of 
interaction (a specific protein) could be different for each drug or class 
of drugs. 
The antagonistic effect of protein synthesis inhibition by Sm on the 
cytotoxicity of 5-FU, ARA-C, and MTX is similar to the effect of pre-
incubation with anguidine (6,19), This effect has been called protection, 
but "antagonism" probably describes this phenomenon better. When MTX was 
preceded by cycloheximide, much higher doses of MTX were tolerated by the 
tumor bearing mice, but there was no improvement in the therapeutic effect 
(20). Similar antagonism has been noted between L-asparaginase administered 
before MTX or ARA-C in animals bearing L5178Y leukemia (5). These data 
suggest that protein synthesis inhibition prior to incubation with an anti-
metabolite either inhibits the active transport or the intracellular ac-
tivation. L-asparaginase it is known to inhibit formation of MTX-polygluta-
mates thus decreasing the toxicity and antitumor activity of this drug (21). 
Similarly, inhibition of ARA-C transport by L-asparaginase has been 
suggested (5). These observations are also consistent with the work of 
Capizzi et al. (22). Patients treated with ARA-C or MTX and L-asparaginase 
for lymphocytic and non-lymphocytic leukemias showed a significantly higher 
number of complete remissions in comparison to patients treated with ARA-C 
or MTX but without L-asparaginase (12-14). L-asparaginase was only active 
when administered after the antimetabolite. 
The absence of a modulatory effect seen during the first three hours of 
simultaneous incubation with both Sm and 5-FU may indicate neutralization of 
two oppossing processes: "preincubation" and "postincubation" effects. To 
avoid such difficult to interprete situations we abandoned simultaneous 
incubations in the following experiments. The general interaction mechanism 
between antimetabolites and PSI, could be a delay in the repair of the 
damage induced by the drugs. Preincubation with Sm antagonizes the cytotoxi-
city of doxorubicin, just as it did with the antimetabolites. This reaction 
is also consistent with that found for anguidine (19). The intracellular 
accumulation of doxorubicin is not believed to be caused by an active inward 
transport (23), and it seems improbable that Sm may interfere with this 
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process. On the contrary, evidence has been presented for an active efflux 
mechanism across the plasma membrane. If Sm were to inhibit synthesis of 
this transport protein, the effect would be the opposite of what was obser-
ved and it would be similar to what is seen by metabolic inhibitors that 
increase doxorubicin cellular accumulation and cytotoxicity (24,25). From 
the above, it may be concluded, that Sm acts on the doxorubicin metabolism 
rather than membrane transport. 
Melphalan showed the same antagonistic effect after preincubation with a 
low Sm concentration as was seen with cisplatin (17). However, preincubation 
with higher Sm concentrations did not potentiate the effect of melphalan. 
This differs from the findings of Hromas et al. (6) who found a significant 
potentiation of melphalan cytotoxicity on CHO cells when pretreated with 
anguidine. 
The synergism between bleomycin and Sm is very interesting. Both preincu-
bation and post incubation are effective. The picture is somewhat similar to 
that seen with cisplatin (T/C ratio 0.46 versus 0.58), however, postincu-
bation with Sm showes the stronger modifying effect than in case of cis-
platin (17). 
The antagonism of Sm and vincristine may be due to a reduction in the 
cell cycle transverse time and an accumulation of cells in the late S phase 
(17). As this kind of effect was lethal to only a small number of cells, the 
rest will be protected from vincristine cytotoxicity by not entering mito-
sis. Potentiation seen in postincubation experiments may reflect a delay in 
the recovery after inhibition of the mitotic spindle figure or of DNA 
synthesis. 
In general preincubation with Sm antagonized the cytotoxic effect of all 
the S phase specific drugs, while post incubation potentiated their effect. 
Preincubation potentiated the cytotoxicity of all nonS phase specific drugs, 
while postincubation has less or no effect on these drugs. 
In conclusion: Sm in combination with various cytotoxic drugs shows a 
strong schedule dependent modification in the cytotoxicity. Especially 
strong potentiating effects were seen with the antimetabolites, and with 
vincristine and bleomycin. These warrant further investigations in vitro and 
in vivo. 
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SUMMARY 
Single dose pharmacokinetics of sparsomycin (Sm) and three Sm analogues: 
deshydroxy-Sm (dSm), ethyl-deshydroxy-Sm (EdSm) and n-pentyl-Sm (PSm) was 
studied in BCBA/Rij mice. In previous studies these three analogues showed 
good antitumor activity in several ascitic murine tumors, while Sm itself 
did not. EdSm was the only compound that was active on murine L1210 leukemia 
s.c. when administered i.v. To explain this observation, the pharmaco­
kinetics and the areas under the curves (AUCs) were studied at the LD10 
level. The LD10 values (pmol.kg-1) were: 24 (Sm), 40 (dSm), 167 (EdSm) and 
approximately 102 for PSm. The dose/AUC relation was constant for all com­
pounds until LD10. The AUG at LD10 of EdSm was 250% higher than that of Sm. 
dSm showed AUG at LD10 that was 25% lower that that of Sm. PSm showed the 
AUG at the estimated LD10 dose that was twice as high as that for Sm. 
However after reduction for protein binding to free drug AUG, this value 
decreased to 37% of the free drug AUG of Sm. Protein binding of other 
compounds was negligible. The results of this study suggest that EdSm is 
the least toxic compound which produces the highest AUG values at the LD10 
dose. This may explain its higher antitumor activity in L1210 s.c. model. 
INTRODUCTION 
Sparsomycin (Sm, NSC 059729) is a well known inhibitor of the ribosomal 
protein synthesis (1). The drug showed antitumor activity in several rodent 
tumors (2). The use of and investigations on Sm were limited by poor avail­
ability and toxicity of this natural product for more than two decades. 
Since only recently Sm is available through the total chemical synthesis (3) 
and a wide range of analogues underwent in vitro structure-activity re­
lationship studies (4-7). The results of these studies stressed the im­
portance of two structural modifications: deshydroxylation in the R1 pos­
ition (Table 1) and increase of lipophilicity by elongation of the R2 
aliphatic side chain. Three analogues deshydroxy-Sm (dSm), ethyl-deshydroxy-
Sm (EdSm) and n-pentyl-Sm (PSm) showed high antitumor activity on ascitic 
Ρ3Θ8 and L1210 leukemias and RC renal cell carcinoma (T/C 200-400%) (8). 
However, when the ascitic tumors (L1210 and RC) were inoculated s.c. a 
signficant loss of antitumor activity was observed (9). All three compounds 
showed some activity on RC tumor (T/C 140-150%), but only EdSm was active on 
L1210 leukemia s.c. (T/C 140%). To understand this loss of activity and 
select one single most active analogue, we performed a pharmacokinetic study 
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in mice. A possible relationship between AUG at the LD10 dose and antitumor 
activity was investigated. 
Table 1. Sparsomycin and its analogues 
± Χ 
О'" "Н^ ^СНэ 
compound Cn RI R2 
Sparsomycin (Sm) 1 
deshydroxy-Sm (dSm) 2 
ethyl-deshydroxy-Sm (EdSm) 3 
n-pentyl-Sm (PSm) 5 
сн2он 
СНз 
сн3 
сн2он 
- CH3 
- CH3 
- сн2сн3 
- (сн 2) 4 
Cn - number of the carbon atoms determining the lipophilic effect. 
MATERIALS AND METHODS 
Drugs 
Chemical structures of Sm and its three analogues are shown in Table 1. Sm 
and analogues were synthesized as described before (3,5). Drugs were ob­
tained in a freeze-dried form. Prior to the experiment, drugs were dissolved 
in 0.9% NaCl, except for n-pentyl-Sm that was dissolved in 15% propylene-
glycol and 0.9% NaCl, and kept in dark flasks at 40C. Before each exper­
iment the drug concentration in solution was analyzed using HPLC (see 
below). 
Animals 
Male BCBA/Rij mice, 12-14 weeks old, were purchased from TNO (Rijswijk, The 
Netherlands). Groups of 15-20 animals needed for one experiment were selec­
ted for uniform body weight from the larger populations. The body weight 
varied less than 3 g within one group. Until the experiments, the animals 
were housed in standard laboratory conditions: plastic cages, 12/12 hours 
light-dark schedule, 70%-80% relative air humidity, room temperature of 21 +_ 
0.5oC, standard granulated food (Hope Farms, Woerden, The Netherlands) and 
tap water ad libitum. 
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Testing the LD10 
Four groups of 10 BCBA/Rij male mice were used In each experiment within the 
dose range indicated by the pilot experiments. The drugs were administered 
as a single dose i.v. and animal survival was recorded daily for three 
weeks. The LD10 values were calculated from the dose/survival plots using a 
microcomputer program for semilog regression and 95% confidence intervals 
(10). The 95% confidence intervals for LD10 were within 25% - 30%. The 
single LD10 for PSm could not be determined as the drug was poorly soluble 
and the amount of propylene-glycol (approximately 50%) needed in the for-
mulation of such a high concentration was toxic to the mice. The single LD10 
dose could be estimated from the fractionated experiments by multiplication 
of the fractionated LD10 by the number of the doses. Such an estimation cor-
rectly predicted the single LDIO value for dSm and EdSm. 
Pharmacokinetic experiments 
Drugs were injected m the tail vein and the time of injection was re-
corded. The volume of injection was constant: 0.1 ml/lOg body weight. Sub-
sequently, the animals were exsanguinated under pentobarbital anaesthesia 
and blood samples of 0.6-0.8 ml were collected in plastic tubes containing a 
small amount of powdered héparine. Pentobarbital was always administered 3 
minutes prior to exsanguination. Plasma was separated from blood cells by 
centrifugation within one hour and was kept at -20oC pending analysis. Sm 
and dSm were studied at three dose levels: 0.5, 1.0 and 2.0 times LD10. EdSM 
was tested at 0.5 and 1.0 times LD10 because of the very high LDIO for this 
compound and PSm was tested at the doses of 12 and 24 jimol.kg" (12% and 24% 
of the estimated LD10 value, respectively) because of poor solubility of 
this compound. 
Analysis 
Plasma samples were deproteimzed either with 10% trichloroacetic acid (Sm 
and deshydroxy-Sm) or with 7% perchloric acid (ethyl-deshydroxy-Sm and n-
pentyl-Sm). Both acids were from Aldnch (Brussel, Belgium). A semi-auto-
mated high-performance liquid chromatography (HPLC) system (Kratos Analyti-
cal, Ramsey, NJ, USA) was utilized. This system consisted of two spectroflow 
400 pumps, Multiport Streamswitch with two six-way valves (Rheodyne, Cotati, 
CA, USA), a 757 UV-Vis Detector and a OS 610 Multirange strip chart re-
corder. The connection of the sampling valves for the back flushing method 
has been described elsewhere (11). The whole system was operated by means of 
an HPLC solvent programmer 9224 (Kipp Analytical, Rotterdam, The Nether-
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lands). The columns used were: a concentration column (50 χ 3 mm id) filled 
with úiChrosorb RP-8 (10 pm particle size) and an analytical column (100 χ 
4.6 mm id) filled with CP t m Spher С (8 μπι particle size); both packing 
materials were obtained from Chrompack BV (Middelburg, The Netherlands). 
Solvent A (flow 1.3 ml/min) for sample concentration and cleaning of the 
columns consisted of distilled water. Solvent В (flow 1.0 ml/min), to carry 
the sample from the concentration column through the analytical column, 
consisted of methanol (HPLC grade. Fisons, Loughborough, England) in distil­
led water. The following methanol concentrations were used: Sm (15%), 
deshydroxy-Sm (27%), ethyl-deshydroxy-Sm (40%) and n-pentyl-Sm (45%). Drug 
concentrations were determined from the comparison of the sample peak 
heights with those of untreated control plasma spiked with known concen­
trations of the drug. The accuracy of the standard curves was estimated by 
comparison of the concentration/peak heigth ratios for five different con­
centrations over a range of 3 logs. The calibration curve was acceptable 
when the SD of the ratios was lower than 5%. The detection limits for 
different analogues in plasma varied from 10-30 ng.ml" . 
Protein binding assays 
Protein binding of the drugs has been determined with an ultrafiltration 
method. No aspecific drug binding to the filters (Emit free level TM, Syva, 
Palo Alto, CA, USA) was found. Heparinized plasma samples of 3 to 5 animals 
exsanguinated at the same time after injection has been pooled and centri­
fugea through the filters at 2500 g for 20 minutes. Plasma protein binding 
was evaluated at each dose level, 10 and 30 minutes after injection. Drug 
recovery after centrifugation was compared to the total drug concentration. 
The results are expressed as the percentage of the total drug concentration 
retained on the filter (bound to plasma). 
Fitting of the curves 
Curves were fitted using ELSMOS computer program (12) for two compartments 
model. The AUG was calculated from the fitted concentrations using the 
trapezoidal rule and starting from the 5th minute of the experiment. Using 
the exsanguination technique it was impossible to obtain enough data points 
to determine the alpha phase properly. This also is the reason why the 
points before 5 minutes were not fitted, and the AUG was calculated from the 
fifth minute. The t^« 3 and t^j γ were calculated from the β and γ 
elimination rates, respectively, according to: 
0.693 
*1/2Β= 
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RESULTS 
The three analogues showed higher LD10 values than the parent drug (see 
Table 2.) Deletion of the hydroxyl group in R1 position produced higher LD10 
for dSm than for hydroxylated Sm (40 versus 24 umol.kg" ). The more lipo­
philic EdSm showed the highest LD10 167 umol.kg" · The fractionated LD10 
value obtained after administration of PSm for nine daily doses was 11.3 
umol.kg" per inj. The single LD10 was estimated by multiplication of this 
value by 9 (102 umol.kg" ). 
Single dose pharmacokinetics of the four compounds in mice showed Fig. 
2-5 two elimination phases. The t. /5 was similar for all analogues and was 
0.13 + 0.05 hour (8+^3 minutes). At LD10 the gamma elimination phase was 
longest in case of dSm (6-7 hours); in the other analogues t./, w a s ".5 to 
1.4 hours (30 - 84 minutes). The terminal half-life of Sm increased almost 5 
fold at twice the LD10. 
Table 2. Pharmacokinetics of Sm and three Sm analogues in mice. 
compound dose ь1/2 ^ t 1 / 2 ^ A U t' A U C protein dose/ 
^imol.kg (hours) (hours) total free drug binding total 
— ( % ) AUG 
umol.h.l" 
Sm 12.0 0.11 0.9 6.5 5.9 1.8 
10.0 
24.0 * 0.13 1.4 12.9 11.6 1.9 
+ 4 
44.4 0.14 59.3 50.2 45.2 - 0.9 
dSm 20.0 - - 4.7 3.9 4.3 
18.0 
40.0 * 0.2 7.1 9.8 8.0 4.1 
+ 6 
80.0 0.2 6.1 17.9 14.7 — 4.5 
EdSm 83.5 0.08 0.9 13.5 8.4 38.0 6.2 
167.0 * 0.15 1.4 27.3 16.9 + 7 6.1 
PSm 12.0 0.06 0.5 2.2 0.5 5.4 
78.0 
24.0 0.14 0.8 4.6 1.0 5.2 
+ 10 
102.0 ** - 19.2 4.2 _ 5.3 
* LD10 
** estimated LD10 
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Protein binding was concentration independent for all compounds (see Table 
1). Protein binding was proportional to the number of the carbon atoms (Cn) 
present in Rl and R2 substitutions. Hydroxylated compounds had one carbon 
atom less, because of the "masking" effect of the hydroxyl group. The cor-
relation coefficient between Cn and protein binding was r = 0.99. 
plasma cone 
ng/ml 
time ( hours) 
Fig. 2. Pharmacokinetics of Sm administered as a single i.v. bolus to 
BCBA/Rij mice. ( · ) 44.4 pmol.kg-1 ; ( • )24.0 pinol.kg"1 (LD10)j (O) 
12 pmol.kg" . Each point represents a sample from a single mouse. 
The dose/AUC ratios were constant until the LD10 for three compounds. PSm 
showed linear dose/AUC relationship until 22% of the estimated LD10 dose. 
The dose/AUC ratios were smallest for Sm, suggesting lowest total body 
clearance. Deshydroxylation and increase of lipophilicity (dSm, EdSm and 
PSm) increased the dose/AUC ratios by a factor 2.3 for dSm, 3.3 for for EdSra 
and 2.9 for PSm. 
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plasma cone 
na/ml 
des - OH - sparsomycin 
time ( hours) 
Fig. 3. Pharmacokinetics of deshydroxy-Sm administered as a single i.v. 
bolus to BCBA/Rij mice 
(LD10); (O) 20.0 pmol.kg' 
single mouse. 
( · ) 80.0 jmol.kg ; 
-1 
( • ) 40.0 pinol.kg' .-1 
Each point represents a sample from a 
At the LD10, EdSm produced the AUC of 27.3 pmol.h.l versus 12.9 jimol.h.l 
produced by the equitoxic dose of Sm. The AUC of dSm was 9.8 pmol.h.l" 
which was lower than that of Sm. The estimated AUC at LDIO dose of PSm 
should be 19.2 jumol.h.l" which is 1.5 times higher than that of Sm. When 
the total AUCs were reduced to the free drug AUC by subtraction of the 
protein bound fraction, the relations between compounds changed. Free drug 
AUC for EdSm remained 1.5 times higher than that of Sm. The AUC of dSm 
remained approximately 70% of the Sm value while the high total AUC value 
observed for Psm was only 36% of the free AUC of Sm. 
100 
plasma cone 
ng/ml 
ethyl - des - OH - sparsomycin 
Fig. 4. Pharmacokinetics of ethyl-deshydroxy-Sm administered as a single 
i.V. bolus to BCBA/Rij mice. ( • ) 167.0 pnol.kg-1 (LD10); ( О ) 
83.5 ^imol.kg- . Each point represents a sample from a single mouse. 
DISCUSSION 
Previously we have reported that the three analogues dSm, EdSm and PSm 
showed in mice considerably higher LD50 values and higher antitumor ac­
tivity, compared to the parent drug (2,7). The highest activity was shown on 
ascitic tumor models (P388, 1,1210 and RC). Considerable loss of activity on 
the same, sensitive tumors inoculated s.c, prompted us to perform pharmaco­
kinetic studies and dose/AUC relation analysis. 
EdSm, the only compound that showed activity on L1210 leukemia s.c. 
showed in this study 2.5 times higher AUC at LD10 in comparison to Sm. 
101 
plasma cone 
ng/mi 
юЧ 
w1-
n -pentyl - sparsomycin 
time ( hours ) 
Fig. 5. Pharmacokinetics of n-pentyl-Sm administered as a single i.V. bolus 
to BCBA/Rij mice. ( 
point represents a sample from a single mouse. 
) 24.0 junol.kg , ( О ) 12.0 junol.kg . Each 
Even after reduction for protein binding, the free drug AUG was still 1.5 
times higher than that of Sm. dSm showed AUG, both total and free, slightly 
lower than that of Sm, while in case of PSm very low free drug AUCs could be 
predicted. These data may suggest, that the free drug AUG may be related to 
activity on L1210 leukemia s.c. and in this way pharmacokinetic data may 
contribute to the choice of the most suitable analogue. When the tumor and 
the drug are administered i.p·, the AUG in the ascitic fluid may be very 
high and high lipophilicity of the drug may ease drug distribution to the 
tumor cells. This may produce a wrong impression of the antitumor activity 
of a compound. 
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The increase of the dose/AUC ratio seen in case of both deshydroxylated 
analogues suggest that the hydroxyl group of Sm may be an important factor 
inhibiting metabolism and/or excretion of the drug. Increase of lipophili-
city (PSm) increases the dose/AUC ratio too, but the increase is pro­
portionally smaller than the effect of deshydroxylation. EdSm, which is a 
compromise between deshydroxylation and increased lipophilicity showed a 
high LD10 and good antitumor activity. Opposite to a certain AUC-activity 
relation, is the lack of a AUC-toxicity relation. Equitoxic doses of dif­
ferent analogues produced different AUC's. A high AUG at the LD10 dose may 
thus indicate that the compound expresses a different dose limiting toxicity 
compared to the other compounds. The most severe toxicity encountered, when 
the animals were treated with toxic doses of drugs was death due to haemor­
rhage (unpublished). Orbital, rectal and urogenital haemorrhages were most 
frequently observed. Appearance of haemorrhage in mice after treatment with 
Sm was reported in 196Θ (14) and similar phenomenon was described by us in 
beagle dogs (9). The haemorrhagic diathesis seen in dogs was due to ex­
haustion of blood coagulation factors produced in the liver (9). In mice 
treated with Sm and its analogues we observed a striking difference m 
frequency of haemorrhagic events between analogues (un-published). Haemor­
rhage was clearly a dose-limiting toxicity for hydroxylated analogues. 
Approximately 30% of the animals dying at LD50 dose of Sm died due to 
haemorrhage. We did not observe a single case of haemorrhage with both 
deshydroxylated analogue. Lack of this kind of toxicity may explain higher 
LD10 and LD50 for these compounds. Higher therapeutic doses may in turn 
explain higher antitumor activity of these compounds. However, this ad­
vantage of EdSm should be interpreted with caution as it may be a species-
related phenomenon. 
In conclusion: presented data suggest a link between the free drug AUG 
and antitumor activity of EdSm on L1210 leukemia s.c. This compound too, is 
a good candidate for further preclinical studies. 
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Summary. Sparsomycin is a cytotoxic drug exhibiting a 
broad spectrum of in vitro actmty against murine tumors 
and many tumor cell lines It also appears to be a potent 
stimulator of the antitumor activity ol cisplatin against 
LI210 leukemia in vivo However because оГ its toxicity 
the antitumor activity of sparsomycin on murine tumors m 
vivo has been disappointing The purpose of our study was 
to investigate the pharmacokinetics of this drug as well as 
the possible mechanisms that produce sparsom)Cin toxici 
ty Tests on beagle dogs revealed that about 60% of the 
drug is eliminated by metabolic clearance, while 40% is eli­
minated by the kidneys After a single bolus injection of 
0 1 mg/kg sparsomycin without narcosis sparsomycin was 
eliminated with a tß, of 0 6 - 0 7 h the AUC being 
0 3 2 - 0 38 mg h 1 ', and the volume of distribution (Vd) 
0 26 l/kg In addition to being subject to glomerular filtra-
tion, sparsomycin is probably also actively excreted and 
actively reabsorbed by the renal tubuli Sparsomycin itself 
may inhibit its active tubular excretion, thus resulting in a 
decrease in the drug s renal clearance and its accumulation 
in the plasma Sparsomycin appeared to be toxic primarily 
in the liver, disturbing its function and the synthesis of 
plasma proteins Two out of five dogs developed hemor-
rhagic diathesis due to hypofibrmogenemia and deficiency 
of other blood coagulation factors Sparsomycin was not 
toxic to the bone marrow 
Introduction 
Sparsomycin (NSC 0 W 2 9 ) , which was originally isolated 
from a bacterial broth of Streptomua ь/мп0£еіі??[І6] is a 
potent inhibitor of nbosomal protein synthesis [11] Owen 
et al have reported that sparsomycin is active on human 
KD cells in vitro and on several rodent tumors in vivo [16] 
In 1964 the drug was given a phase I clinical trial five pa 
tients received sparsomjem in dailv increasing doses lor 
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12-14 davs The trial was prematurely discontinued be 
cause of retinal toxicitj in two patients [3] Nowadays this 
l>pe of scheduling is no longer used because of the high 
risk of cumulative drug toxicity [2] Further preclinical re 
search was nol performed until 19SI The revival of inter 
est in this drug is justified by the recent development of a 
flexible procedure for its total synthesis [15] and b\ the de 
velopment of some carefully designed new analogs [1 10] 
Synthetic sparsomvein has recently been found to be 
active in vitro in several murine tumors and in many hu 
man tumor cell lines [S] Ihe results of in vivo screening 
tests performed in National Cancer Institute (NC 1) labo 
ratones over the last 20 years [12] have been disappointing 
when compared to the data obtained by Owen et al [16], 
because the NC I was only able lo confirn the antitumor 
activity of sparsomycin (natural product) for P388 leukem 
ia and Walker 256 carcinosarcoma [12] However, even 
though lacking antitumor activity of its own synthetic 
sparsomycin has been found to potentiate the activity of 
cisplatin on С HO cells in vitro [27] and on L12I0 leukemia 
in vivo, inducing 67 r cures in optimalized schedules [25] 
This synergistic effect, which has also been reported for 
other protein synthesis inhibitors [6, 7] may provide an 
important application of sparsomycin in cancer chemo 
therapy 
The reason for the discrepancy between the in vitro 
and in \ivo antitumor activity of sparsomycin probably re 
suits from the toxicity of this drug which does not allow 
effective drug levels to be reached in vivo In a daily χ 9 
schedule (he LDm od sparsomycin m mice is about 40 
times smaller than the single LI),,] dose [12], suggesting 
that sparsomycin accumulates in vivo 
Experimental data suggest that a reasonable therapeu 
tic index can only be achieved by persistent drug adminis 
tration [12] During treatment with sparsomvein the drug 
sensitive proteins disappear from cells and plasma al a 
rate proportional to their turnover rate [24] Thus, proteins 
with a rapid turnover will disappear first and if these pro 
teins are critically important to the integrity ol the host, 
they should be the best indicators of drug toxicity The 
proteins that ire most sensitive to inhibition biosynthesis 
are those with a high m R N A initiation potential e g , fer 
rum [20] and albumin [21], so that lexicological studies 
should be focused on liver export proteins 
To achieve the maximal antitumor effect dose limiting 
toxicities should be clearly defined and the levels o f c n t i 
cal proteins should be monitored 
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The aim of the present investigation was to analyze the 
pharmacokinetics of sparsomycin together with its effects 
on some liver derived proteins in order to determine the 
possible mechanisms of sparsomycin toxicity The results 
should provide guidelines for the development of better 
analogs of this drug 
Materials and methods 
Animali Eleven male beagle dogs (Central Animal Labor­
atory, University of Nijmegen) weighing between 8 8 and 
14 0 kg were used The dogs were fed with standard granu­
lated dog food (Hope Farms. The Netherlands) and had 
free access to tap water During the experiments, the ani­
mals were housed in wire bottomed metabolic cages that 
enabled urine collection 
Drugs Sparsomycin was synthesized as previously de­
scribed [IS] and was aquired in a freeze-dned form The 
injections were prepared aseplically in the hospital pharm­
acy (St Radboud Hospital) The drug was dissolved in 
0 9% NaCl and kept in dark flasks at 4° С for not longer 
than 24 h 
Dose In a pilot study involving 2 dogs, we had previously 
determined that nine daily administrations of 0 1 mg/kg 
sparsomycin was the maximal dose tolerated by the ani­
mals A dose of 0 1 mg/kg (2 mg/m2) daily is close to the 
maximal dose of 0 05 mg/kg (I 85 mg/m2) used in humans 
[3] A I 4-mg/kg dose was considered to be the maximal 
single dose that could be tolerated At the time of this 
experiment, we were not aware of relevant data published 
by the NCI [13] The doses used for continuous infusions 
were calculated from the single-dose experiments, so that 
steady slate levels of 50 and 100 ng/ml could be attained 
The treatment protocols are listed in Table 1 
Sparsomycin analysis Sparsomycin concentrations m plas­
ma and urine were determined using high-performance li­
quid chromatography (HPLC) as previously described [23] 
using a semi automated HPLC svstcm (Kratos Analytical, 
USA) hor urine analysis, the method was slightly modifi­
ed, instead of using methanol as the eluent, IO0» acetoni-
Irile was applied The detection limits were 10 ng/ml for 
plasma and 50-80 ng/ml for urine 
Pharmacokmelu and loxicnlogical studies The dogs were 
lasted for 12 h before each experiment Most of the phar 
macokinetic studies were performed with the dogs under 
pentobarbital anesthesia (initial dose, 30 mg/kg) and sub­
jected to intratracheal intubation During each experiment 
(lasting 5-7 h), the animals received intravenous fluids 
(0 9% Nad and 2% mannitol) at a rate necessary to pro 
duce the required urine flow (for protocol details, see 
Tables 1 and 2) Blood samples were taken via a central ve 
nous catheter, immediately cenlnfuged, and frozen at 
-20° С Urine (7-10 ml) was collected through a urinary 
catheter At the end of each collection period, the bladder 
was emptied by gentle massage All urine analyses for the 
determination of sparsomycin levels, creatinine concentra­
tions, and urinary pH were performed in duplicate Urine 
samples were kept at 20° С until analysis After the dogs 
had recovered from anesthesia, they were returned to met­
abolic cages, where urine collection and blood sampling 
were continued for 24 h On days 2-8 (expt 1 a, dog 632), 
the sparsomycin concentration in plasma was determined 
in blood samples taken 5 mm before, 5 mm after, and 60 
mm after the drug injection On days 1 and 9, the already 
described single-dose procedure was repeated Another 
dog received a single dose of 1 4 mg/kg sparsomycin 
(expt 7, dog 751), and the drug concentration was deter­
mined in bile samples collected through a catheter preop-
eratively inserted in the choledochal duct Two dogs re­
ceived continuous infusions of sparsomycin for 3 5 and 
4 h 1 received 0 043 mg/kg per hour (expt 8, dog 868), 
and the other was given 0 025 mg/kg per hour (expt 9, 
dog 785) 
All pharmacokinteic parameters were calculated from 
plasma and urine concentrations according to well-known 
procedures [22] 
Table 1. Treatment protocol 
bxpl/ 
dog no 
1/632 
3/890 
4/892 
5/063 
6/008 
Single doses 
2/350 
7/751 
8/868 
9/785 
10/160 
11/172 
12/160' 
13/172" 
Dose 
(mg/kg) 
01 
01 
01 
01 
01 
01 
14 
0 043 
mg/kg/h 
0 025 
mg/kg/h 
01 
01 
05 
05 
Schedule 
Q01Dx09 
Q01Dx09 
Q01Dx09 
Q01Dx09 
Q01Dx09 
QOlDxOl 
QOlDxOl 
Coni infusion 
(3 5h) 
Cont infusion 
(4 Oh) 
Q01DX01 
Q01DX01 
Q0115X01 
Q01DX01 
Anesthesia 
on 
_ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
-
-
-
-
day 1 
Anesthesia 
on day 9 
_ 
+ 
+ 
-
-
Additional 
hydration 
_ 
-
+ 
+ 
-
Follow up 
(days) 
60 
60 
4" 
60 
4· 
5 
0= 
5 
5 
5 
5 
5 
5 
• The follow-up was shortened due to death 
ь
 The experiment was repeated on the same dogs 3 months afler the experiment whose results are shown here 
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Toxicohgiial !,lud\ Dogs 632 890,892,063 and 008 ν,ere 
subjected to toxicologicil stud\ lollowing nine daily doses 
of 0 1 mg/kg sparsomycin Dogs 892 and 061 additionally 
received daily hydration (0 S 1 glucose saline as a hypoder 
mie clysma) in order to minimize the effects of dehydra 
tion Blood and urine samples were analyzed for changes 
in biochemical and hematological parameters Additonal-
]y, four single-dose experiments were performed (expts 
10-13 dogs 160 and 172) without anesthesia, and a phar­
macokinetic study was perlormcd to evaluate exclusively 
the dynamics of faclor-VII changes Factor VII levels were 
determined using factor Vll-deficient human plasma and 
dog brain thromboplastme [18] I he 100'о value (±SD) 
was derived from the results obtained for 12 healthy 
beagles not involved in this stud\ Thrombolests were per­
formed according to the method of Owren [17] Student s 
/ test was applied to assess the significance of the differ­
ences between day-1 and day 9 \alues, the accepted level 
of significance was Ρ < 0 05 
Eve toxtati In each of the dogs that received a 9-day 
course, fundoscopy was performed three times, ι e , on the 
1st, 9th, and 16th days of the experiment As dog 892 was 
killed after the experiment and dog 008 died on day 13, 
their retinas were subjected to histological evaluation 
Results 
The pharmacokinetic results are summarized in Table 2 
Bolus injection ofOI mg/kg tpartomycin Hilhoul anesrhaia 
Sparsomycin that had been administered to the 2 dogs that 
were not under pentobarbital anesthesia (expts 1 and 2) 
was rapidly eliminated from the circulation as shown by 
the following values tß, ,, 0 60 and 0 68 h, AUC, 0 32 and 
0 38 mg h I"1, and volume of distribution (Vd), 0 26 and 
0 26 1/kg The drug was eliminated mainly by nonrenal 
clearance (CLNR:>m), with 40% of the administered dose be-
ing consistently recovered in the urine after 24 h 
Bolus injections ofOI mg^kg under anesthesia 
The dogs that received bolus injections while under pento-
barbital anesthesia (expts 3 and 4) eliminated sparsomy-
cin less rapidly having tß, ι values of 0 7 and 0 76 h In 
these experiments, the AUCs values increased to 0 99 and 
0 78 mg h I ' mainly because of a slow γ-phase with Ιγ,
 г 
values of 7 9 and 9 4 h The results of expt 3 are shown in 
Fig 1 
The increase in the AUC values was mainly due to re­
duced CL S R S m , as the renal clearance (CLRSm) remained 
the same, ι e , about 20 ml/min As a consequence of the 
Table 2 Phdrmacokinetic data for sparsomycin administered as an ι \ bolus or by continuous infusion 
Experiment Lxpt Dog Body Mean tß, . ALO Vj CLn, CLRbm Percentage CL¡,„ 
no weight urine (h) (mg h I ') (1/kg) (ml/mm) (ml/mm) oflhedose (ml/mm) 
(kg) flow ± SD excreted 
(ml/mm) in urine 
Bolus injection 
without anesthesia 
(0 1 mg/kg) (day 1) 
Bolus injection 
under anesthesia 
(0 1 mg/kg) (day 1) 
Bolus injection 
under anesthesia 
(0 1 mg/kg) high 
urine How (day 1) 
Prolonged drug admm 
0 1 mg/kg Q0IDx9 
(day 9) 
Bolus injection 
under anesthesia 
(1 4 mg/kg) (day 1) 
Contmous infusion, 
under anesthesia, 
high urine flow 
0 043 mg/kg/h 
0 025 mg/kg/h 
1 
2 
3 
4 
5 
6 
lb-· 
3a 
4a ь 
7 
8 
9 
632 
350 
890 
892 
063 
008 
632 
890 
892 
751 
868 
785 
125 
Π I 
130 
125 
118 
88 
107 
11 9 
11 7 
112 
140 
13 5 
0 6 ± 0 5 
0 7 ± 0 6 
0 2 ± 0 0 5 
O2±0O5 
17±008 
19 ±0 08 
0 2 ± 0 5 
02 + 004 
0 3 ± 0 0 8 
101009 
1 3 + 046 
10±032 
0 60 
0 68 
0 70 
0 76 
1 17 
0 83 
0 76 
1 17 
064 
10 
0 60 
0 54 
0 32 
0 38 
0 99 
0 78 
0 40 
0 34 
187 
174 
0 74 
10 80 
0 72 
0 35 
0 26 
0 26 
0 26 
0 57 
0 42 
0 36 
0 26 
0 27 
0 32 
0 25 
-
-
_ 
-
4 0 4 ± I 7 
34 3± 3 
4 2 3 ± 7 
35 7 ± l l 
_ 
359±16 
21 1+ 9 
_ 
47 9 ± 9 
453 + 7 
24 6 
23 8 
184 
216 
34 4 
29 3 
36 
105 
210 
_ 
30 3 
45 0 
40 0 
39 5 
84 0 
81 0 
70 0 
68 0 
38 0 
100 0 
80 0 
55 0 
62 0 
73 0 
62 0 
60 2 
22 0 
26 7 
49 2 
43 1 
95 
105 
26 4 
25 6 
49 0 
617 
Expenmeni lb was performed without anesthesia 
Additional hydration on days 2-8 
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renal « e r rolt ng/min 
plasma cone ng/ml 
CL R S m ml/ггнп 
SPARSOMYCIN 
01 mg/kg 
d a y l 
a^#-
dog 890 
гУА-
2ih 
big 1 I xpenment 1 plasma concentntion lime curve ( · · ) 
and renal excretion raie lime profile ( > of sparsomvun act 
ministered as a bolus ι \ dose (0 I mg kg) to dog K90 under 
anesthesia on ddv I of ihe experiment The percentage of the dose 
recovered in the urine afler 24 h is indicated on the last rendi 
excretion rate bar ( hanges in thi С I, „ ( ) and С 1
 Ks ( ) 
are shoun in the чрріграіі of the ligure φ 07h ι/ 79h 
decreased CL S R S m , most of the drug was excreted in the 
urine (84% and 80% of the administered dose) The volume 
of distribution (Vj) values in these two experiments were 
0 26 and 0 57 1/kg These results were obtained with a rela­
tively low urine flow of 0 2 ml/mm 
Influence of high urine flow on renal drug clearance 
An increase in the urine flow to I 7 and I 9 ml/mm in 
cxpts 5 and 6, respectively, resulted not only in increases 
in the CLR S m to 34 4 and 29 1 ml/min, respectively, but al­
so an increase of the C L S R 4 m to about 14nil/min (see 
Fig 3) The proportions of the drug recovered in the urine 
were 70°[) and 68%, respectively The elimination values, 
1(1,
 :
, did not drop in these experiments but increased to 
1 17 and 0 83 h, respectively An increase in the urine flow 
resulted in the disappearance of the γ phase and low AUC 
values of 0 4 and 0 34 mg h 1 ' Despite the high urine 
flow, the CI
 R S m decreased significantly during the 4th h of 
the experiment but thereafter increased Under vigorous 
hydration, the V,, values in these experiments increased to 
0 42 and 0 36 1/kg, respectively (a 35% increase) 
^Чя 
r»nol «мсг rol· ng/mm 
plasma conc ng/ml 
10' 
' CL R S m ml/nw 
• CLCH tri/tnn 
SPARSOMYCIN 
01 mg/kg 
day S 
\ , 
V \ 
V 4 -#-4 
bv dog 690 
-У/ 
В 9 2¿h 
Fig 2 I xpenment Ча sparsoimun jdminisiered as a bolus ι ν 
dosi. (0 l mg kg) lo dog 890 under anesthesia on das 9 (ihe lasi of 
nine daiK doses) if) I 17 h the / phase was absent hor further 
details see the legend to hg 1 
Elimination profile of spanoimcin afler dailv 
adminiilralwn (x9) 
Dogs 632, 890, and 892 were given nine daily ι ν sparso-
mycin doses of 0 1 mg/kg In dog 632, a pharmacokinetic 
study without anesthesia was performed on days 1 (expt 1) 
and 9 (expt I a), and on days 2-8, additional blood sam 
pies were taken 5 mm before the injection, and 5 and 60 
mm after the injection 
Dog 63 ' became ill during the treatment course Vom­
iting and anorexia resulted in weight loss (—18 kg) and 
dehydration On day 9 the dog produced only 110 ml con­
centrated urine per day (normal level, 500-7SO ml/day) 
From days I to 8, the daily measurements of plasma drug 
levels (expt la) revealed that the peak levels (5 min after 
injection) remained the same i e , 529 ±53 ng/ml This 
was also the case for the drug levels 60 mm after the injec­
tion, ι e , 94± 16 ng/ml Residual drug levels at 5 mm be­
fore the iniection were detectable only on da\s 5 (14 ng/ 
ml) and 7(10 5 ng/ml) On day 9 (expt 1 b), the drug eli­
mination profile changed significantly the residual drug 
level increased to 75 ng/ml, there being a peak value of 
605 ng/ml and a 60-mm value of 210 ng/ml The |)-phase 
with a φ, , of 0 76 h was followed by a γ-phase with a ty, , 
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1 LFh Р-Пгь-чГ α " ""^" 
li 
г CLus» ml/n»n 
renal «жег ral · ng/min 
plasma conc ng/ml 
SPARSOMYCIN 
01 mg/kg 
day1 
\ 
\ 
\ . 
[/^г 
\ 
\ 
\ 
dog 008 
renal вжег rale ng/mm 
plasma conc ng/ml 
Fig. 3. Гхрептепі 6 sparsomycin administered as a bolus ι ν 
dose (0 1 mg kg) to dog 00X under anesihesia with vigourous hy­
dration on da> I of the experiment 1(1 , 0 8.1 h. Ihe γ-phase was 
absent hor further details, see the legend to Fig 1 
of 20 h The AUC' increased to 1 87 mg·h I " 1 . Dog 632 re­
covered promptly within 10 days of the last sparsomycm 
injection; it started to gain weight and had normal diure­
sis. 
Dogs 890 and 892 (expls. 3 and 4) were subjected to a 
procedure similar to that used for dog 632, except that the 
pharmacokinetic studies on days 1 and 9 were performed 
under anesthesia Dog 892 received additional hydration 
throughout the experiment (days 2-8 , 0 5 I saline-glucose 
as a daily hypodermoclysis). The elimination profile of 
sparsomycin in expts. 3 and 4 on day I have been de­
scribed above. On day 9 (expts. 3a and 4a), the drug-elimi­
nation profiles were different. Dog 890, which did not re­
ceive additional hydration, showed a markedly increased 
tß , , 2 value of 1.17 and an AUC value of 1.74 mg h l ' 9 
(expt. За; Fig 2). Apparently, the slow γ-phase had disap­
peared, and 100% of the administered dose was recovered 
in the urine The total body clearance (CL b m ) decreased to 
10.5 ml/min and was equal to the CL,,;,,,,. Dog 892, which 
was hydrated on days 2-8, showed an unchanged drug-eli­
mination profile in expt 4a, ι e , a tß, , value of 0 64 h, an 
AUC of 0.74 mg · h • I ~ ', a persisting γ-phase. The C L S m re­
mained as high as on day I, and 80% of the initial dose 
was recovered in the urine. 
SPARSOMYCIN 
1 LB mg/kg 
" ^
 r 
dog 751 
10' 
0 1 2 3 4 5 6 7 8 9 rah 
Fig. 4. experiment 7 sparsomycin administered as a bolus ι ν 
dose (1.48 mg/kg) to dog 751 under anesthesia The percentage of 
the dose recovered in the urine after 6 h is indicated on the last 
renal excretion rate bar. Sparsomycin concentrations in the bile 
( ) and the percentage of the dose recovered in the bile are 
indicated tf) , 1 0 h . ty , 6 7 h 
The pentobarbital sleeping times after an initial dose of 
30 mg/kg pentobarbital were recorded for both dogs dur­
ing the first and second anesthesia On day I, dogs 890 and 
892 woke up after 1.1 and 1.4 h, respectively, and an addi­
tional pentobarbital dose was necessary to keep them 
asleep. On day 9, the times were 23 and 30 h, respectively, 
for the same pentobarbital dose. When dog 892 woke up 
on day 10, it was still stick and hypothermic, and it re­
mained so until day 13, when it was killed for humanitar­
ian reasons. Death was not directly due to sparsomycin 
toxicity, but rather was attributable to an unexpected delay 
in pentobarbital metabolism. 
High sparwmycin dose: I.4S mg/kg as an ι. v. bolus 
In expt. 7, sparsomycin at a dose of 1.48 mg/kg was inject­
ed under anesthesia as an i.v bolus (Fig 4) The tß,
 ; was 
I Oh, and the AUC was 10 8 m g - h - 1 " ' . The dog died after 
10 h, and the amount of the drug recovered in the urine up 
to the time of death was 55% of the administered dose. Si-
multaneously measured sparsomycin concentrations in the 
bile revealed that only 2% of the administered dose had 
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been eliminated in an unchanged form by this route Auto­
psy failed to reveal the cause of death 
Continuous infusion о/ чрапотиш 
Sparsomvcin given as a continuous ι ν infusion 
(0 041 mg kg per hour, e\pl 8) resulted in steady-stale 
plasma concentrations during the first 100 mm of the 
experiment At the same time the С I
 R S m increased from 
20 0 to 45 0ml/min, thereby approximating the creatine 
clearance, CL
r R (mean, 47 9 ±9 0 ml mm) The С LRbm re­
mained at a constant level of 40-45 ml min lor only 60 
mm and then started to decline, this resulted in increased 
sparsomycin levels in the plasma After the discontinua­
tion of sparsomycin infusion, the drug was eliminated with 
a ψ,
 ; of 0 60 h When the sparsomvcm plasma concentra­
tion dropped to about 60 ng/ml, the ( LRSm increased once 
again to 50 ml/mm but had decreased by the end of exper­
iment The CLSrn ob->erved during this experiment was 
49 0 ml/min, while 62% of the sparsomycin dose was ret 
overed in the urine 
The urine pH dropped from 7 7 at the beginning of the 
experiment to 6 5 at the end of drug mlusmn, and had re­
turned to a value of 8 0 at the end of experiment The urine 
flow was constant during the drug infusion, but increased 
from 1 0 to 2 5 ml/min immediately after discontinuation 
of the infusion 
The same experiment was repeated using one half of 
the previous dose (0 025 mg/kg per hour, expt 9), the re­
sults are shown in Fig 5 After an initial rise in the CLR S l n 
to 149 ml/min. the clearance deteriorated to values lower 
than the mean CTC R (45 4±7 0 ml/min) After an initial 
steady state, the plasma levels of sparsomycin began to in­
crease during the 2nd h of the experiment Again, after dis­
continuing drug infusion, sparsomycin was eliminated 
with a tß,
 2 of 0 54 h The CLRbm was restored to a value of 
50 ml/mm when the plasma levels dropped below 60 ng/ 
ml The CLSm was 61 7 ml/min, and 7Wa of the sparsomy-
cin dose was recovered in urine alter 24 h To control var 
lations in the urine flow, a volumetric infusion pump with 
a constant fluid-infusion rale of 3 0 ml/min was used Af-
ter an initial equilibration time of 30 mm, the urine flow 
remained constant at I I ±0 26 ml/mm until sparsomycin 
infusion was terminated, at which time the urine flow in-
creased to 2 3 ml'min The changes in urine pH were simi-
lar to those observed in expt 8 
Toxicology 
As a result of daily treatment with 0 I mg/kg sparsomycin 
for 9 days, the 5 animals (dogs 632, 890, 892, 063, and 008) 
lost body weight (mean loss, - 1 8 kg, not significant see 
Table 3) and became anorexic One dog (008) died because 
of dehydration, uremia, and hemorrhagic diathesis on day 
13, while another (892) was killed on day 13 because it did 
not recover from the pentobarbital anesthesia given on 
day 9 The dogs drank water normally but vomited imme-
diately after This phenomenon was most apparent about 
1 h after drug injection and resulted in significant hemo 
concentration and a decrease in urine production (dogs 
632, 890, and 008) The dogs that were additionally hydrat 
ed (063 and 892) exhibited less hemoconcentration and 
normal diuresis (about 500 ml/day) Decreased renal 
creatinine clearance and weight loss were seen in all 5 
renal вжег rate ng/mm 
plasma cone ng/ml 
SPARSOMYCIN 
0.025 mg/kg/h 
^ infusion H 
/ V 
/ dog 785 
-//-r-
Fig 5 fxpenment 9 sparsomycin administered as a continuous 
infusion (0 025 mg/kg per hour) to dog 78S under anesthesia with 
vigourous hydration tp 0 54 h ty , about 8 h For further de 
tails, see the legend to Fig 1 
dogs During therapy, the urinary sodium excretion was 
significantly reduced to values of <10mFq/l per day, 
while the urine osmolality remained relatively high In the 
2 dogs that received additional fluid and sodium, the uri­
nary sodium excretion level increased to > 20 mEq/1 per 
day Despite the considerable decrease in the creatinine 
clearance (P = 0 02), the plasma creatinine values re­
mained unchanged, and plasma urea levels decreased in 
all but 1 dog (P = 0 09) Dog 008 developed overt renal 
msufficiency and died on day 13 In addition to general­
ized hemorrhagic diathesis, a regenerating proximal tubu­
lar necrosis was found at autopsy 
Small amounts of glucose were found in one urine 
sample (dog 632) after 9 days of treatment The loss of 
urine protein never exceeded 2 g/day (61 collections) 
In all dogs, plasma electrolytes remained at normal le­
vels during and after sparsomycin therapy However, the 
plasma Ca 2 f level dropped significantly (P = 0 02), prob­
ably because of the decrease in plasma albumin 
Total plasma protein (TP) decreased from 60 h to 
55 g/l but this decrease was masked by hemoconcentra­
tion The plasma albumin level decreased from 29 7±1 8 
to 21 2 ± 2 7 g/l in 8 days (P - 0 003, Table 3) The mean 
disappearance half-life time (t| / 2) was 20 5 days After the 
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discontinuation of sparsomycin, plasma albumin returned 
to the pretreatment values within 10 days. The levels of 
plasma globulins (TP-albumin) did not change during the 
experiments. 
The plasma fibrinogen level decreased dramatically 
from 1276±98 to 291 ± 2 6 5 (P = 0.003). The disappear­
ance t.
 2 was 3.5 days The 2 dogs with the lowest plasma 
fibrinogen level on day 9 (dog 892, 160 ml/1; dog 008, 
< 1 0 0 m g / l ) showed a considerable tendency towards 
bleeding in the last 2 days of sparsomycin treatment. In 
these 2 dogs, gingival bleeding and bloody diarrhea were 
observed. Both dogs died or were killed on day 13. Prior to 
death, both dogs had supranormal plasma fibrinogen le­
vels. 
The level of plasma factor VII decreased rapidly after 
the first sparsomycin dose. The mean disappearance t | / 2 
was 5.6 ± I 5 h (see Fig. 6). The effect of the five-times-
higher sparsomycin dose was only slightly stronger, the t , ^ 
being 4.2 h Six to ten hours after drug injection, a plateau 
of 31 ± 8 % of the normal value was observed. At 24 h fol­
lowing a single sparsomycin dose of 0.1 mg/kg, the level 
of plasma factor VII started to recover (see Fig. 7). The 
recovery was slower than the disappearance and only 
reached the 100% level 50 h after the injection. Later on, a 
small overshoot of plasma factor-VII levels was observed. 
The recovery after a 0.5-mg/kg dose was delayed for an 
Fig. 6. Changes in plasma factor-VII levels after sparsomycin ad­
ministration, the sparsomycin doses and schedules are indicated. 
The SD from the 100% level (mean for 12 normal dogs) is indicat­
ed by dashed lines 
Table 3. Changes in toxicological parameters measured before treatment (day 1) and on day 9 of treatment with sparsomycin (0.1 mg/kg 
per day)·1 
Units Day 1 Day 9 Comments 
Body weight 
Hemoglobin 
Hematocrit 
WBC 
PMN leukocytes 
Lymphocytes 
Thrombocytes 
Reticulocytes 
Total protein 
Albumin 
Fibrinogen 
Thrombotest 
SCOT 
SGPT 
LDH 
Alkaline phosphatase 
γ-GTP 
Na+ 
K* 
Ca** 
Glucose 
Urea 
Creatinine 
Creatinine clearance 
kg 
mmol/1 
1/1 
xlOVl 
xlO'/l 
χ I0V1 
xlO'/l 
%0 
g/i 
g/1 
mg/l 
% 
IU/1 
IU/1 
IU/1 
IU/1 
IU/1 
mmol/l 
mmol/l 
mmol/l 
mmol/l 
mmol/l 
μπιοΐ/ΐ 
ml/min 
MB 
96 
± 
+ 
046± 
102 
68 
27 
1590 
90 
60 4 
29 7 
1276 0 
>100 
310 
52 4 
352 6 
38 6 
80 
147 0 
3.3 
24 
5.2 
6.5 
66 6 
34 4 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
+ 
+ 
17 
1.1 
0 04 
1 7 
10 
09 
59 
5 
6.9 
1.8 
98 
9.7 
135 
81 
107 
42 
26 
04 
02 
0.6 
19 
18 
7 
100 
109 
05 
169 
12.7 
20 
1100 
04 
55 0 
212 
2910 
9 
55.8 
65.4 
289 0 
64 6 
176 
143 0 
33 
22 
4.4 
3.1 
65 0 
174 
± 
± 
± 
± 
± 
+ 
± 
± 
+ 
+ 
18 
01 
0 05 
12 
10 
10 
29 
08 
11 
3 
±265 
± 
± 
± 
4 
28 
24 
±151 
± 
± 
+ 
± 
± 
± 
± 
± 
± 
24 
94 
8 
07 
01 
1.1 
07 
103 
92 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
0 02 
ns 
0 003 
0 003 
0 003 
ns 
ns 
ns 
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Recovery within 10 days 
Recovery within 2-3 days 
Two dogs died; 
during the experiment, their 
WBC counts rese to reach 
66.1 and 49 2 jusl prior to death 
Recovery within 3-5 days 
Recovery within 10 days 
Recovery within 2 days 
Recovery within 3 days 
All liver enzymes returned 
to normal levels within 10 days 
One dog had overt hepatitis 
Recovery within 10 days 
Recovery within 2-4 days 
Recovery within 10 days 
One dog did not recover until 21 days 
after sparsomycin administration 
One dog died because of uremia 
ns, not significant 
a
 Mean ± SD for 5 dogs 
WBC, leukocytes, PMN leukocytes, granulocytes (PMN-polymorphonuclear leukocytes) 
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FACTOR VII % 
• 01 mg/kg 
^ 0 5 m g / k g 
& 01 mg/kg -9 day 9 
Fig. 7. Recovery of plasma factor VII levels after the final spar­
somycin administration 
additional 24 h and was slower than in the case of the low 
er dose the 100% value was not reached until 108 h after 
drug injection When sparsomycin was administered for 9 
days (dog 063), plasma factor-VII levels remained at a pla­
teau for 9 days After the discontinuation of sparsomycin 
therapy, the plasma factor-VII recovery approximately 
paralleled that observed after a single 0 5-mg/kg dose 
Dog 785 appeared to be deficient in factor VII, having 
'plateau' levels of this protein even before drug adminis­
tration The administration of sparsomycin did not change 
this plateau level 
The thrombotest findings showed control levels 
(> 100%) for 2 days and later started to decline rapidly On 
day 9, a mean value of 9%±4% had been reached (P -
0 002) The 2 dogs with hemorrhagic diathesis had values 
of 5% and 6% 
The liver enzymes serum glutamine-oxolate transferase 
(SCOT), serum glutamme-pyruvate transferase (SGPT), 
alkaline phosphatase, and γ-glutamyl transpeptidase (γ-
GTP) showed elevated levels during and after treatment 
with sparsomycin There was no apparent difference be­
tween anesthesized and nonanesthesizcd dogs However, 
the significance of these changes was difficult to evaluate 
because of considerable scatter One of the dogs (061) de 
veloped overt toxic hepatitis after the discontinuation ol 
treatment The derangements in liver enzyme levels m this 
dog were maximal on day 15, when SCOT increased lo 
280IU/1, SGPT to 1,250 IU/1, and γ GTPto 60 IU/1 Lac­
tate dehydrogenase (LDH) and alkaline phosphatase were 
not excessively elevated The derangements disappeared 
spontaneously, and all liver enzymes in all dogs were at 
normal levels on day 21(12 days after last sparsomycin in­
jection) 
Eve toxicity 
There were no changes in retinal appearance when eyes 
were checked by performing routine fundoscopy At auto­
psy (dogs 892 and 008), no morphological changes in the 
retina were seen 
Discussion 
In our experiments, we treated dogs with a sparsomycin 
dose similar to the maximal dose used in phase-l trials in 
humans [3] 
Dogs under anesthesia had much lower CL»,RSm values 
than dogs without anesthesia This might have been due to 
the specific (enzyme saturation) or nonspecific (decrease 
in liver blood flow) effects of pentobarbital The increase 
in CLS R S m values in expts 5 and 6 when vigorous hydra­
tion was performed, the expansion of the Vj, and the rela­
tive decrease in the amount of the drug recovered in urine 
all point to the second possibility 
In dogs with a low urine flow, a slow γ phase ιγ,
 2, 
about 8 0 h) was seen The CLRSm was very low at this time, 
suggesting that all of the filtered sparsomycin was (active­
ly'') reabsorbed by the renal tubuli This phenomenon 
might be an important factor in producing increased drug 
toxicity However, the γ-phase was not seen in the 2 non-
anesthesized dogs An increase in the urinary flow (expts 5 
and 6) may result in a decrease in the tubular resorption of 
the drug and, therefore, a disappearance of the γ-phase 
On the other hand, dehydration and low urine flows prob­
ably result in an increase in urine sparsomycin concentra­
tion along with a decrease in the level of the enzyme re­
sponsible for drug reabsorption In such a case, all of the 
filtered sparsomycin is excreted in urine (expt la) Addi­
tional hydration and normal diuresis would prevent this 
effect (expt 4a) 
Prolongation of the pentobarbital sleeping time indi­
cates that the activity of cytochrome P450 is low Thus 
sparsomycin might influence the liver metabolism of other 
drugs 
Drug accumulation did not exclusively occur in anes 
thesized dogs In dog 632 (expt I a), the blood sparsomy­
cin levels were not elevated until the last day of treatment 
This observation suggests that, in spite of decreased spar­
somycin renal excretion, the liver metabolism or binding 
capacity was still active or undersaturated until the 9th day 
of treatment From the rapid deterioration of the general 
condition of this dog, it was clear that the observed plasma 
drug accumulation would have resulted in lethal toxicity if 
the experiment had continued 
Continuous sparsomycin infusion provided other in­
teresting data, particularly that the CLRSm could be in­
creased far above the mean CLCR This shows that spar­
somycin is also actively excreted by renal tubuli Active 
excretion can be 'auto-inhibited' by sparsomycin, so that 
the drug clearance drops This results in acute drug accu­
mulation in the plasma This phenomenon cannot be 
compensated for by vigorous hydration and increased 
urine flow Note that a similar phenomenon was also ob­
served for ι ν bolus injections in expts 5 and 6 (Fig 3) 
the CLRSm dropped at the end of experiment but climbed 
again when the sparsomycin plasma levels were no longer 
measurable It is dilficult to propose a reasonable explana­
tion for this phenomenon, as up to now, only a few pro­
tein-synthesis inhibitors have been studied clinically How­
ever, on the basis of our observations, it can be speculated 
that sparsomycin either inhibits the synthesis of a short­
lived transport enzyme in the renal tubuli or that it satu­
rates the capacity of such an enzyme Another possibility is 
that pentobarbital interacts with sparsomycin at the level 
of the renal tubuli 
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hrorn the results of our continuous infusion studies it 
can be anticipated that the use of a higher sparsomycin 
dose would result in nonlinear kinetics with delayed elimi-
nation This did occur, and proved fatal in cxpt 7 (see 
big 4) 
The increase in the urine flow and CL|(sm after the dis-
continuation of drug infusion suggests the existence oían 
unknown vasodepressive activity produced by sparsomy-
cin 
In the view of dose scheduling in the phase-l study per-
formed in 1964 [1], it might be argued that the eye toxicity 
observed in these trials might also have been due to drug 
accumulation This supposition is based on the following 
considerations The human blood retina barrier is usually 
impermeable to water-soluble drugs [4] Moreover, exten-
sive studies on healthy animals have also failed to confirm 
the retinal toxicity seen in humans [14] Our present find-
ings of an absence of eye toxicity are in agreement with 
those of previous studies The permeability of the blood-
retinal barrier, however, can increase in different diseases 
[4], and it is also conceivable that it could be changed un-
der different debilitating conditions, e g , after eye irradia-
tion and/or cancer cachexia Both patients who suffered 
from retinal toxicity had a low initial body weight (50 kg) 
Thus, it is possible that increased drug plasma levels in 
combination with increased blood-retinal barrier perme-
ability could be the reasons for the eye toxicity seen in 
humans 
Our study of beagle dogs was extended in order to 
answer some questions concerning the toxicology of spar-
somycin These studies revealed the influence of 
sparsomycin on liver function Several of the proteins 
studied showed a decrease in their levels that was propor-
tional to their normal turnover time 
Plasma factor VII, which is known to have a short bio-
logical half-life of 4-6 h in humans, showed rapid changes 
after sparsomycin administration to dogs After an initial 
decay to a 10% level, a plateau was observed in all cases 
This plateau, however, was an artefact of the method ap-
plied, as human plasma free of factor VII was used This 
phenomenon has been described and quantified by Poller 
et al [18] in factor Vll-dcfiuent dogs Our results, there 
fore, indicate the total disappearance of factor VII Irom 
the plasma of dogs treated with sparsomycin Using our 
method, however, we were able to determine the length of 
time between the inhibition and restoration of plasma fac-
tor-VIl svnlhesis. this being one aim of the study As in un-
treated factor VII-deficient dogs [18], the absence of this 
coagulation factor did not increase the risk of spontaneous 
hemorrhage 
The disappearance of factor VII from plasma was not 
related to the sparsomycin dose, as 0 5 mg/kg had nearly 
the same effect on this protein as 0 I mg/kg dose and con 
tinuous infusion This suggests that, over a broad dosage 
range, the toxicity of sparsomycin may be dependent not 
on the dosage but on the lenght of the thcrapv and the dis-
appearance of critical proteins ( horizontal' limit) High 
sparsomycin concentrations may inhibit a wider range of 
cellular biosynthesis and a wider range of potentially criti-
cal proteins (respiratory enzymes') and thereby cause 
death ('vertical' limit) 
Factor VII assays, although useless for predicting the 
risk of hemorrhage, might provide sensitive d)namic pa-
rameters for showing the persistence of protein-synthesis 
inhibition in liver cells Theoretically, in our experiments, 
each daily dose was administered just before the recovery 
of I actor VII plasma levels The drug doses should have 
been more spread out during the second part of experi-
ment, as sparsomycin appeared to accumulate in plasma 
It is also of interest to note that the recovery of factor VII 
levels was several times slower than its disappearance, 
which suggests either low synthetic priority or increased 
consumption of factor VII 
The decrease in plasma fibrinogen levels was well 
correlated with drug toxicity, and the duration of therapy 
was clearly limited by this effect The disappearance ι
 ; 
value of 3 S days was very similar to that of human fibri­
nogen, ι e , 3-4 days [9] After the discontinuation of ther­
apy, fibrinogen synthesis recovered promptly, but the ex­
act time of recovery was not estimated in our study Plas­
ma fibrinogen reached supranormal levels 2 days after the 
last sparsomycin dose This, together with a tremendous 
increase in the number of young leukocytes, suggests an 
acute phase reaction, probably as a response to local da­
mage to liver cells The rapid recovery of plasma fibrino­
gen levels suggests a high priority for its synthesis, which 
may explain the suppression of albumin [19] and factor-
VII synthesis 
On day 9, the mean plasma albumin levels had de­
creased by 8 5 g/l The decrease was slower than that ob­
served for factor VII and/or fibrinogen, and probably did 
not contribute to the toxic effect of sparsomycin The dis­
appearance t was only a little lower than the supposed bi­
ological t of albumin in humans [8] 
The liver enzymes SCOT, SGPT, LDH, alkaline phos­
phatase, and γ GTP exhibited moderately elevated levels 
during and after the treatment However, it is difficult to 
differentiate the effect of sparsomycin from the effect of 
combined pentobarbital/sparsomycin toxicity A spon­
taneous return to normal levels occurred within 10 days 
The decrease in creatinine clearance observed in all 
dogs might have been due primarily to prerenal factors 
Dogs treated with sparsomycin vomited frequently and 
were unable to retain water after drinking Additional sub­
cutaneous hydration was insufficient to restore normal 
creatinine clearance levels 
During treatment with sparsomycin, no bone-marrow 
toxicity was observed This is in accordance with the find­
ings of earlier toxicological studies [14] and recent in vitro 
studies [5] During the treatment course, we found de­
creased numbers of reticulocytes (P = 0 01) 
In conclusion, our observations so far allow the fol­
lowing speculations about the pharmacokinetics and toxi­
city of sparsomycin This drug is mainly eliminated by 
metabolic clearance (60%), and this may be inhibited or 
saturated after prolonged drug administration This results 
in drug accumulation in plasma Slow release of the drug 
from its binding sites and the enterohepatic circulation of 
sparsomycin in combination with renal-tubular resorption 
mechanisms may produce chronic, low plasma sparsomy­
cin levels (below detection limits) and protracted toxicity 
Acute auto inhibition' of tubular excretion results in a de­
crease in renal drug clearance and, in the case of continu­
ous infusion, increased drug plasma levels The signifi­
cance ol this mechanism for drug toxicity is unknown A 
decrease in the activity of liver microsomal enzymes (e g , 
cytochrome P450) after prolonged sparsomycin adminis­
tration might change the metabolism of other drugs ad-
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ministered concomiuntlv with sparsonncin jnd thereabv 
potentiate their tovititv 
The dose limiting toxicity lor sparsomycin іь liver toxi­
city and hemorrhage The monitoring ol plasma llbrino-
gen levels and thromhotest data should provide valuable 
indications of sparsomycm toxicity Changes in Гасюг- ІІ 
levels might be a uselul dynamic parameter lor showing 
the effect of sparsomycm on the host liver The renal toxi­
city of sparsomycm should not be considered as dose li­
miting until prerenal factors have been definitively ex­
cluded 
In future studies a prolonged daily schedule of spar­
somycm or its continuous infusion should be used with 
caution To avoid drug accumulation without losing anti­
tumor activity, the dose schedule should be spread out, 
and vigorous hydration should always be employed An­
other possibility would be the introduction of more lipo­
philic sparsomycm analogs that are more easily eliminated 
by the liver, and not by the kidneys Such analogs have re­
cently been developed by our group [1, 10], and prelimi­
nary studies have indicated that they have favorable in vit­
ro [1] and in vivo antitumor activity [26] 
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SUMMARY 
Sparsomycin (Sm) is a well known inhibitor of protein synthesis with anti-
cancer potential. In order to minimize toxicity of this drug and increase 
its activity, several analogues were synthesized. Deshydroxy-Sm (dSm) ap-
peared to be a good candidate for further investigations because of its 
lower toxicity and significantly higher antitumor activity in several 
ascitic tumors m mice. Pharmacokinetic evaluation in beagle dogs was per-
formed with and without anaesthesia using either single i.v. bolus or con-
tinuous infusion administrations. Anaesthesia did not markedly influence the 
pharmacokinetics. Pharmacokinetic profile of dSm was similar to that of Sm. 
The drug was eliminated with a terminal t, /, 0 of 0.8 +^  0.08 hours (48 +_ 5 
minutes). The mean volume of distribution was 0.4 +^  0.06 l.kg . The mean 
total body clearance was 6.3 +_ 0.8 ml.min- .kg" . The drug is eliminated 
mainly by the kidneys (54%). Active tubular secretion and active tubular 
reabsorption of the drug were observed. The pharmacokinetics was linear. The 
lethal dose was 0.73 mg.kg- , administered in 3.2 hours continuous infusion. 
The results of this study provided additional data useful in selection of 
potentially useful analogues for further preclinical studies. 
INTRODUCTION 
Sparsomycin (Sm) is a well known inhibitor of nbosomal protein synthesis 
(1) with a recognized anticancer potential (2,3). The use of this drug was 
limited until 1981 because of the poor availability from the natural 
sources, high costs and toxicity. 
Since 1981 Sm is available through the total synthesis (4) and several 
analogues have been synthesized (5,6,7). These analogues were subject of 
extensive structure-activity relationship studies on in vitro models (5,6,7 
and 8). A novel route of synthesis was introduced in 1987 from L-alanine 
instead of D-cysteine (6). As a result of this a novel Sm-compound : 
deshydroxy-Sm (dSm) has been synthesized without the hydroxyl group at RI 
position (Fig. 1). Preclinical evaluation of dSm revealed unique properties 
of this compound (9). dSm appeared more lipophilic than Sm because of the 
exposure of an additional carbon atom normally "masked" by the hydroxyl 
group (9). The increase in lipophilicity was also accompanied by a fivefold 
increase of water solubility, probably because of increased aggregation of 
the molecules. The LD50 values for dSm in mice were significantly higher 
than that of Sm (23.2 and 11.3 mg.kg" , respectively)(10). dSm appeared to 
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be active on ascitic P388 and L1210 leukemias (T/C = 153% and 206%, respect­
ively), and RC renal cell carcinoma (T/C = 277%) when administered i.p. 
daily χ 9. There was only slight activity on ВІ6 melanoma (T/C = 131%) and 
no activity on C38 colon carcinoma. In the same tumor models the parent drug 
was only borderline active on L1210 leukemia (T/C = 125%) (10,11). Because 
of promising activity, dSm appeared to be one of the candidates for further 
preclinical development. 
0 0 R' 0. 
H 
н 
Fig.l. Structure of Sparsomycin (RI - CHjOH , R2 - CH 3) and deshydroxy-Sm 
(RI - CH 3 , R2 - CH 3). 
In a previous report on pharmacokinetics of Sm in beagle dogs we described 
unusual behaviour of Sm plasma concentrations during continuous infusions 
(12). However, these data could not be interpreted because of the pento­
barbital anaesthesia that influenced drug distribution and excretion (12). 
In the present study, Ethrane/N-O anaesthesia was used and it was compared 
to experiments without anaesthesia. The results of this study help to under­
stand the mechanisms determining the pharmacokinetic behaviour of Sm and 
dSm. 
MATERIALS AND METHODS 
Animals 
Seven beagle dogs; four males (8.6 - 14.6 kg) and three females (8.2 - 10.4 
kg) were obtained from the Central Animal Laboratory of the University of 
Nijmegen, The Netherlands. The dogs were fed with a standard granulated food 
(Hope Farms BV, Maerden, The Netherlands) and had free access to tap water. 
After experiments, the animals were housed in the metabolic cages enabling 
urine collection for at least 24 hours. 
Drugs 
dSm was synthesized as described earlier (6) and was obtained in a freeze-
dried form. The injections were prepared aseptically. The drug was dissolved 
in 0.9% NaCl and was kept in dark flasks at 40C for up to 24 hours. 
0Ж мАч с н 
121 
Pharmacokinetic studies 
The dogs were deprived of food for the last 12 hours before each experiment. 
Exp. 3 - 6 and θ were performed under Ethrane (Abbot, Campoverde, Italy) and 
NjO anaesthesia with thiopenthal (Penthotal, Abbot, Campoverde, Italy) in­
duction (15 mg/kg). Three studies (exp. 1, 2 and 7) were performed without 
anaesthesia and without additional hydration. During each experiment under 
anaesthesia that lasted for 5-7 hours the animals received intravenous 
fluids (0.9% NaCl and 2% mannitol) at the rate of 2.7 ml.mm . The infusion 
rate was controlled by an infusion pump (IVAC, type 531, San Diego, CA, 
USA). Continuous infusions of dSm were administered by a 60 ml syringe 
driver (Infors HT type 5003, Basel, Switzerland) delivering 10 ml per hour. 
The accuracy of the infusion rate was controlled every hour. The remainder 
of the solution was regularly checked for definitive drug concentration (see 
analysis). During experiments, rectal temperature and heart rate (ECG) were 
continuously monitored. Blood samples were drawn through a central venous 
catheter. Samples were centnfuged within 1 hour after collection. Plasma 
was separated and stored at -20oC pending analysis. 
During the whole period under anaesthesia urine was collected through a 
urinary catheter every 10 m m . At the end of each collection period the 
bladder was flushed with 5 ml of salme. Urine samples were made in dupli­
cate for the determination of drug and creatinine concentrations and pH. 
Urine samples were kept out of light at -20oC pending analysis. After the 
dogs woke up from anaesthesia, they were returned to a metabolic cage where 
urine collection and blood sampling were continued for a total of 24 hours. 
Drug analysis 
dSm concentrations in plasma and urine were determined using a high per­
formance liquid chromatography (HPLC) method previously described (13). The 
equipment used was a semi-automated HPLC system from Kratos Analytical, 
Ramsey, NJ, USA. The detection limits for dSm were 10 ng.ml in plasma and 
50 ng.ml in urine. 
Fitting of the curves 
The curves were fitted using semi-log regression on the curve sections 
derived graphically. The area under the fitted concentrations versus time 
curve (AUC) was calculated using the trapezoidal rule. All other pharmaco­
kinetic parameters were calculated according to the following formulae. 
C LdSm = D * A U C " 1 (ml.min"1.kg-1) 
Vd = C L d S m . t 1 / 2 . 0.693-
1
 (l.kg-1) 
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CL_jg = CL(-Sm . % of the dose recovered in urine (ml.min .kg ) 
CLNRdSm = CLdSm " CLRdSm (mi.min-1.kg-1) 
where: 
t1 ¡2 - elimination half-life in the beta phase (hours). 
D - dose (mg.kg" ) 
Vd - volume of distribution in the beta phase (l.kg~ ). 
CLjg - total body clearance of dSm. 
CL-jg - renal clearance of dSm. 
^"NRdSm _ non-renal clearance of dSm. 
RESULTS 
dSm was administered to the dogs either as an i.v. bolus (exp. 1-4) or 
continuous infusion (exp. 5-8). Plasma concentration versus time curves 
showed one distribution and one elimination half-life. The t^ /2a w a s aP~ 
proximately 0.03 hours (2 min) but this could not be determined accurately. 
The t. /J g was 0.8 +^  0.08 hours (48 ^  5 min, mean +__ SD). The mean Vd in the 
beta phase was 0.44 +_ 0.06 l.kg" . The CL^g was dose independent and was 
6.3 +^  0.8 ml.min .kg" . The СЪ„,_ was also dose independent and was 54 +^  
6% of the CLj S m. The CLR(jSm w a s t h e s a m e a s tl:le C LCR v a l u e t 3 · 4 ml .min . 
kg" ). The relation between the dose and AUG was linear (r=0.99) and the 
slope was 2.2. 
The highest dose tested, 0.73 mg.kg" administered as a 3.2 hours in­
fusion, appeared lethal. Dog 172 died during the first night after the 
experiment. This could be the reason of approximately 10-20 % under­
estimation of the CL_.jSra as urine could not be collected for the full 24 
hours. 
A typical i.v. bolus experiment (exp. 4) is presented in Fig. 2. During 
this experiment the urine flow decreased from 1.6 ml.min" at the beginning 
of the experiment to 0.14 ml.min 30 minutes later. Urine flow recovered 
during the 2nd and 3rd hour of the experiment. Plasma pharmacokinetic pro­
file of dSm during continuous infusions is presented in Fig. 3. 
Analysis of plasma concentration versus renal excretion rate function in 
comparison to renal glomerular filtration (Rçp) is shown in Fig. 4. The 
curve showed that the renal excretion rate exceeded the RQ- at con-
centrations between 200 and 700 ng.ml" . At concentrations lower than 100 
ng.ral" renal excretion rate was lower than the Rçp· Similar pictures were 
observed in all other experiments except exp. 8. At the highest dose tested 
(0.73 mg.kg" in 3.2 hours) renal excretion rate was lower than Ρ ™ and the 
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curves were parallel. (Fig. 5). The changes of the renal excretion rate were 
not related to the variations in urine flow. 
Fig. 2. Plasma (9- I) and renal pharmacokinetics(-
-1 
•) of dSm admi­
nistered as an i.v. bolus of 0.57 mg.kg (exp.4). The t./, β = 0 · 8 6 
hour (52 minutes). Urine flow ( ) showed a characteristic 
depression 30 min after the beginning of experiment. 
The urine pH in all experiments was usually higher than 8.0 at the beginning 
of the experiment, decreased to the values of 6.7 - 7.7 in the second and 
third hour of the experiment, and remained at this level until the end of 
urine sampling. 
To assess the influence of anaesthesia on plasma and renal pharmaco­
kinetics of dSm, similar experiments were done in unanaesthesized dogs (exp. 
1 and 2) which did not receive additional hydration. The dogs were rather 
sick after drug administration and vomited frequently in the first three 
hours. The dogs did not urinate spontaneously until 7 - 8 hours later, when 
they passed 50 - 100 ml of highly concentrated urine. In exp. 2 possibly one 
earlier urine sample was lost and the drug recovery in urine could not be 
determined. The CL(jsm ^ n t^ 1 6 3 5 experiments were similar to those obtained 
under anaesthesia. 
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Table 1. Pharmacokinetic data on dSm in beagle dogs. 
Exp. 
nr. 
1. * 
2. * 
3. 
4. 
5. 
6. 
7. * 
θ. 
Means 
+_ SD 
dog 
nr. 
16 
634 
891 
785 
160 
15 
16 
172 
: 
sex 
F 
F 
M 
M 
M 
F 
F 
M 
body 
weight 
(kg) 
9.7 
10.4 
14.6 
14.0 
11.6 
8.2 
9.2 
8.6 
dose 
(mg.kg-1) 
0.31 
0.32 
0.42 
0.57 
0.14 
0.22 
0.23 
0.73 
type ь1/2 S 
of exp. (hours) 
iv bolus 
iν bolus 
iv bolus 
iv bolus 
3.2 h. inf. 
4 h. inf. 
2 h. inf. 
3.2 h. inf. 
0.6 
0.7 
0.8 
0.9 
0.8 
0.8 
0.8 
0.9 
0.8 
0.08 
C
S s 
(ng.ml-1) 
118 
148 
+ 300 
542 
AUC 
(mg.h.l-1) 
0.8 
0.8 
1.2 
1.4 
0.4 
0.6 
0.7 
1.7 
Vdß 
(l.kg-1) 
0.4 
0.4 
0.5 
0.5 
0.4 
0.4 
0.4 
0.5 
0.4 
0.06 
CLdSM 
6.7 
6.9 
6.7 
6.9 
5.6 
6.0 
4.8 
7.1 
6.3 
0.8 
CLRdSm 
ml.min" 
3.9 
-
3.8 
3.9 
2.8 
3.3 
2.9 
3.1 
3.4 
0.5 
CLCR 
•
1
.»cg-
-
-
3.5 
3.5 
3.8 
2.3 
-
3.7 
3.4 
0.4 
CLNRdSm 
1 
2.8 
-
2.9 
3.0 
2.8 
2.7 
1.9 
4.0 
2.9 
1.2 
* experiments without anaesthesia. 
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Fig. 3. Plasma pharmacokinetics of dSm actninistered as continuous infusions. 
-1 —1 
( о ) exp. 5, 0.14 mg.kg in 3.2 hours. ( • ) exp. 6, 0.22 mg.kg 
in 4 hours. ( • ) exp. 7, 0.23 mg.kg- in 2 hours without narcosis. 
( · ) exp. Θ, 0.73 mg.kg" in 3.2 hours. In all cases, the t 1 /jS w a s 
0.83 + 0.02 hours (50 + 1 minutes). 
The CIiD(3sm
 a n d CLNRdSm v a l u e s l n exp. 1 were also within the range found 
during experiments under anaesthesia. The ti/^ß3 0 · 6 2 hours (37 minutes), 
was only slightly shorter than under anaesthesia and the Vd was smaller. 
During continuous infusion experiments (exp. 5-8) the steady state (C ) 
was reached after 2 - 3 hours of infusion (Table 1). С was reached in all 
but one experiment. In this experiment without anaesthesia (nr 7) dSm was 
infused for only 2 hours. Initially it was intended to infuse the drug for 3 
- 4 hours, but the dog was restless and vomited frequently so it was decided 
to terminate the infusion after 2 hours. The С reached during continuous 
ss
 3 
infusions were in a linear relation with the dose rate (r = 0.99). After 
discontinuation of infusion the drug was eliminated with a mean t./τ0= 0.83 
+_ 0.02 hours (50 +_ 1 m m ) . 
In exp. 5, exceptionally, urine was collected 48 longer than usually and 
also blood samples were obtained regularly in this time. In the second day 
of experiment plasma concentrations of approximately 20 - 50 ng.ml were 
again detectable and formed a bell-shape curve for about 8 hours. Highest 
plasma concentrations were seen 32 hours after beginning of experiment. In 
the same time no drug in urine was detectable. 
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О 400 800 
plasma conc(ng ml"1) 
Fig. 4. Tubular titration curve in exp.4. lUp was calculated from the mean 
CL-p.1.25. The curves were constructed from the renal excr. rate 
values in 10 minutes urine portions and fitted plasma con­
centrations. At low dSm plasma concentrations active tubular re-
absorption is responsible for renal excretion rates lower than R Q F · 
At higher dSm plasma concentrations active tubular excretion causes 
renal excretion rates higher than Hçp· 
DISCUSSION 
In pharmacokinetic evaluation of new drugs in dogs, the choice of 
anaesthesia plays an important role. In a previous study we have reported an 
unusual behaviour of plasma concentrations of Sm during continuous infusion 
(12). However, the data could not be interpreted definitely as the pento-
barbital anaesthesia used in these studies influenced drug distribution as 
well as renal and total-body clearances (13). In the present study we used 
Ethrane/Nn0 anaesthesia which proved to have much less influence on drug 
pharmacokinetics. The data obtained in this study during experiments under 
anaesthesia are very well comparable to those obtained during three exper-
iments without anaesthesia. To obtain sufficient urine flow and constant 
CL__, intensive hydration with saline and 2% mannitol was necessary. Even 
under these conditions a clear depression of the urine flow was always 
observed within 20-3 0 minutes after administration of the drug. 
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Fig. 5. Tubular titration curves in exp. 8. Renal excretion rate 
constantly below the RQJ, values. 
In dogs without anaesthesia and without additional hydration, administration 
of dSm was accompanied by oliguria that lasted for 7 - 8 hours. These dogs 
additionally lost fluids by vomiting. The drug was detectable in the gastric 
juice in only trace amounts (unpublished observation). Depression of the 
urine flow did not cause the decrease of CL-- and/or C L R d S m except for the 
extreme cases when the urine flow was approximately 0.1 ml.min 
Depression of the urine flow may suggest vasoactive properties of dSm. 
Protein synthesis inhibitors are known to inhibit de-novo synthesis of 
prostaglandin-synthase which has an extremely short half-life of 5-10 
minutes (14). Inhibition of the key enzyme for de-novo synthesis of several 
kinds of prostaglandins may induce temporary disbalance and higher activity 
of the species with longer half-lives. When eventually both types of 
Prostaglandines, vasoconstrictive and vasodilatative, will disappear, 
balance will be restored and the diuresis will reappear because of the 
intravascular accumulation of fluid and mannitol. Restoration of the urine 
flow even before termination of drug infusion is very suggestive for such a 
mechanism. 
Analysis of the plasma concentration and renal excretion rate function 
was performed following the computer models elaborated by Heekman and Van 
Ginneken (4) and showed the combination of three effects. At first, dSm is 
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excreted by the RGp· Secondly, the drug is actively secreted by the renal 
tubuli what is suggested by the renal excretion rate higher than "çp· 
Thirdly, the drug is actively reabsorbed by the tubuli. At the highest dose 
tested (exp. Θ, 0.73 mg.kg" in 3.2 hours) tubular secretion was saturated 
and the renal excretion rate was less than Rçp» suggesting that renal 
tubular secretion may be easier saturated than the renal tubular reabsorp-
tion which can result in decrease of CLpHcm· 
In the present study, dSm was tested at the doses comparable to those of 
Sm studied before (12). The pharmacokinetics of dSm and Sm are essentially 
the same. The phenomenon of exponentially increasing Sm plasma con-
centrations during continuous infusion is probably related to the type of 
anaesthesia. At the same dose, dSm plasma concentrations did not show any 
abnormal behaviour. Sm as well as dSm are cleared from the plasma by an 
additional non-renal clearance (a.o. tissue binding?) and this clearance may 
be saturated by pentobarbital used in previous study, but not by other 
anaesthetics. This might be an explanation for the increase in plasma con-
centrations seen during continuous infusion of Sm. In that case, rapid 
decrease of CL_S suggested during these studies is only apparent and is an 
effect of unchanged CL R S divided by the increasing Sm plasma con-
centrations. The suggestion of tissue binding may be supported by the 
finding that unchanged dSm may be detected in plasma 32 hours after the 
beginning of experiment, suggesting that some of the drug may be bound to 
the tissues and released thereafter. dSm may also circulate in the entero-
hepatic loop. 
In conclusion, dSm and Sm showed similar pharmacokinetics. The dose/AUC 
relation is linear until the lethal dose. A saturable tubular clearance is 
proposed. dSm may be a good candidate for further preclinical development. 
REFERENCES 
1. Monro RE, Celma ML, Vazquez D. Action of sparsomycin on ribosome-
catalyzed peptidyl transfer. Nature 1969;222:356-358. 
2. Ottenheijm HCJ, van den Broek LAGM, Ballesta JPG, Zylicz Z. Chemical and 
biological aspects of sparsomycin, an antibiotic from Streptomyces. In: 
Progress in Medicinal Chemistry. Ellis GP, West GB (eds), Elsevier 
Science Publications, Amsterdam, 1986, pp 219-268. 
3. Owen SP, Dietz A, Camiener GW. Sparsomycin, a new antitumor antibiotic. 
II; Discovery and biological properties. Antimicrob Agents 1962;772-779. 
4. Ottenheijm HCJ, Liskamp RMj, van Nispen SP, Boots HA, Tyhuis MW. Total 
129 
synthesis of the antibiotic sparsomycin, a modified aminoacid monoxo-
dithioacetal J Org Chem 1981;46:3273-3284. 
Broek vd LAGM, Liskamp RMJ, Colstee JH, Lelieveld Ρ, Remacha M, Vazquez 
D, Ballesta JPG, Ottenheijm HCJ. Structure activity relationships of 
sparsomycin and its analogues. Inhibition of peptide bond formation in 
cell-free systems and L1210 and bacterial cell growth. J Med Chem 
1937;30:325-33. 
Broek vd LAGM, Lázaro E, Fennis PJ, Missler FA, Lelieveld Ρ, Ballesta 
JPG, Ottenheijm HCJ. Structure-activity relationship studies on sparso­
mycin analogues. Lipophilic analogues as strong inhibitors of protein 
synthesis and cell growth. J Org Chem, 1988, in press. 
Liskamp RMJ, Colstee JH, Ottenheijm HCJ, Lelieveld Ρ, Akkerman W. 
Structure-activity relationships of sparsomycin and its analogues. 
Octyl-sparsomycin: the first analogue more active than sparsomycin. J 
Med Chem 1984;27 : 301-306. 
Ottenheijm HCJ. SAR of antitumor agents; endeavours involving sparso­
mycin. In: Innovative approaches in drug research. Harms AF (ed). 
Amsterdam, Elsevier Science Publishers BV, 1986, pp 42 5-435. 
Zylicz Z, Wagener DJT, Garzotto M, Vree ТВ, van der Kleijn E, Lelieveld 
Ρ, Ballesta JPG, van den Broek LAGM, Ottenheijm HCJ. Comparison of in 
vitro and in vivo biological activity of two homologous series of 
sparsomycin (Sm) analogues. Proc. 15th Int. Congress of IUCC. Istanbul, 
Turkey, 19-24 July 1987. Progress in Chemotherapy. Anticancer section. 
Vol.3, pp. 292-299. 
Zylicz Z, Wagener DJT, van Rennes Η, van der Kleijn E, Lelieveld Ρ, van 
den Broek LAGM, Ottenheijm HCJ. In vitro antitumor activity of sparso­
mycin and its analogues in eight murine tumor models. Invest New Drugs, 
1988 submitted. 
Zylicz Z, Wagener DJT, van Rennes Η, van der Kleien E, van den Broek 
LAGM, Ottenheijm HCJ. Antitumor activity of Sparsomycin (Sm, NSC 059729) 
and its analogues (Abstract). Invest New Drugs 1987;5:84. 
Zylicz Z, Wagener DJT, Fernandez del Moral P, van Rennes Η, Winograd В, 
van der Kleien E, Vree ТВ, van Haelst U, van den Broek LAGM, Ottenheijm 
HCJ. Pharmacokinetics and toxicology of sparsomycin in beagle dogs. 
Cancer Chemother Pharmacol 20:115-124,1987. 
Winograd B, Oosterbaan MJM, van der Kleijn E, Liskamp RMJ, Ottenheijm 
HCJ, Wagener DJT. Determination of sparsomycin in plasma and urine of 
the dog by means of reversed-phase high performance liquid chromato­
graphy and first pharmacokinetic results. J Chromatogr (Biomed Appi) 
130 
1983;275: 145-153. 
14. Fagan JM, Goldberg AL. Inhibitors of protein and mRNA synthesis cause a 
rapid block in prostaglandin production at the prostaglandin synthase 
step. Proc Natl Acad Sci USA 1986;33:2771-2775. 
15. Heekman Ρ, van Ginneken CAM. Kinetic modelling of the renal excretion of 
iodopyracet in the dog. J Pharmacokin Biopharm 1982;10:77-92. 
131 

CHAPTER 1 1 
DOSE-DEPENDENT PHARMACOKINETICS OF ETHYL-DESHYDROXY-SPARSOMYCIN 
IN BEAGLE DOGS 
Zbigniew Zylicz, D.J. Theo Wagener, Véronique de Valk-Bakker, 
Tom В. Vree, Eppo van der Kleijn, Leon A.G.M, van den Broek, 
Harry C.J. Ottenheijm. 
Submitted to: Cancer Chemother. Pharmacol. 
133 
SUMMARY 
Sparsomycin (Sm) is a known inhibitor of protein synthesis. Some analogues 
of this drug proved to be less toxic and more active in several murine tumor 
models. Ethyl-deshydroxy-Sm (EdSm) was found to be one of the promising 
compounds of this class. The preclinical pharmacokinetics of EdSm was inves­
tigated in beagle dogs under anaesthesia. A dose range of 0.16 - 0.5 mg 
EdSm.kg was investigated. EdSm was administered either as an i.v. bolus or 
4 - 5 hours i.v. infusion. The t. /, β in the i.V. bolus experiments was 0.3 
hours and t^ /j γ varied from 2,0 to 4.2 hours. EdSm administered as an 
infusion produced higher AUG values than the same dose administered as an 
i.v. bolus. This was due to decrease of the renal clearance occunng 3 - 5 
hours after the start of infusion. EdSm was actively secreted as well as 
actively reabsorbed by the renal tubuli. Both processes were saturable. The 
dose/AUC relation was non-linear. Two dogs died after the experiments (0.4 
and 0.5 mg EdSm.kg" ) because of inhibition of respiratory center and heart 
arrhytmia. The lethal doses were lower than the lethal doses seen for other 
analogues. The drug was considered more toxic than the other analogues due 
to non-linearity of its pharmacokinetics. 
INTRODUCTION 
Sparsomycin (Sm, NSC-059729) is a well known inhibitor of protein synthesis 
(1) with anticancer potential (2). The drug administered daily for 1 3 - 1 7 
days appeared to be too toxic to be used in humans (3), however recently 
prepared analogues of this drug are very promising as they are less toxic 
and more active in vitro and in vivo than the parent drug (4,5,6,7). Some 
modifications of the chemical structure (see Fig.1) are of particular im­
portance. Increase of drug lipophilicity by elongation of the R2 side chain 
appeared to increase in vitro effectivity of the drug (8). Removal of 
hydroxyl group from the RI position made the compound better water soluble 
and significantly increased the LD50 and antitumor activity in mice (8). One 
compound, ethyl-deshydroxy-Sm (EdSm), appeared to be outstanding because of 
good water solubility, high LD50 and good in vivo antitumor activity. This 
compound showed activity on ascitic P388 and L1210 leukemias (T/C=150 and 
172%, respectively), and on RC renal cell carcinoma (T/C=197 % ) . When the 
sensitive tumor (L1210) was inoculated s.c. EdSm was the only active Sm 
analogue (T/C=139%) (8). EdSm also showed significant potentiation of cis-
platin activity in the same L1210 s.c. model (unpublished). Similar poten-
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tiation activity was found previously in L1210 i.p. model with Sm (9). 
Furthermore, EdSm's dose-limiting toxicity was neurotoxicity, while lethal 
toxicity of Sm consisted of haemorrhage (unpublished). The last type of 
toxicity was seen in all hydroxylated compounds, but not in deshydroxylated 
Sms. Thus, EdSm appeared to be one of the promising analogues to be studied 
in phase I in man. Here we report the preclinical pharmacokinetics of EdSm 
in beagle dogs. This model has been used for the studies on Sm toxicity and 
pharmacokinetics previously (10). 
0 0 R' 0 
H 
H 
Fig. 1. Structure of sparsomycin (Sm) 
Sm: Ri - CH20H R2 - CH3 
EdSm: Ri - CH3 R2 - CH2-CH3 
MATERIALS AND METHODS 
Animals 
Five beagle dogs, two males (weight 10 - 13.5 kg) and three females (weight 
9 - 10.5 kg) were obtained from the Central Animal Laboratory of the Uni-
versity of Ni]megen. The dogs were used several times in the pharmacokinetic 
experiments with at least a 3 month rest period between tests. Before the 
dogs were accepted for these experiments, their general condition, body 
weight and kidney and liver functions were evaluated. The dogs were fed a 
standard granulated dog food (Hope Farms, Woerden, The Netherlands) and had 
free access to the tap water. The pharmacokinetic experiments were performed 
under anaesthesia (see below), after which the animals were housed in meta-
bolic cages enabling urine collection for a total of 24 hours. 
Drug and formulation 
EdSm was synthesized following a modified method (10) and was obtained in a 
freeze dried form. The drug was dissolved in 0.9 % NaCl in a concentration 
of 1.0 mg.ml" . The solutions were prepared aseptically by the hospital 
pharmacy. The dissolved drug was stored in dark flasks at 40C for at most 24 
hours. 
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Pharmacokinetic experiments 
The dogs fasted for the last 12 hours before each experiment. Experiments 
were performed under Ethrane (Enflurane, Abbot, Campoverde, Italy) and N20 
anaesthesia with thiopenthal (Penthotal, Abbot, Campoverde, Italy) induction 
(15 mg.kg ). This anaesthesia was found superior to previously used pento­
barbital anaesthesia (10) as it produced more stable circumstances and did 
not depress renal and non-renal clearances (13). Each experiment lasted for 
5-7 hours. The animals received intravenous fluid (0.9% NaCl and 2% man-
nitol) at a rate of 2.7 ml.min" . The infusion rate was controlled by a punp 
(IVAC, type 53 1, San Diego, CA, USA). Continuous infusions of EdSm were 
administered using a 60 ml syringe driver (Infors HT, type 5003, Basel, 
Switzerland) at a rate of 10 ml.h" per hour. The accuracy of infusion rate 
was controlled every hour. Definite drug concentration was determined in the 
remainder of the solution (see analysis). During these experiments, the 
rectal temperature and heart rate (ECG) were continuously surveyed. Blood 
samples (5 ml) were drawn in hepannized vacuum tubes through a central 
venous catheter. The samples were centnfuged within one hour of collec­
tion. Plasma was separated and stored at -20oC pending analysis. 
During whole period under anaesthesia urine was collected through a 
urinary catheter every 10 min; except in exp. 5 where urine samples were 
collected every 20 minutes. At the end of each collection period, the blad­
der was flushed with 5 ml 0.9% NaCl. Urine samples were made in duplicate 
for determination of the drug and the creatinine concentrations. Urine 
samples were kept in the dark at -20oc pending analysis. 
Drug analysis 
EdSm concentrations in plasma and urine were determined using the reversed 
phase HPLC method as described previously (11). Plasma samples were depro-
teinized with 10% trichloroacetic acid (Aldrich, Brussel, Belgium). A 
semiautomated HPLC system from Kratos Analytical (Ramsey, NJ, USA) was used. 
The system consists of two spectroflow 400 pumps, Multiport Streamswitch 
with two six way valves (Rheodyne, Cotati, CA, USA), a 757 UV-Vis Detector 
and DS 610 Multirange strip chart recorder. The system was operated by means 
of an HPLC solvent programmer (type 9224, Kipp Analytical, Rotterdam, The 
Netherlands). The connection of the sampling valves for the reverse 
flushing method has been described elsewhere (11). The columns used were a 
concentration column (50 mm χ 3 ram id) filled with LiChrosorb RP-3 (10 jum 
particle size) and an analytical column (100 mm χ 4.6 mm id) filled with 
CP m Spher С (Θ jum particle size); both packing materials were from Chrom-
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pack BV, Middelburg, The Netherlands. Solvent A (flow 1.3 ml.min ) for 
sample concentration consisted of distilled water. Solvent В (flow 1.0 
ml.rain ), to flush the sample from the concentration column through the 
analytical column, consisted of 40% methanol (Fisons, Loughborough, England, 
HPLC grade) in distilled water. Drug concentrations were determined by the 
comparison of the sample peak heights with standards made from untreated 
control plasma spiked with known concentrations of the drug and incubated 
for 1 hour at 370C. The accuracy of the calibration curves were estimated by 
comparing the concentration to peak height ratios for five different concen­
trations. The calibration curve was acceptable when the SD of the ratios was 
lower than 5%. The detection limits for EdSm in plasma was 10 ng.ml and in 
urine 50 ng.ml" . 
Protein binding assays 
The protein binding of EdSm was determined using an ultrafiltration method. 
Prior to these studies, no aspecific drug binding to the filters (EMIT free 
level TM, Syva, Palo Alto, CA, USA) was found. Heparinized plasma samples 
were centrifugea through the filters at 2500 g for 20 min. Drug recovery 
after ultrafiltration was subtracted from the total drug concentration 
obtained from the deproteinized sample. The amount of drug retained on the 
filter is expressed as the percentage of the total drug concentration. 
Fitting of the curves 
Curves were fitted by semi-log regression of the graphically identified 
elimination phases and by the usual stripping method. The AUC was calculated 
using the trapezoidal rule for the fitted concentrations. Other pharmaco­
kinetic parameters were calculated from the following equations: 
CLEdSm = D ' A U C ~ 1 (ml.min"1.kg-1) 
CLREdSm = C LEdSm ' * o f t h e d o s e recovered in urine (ml.min" .kg" ) 
^NREdSm = C LEdSm " CLREdSm (ml.min"1.kg-1) 
where: 
D - dose (mg.kg" ) 
t.| /j ~ elimination half-life 
CL·.« - total body clearance of EdSm 
^REdSm ~ r e n a : l- clearance of EdSm 
^NREdSm " n o n ~ r e n a l clearance of EdSm 
AUC - area under the concentration versus time curve. 
The tubular titration curves were constructed and interpreted according 
to the model elaborated by Heekman and Van Ginneken (12). 
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RESULTS 
i.V. bolus experiments 
EdSm administered as an i.v. bolus at the dose levels of 0.24 - 0.5 mg.kg 
showed one distribution alpha phase and two elimination phases, t^ , ^ was 
approximately 0.03 hours (2 minutes) but it was difficult to determine it 
accurately. The t 1 /^  ß w a s ".3 - 0.6 hours (20 - 36 minutes), and t-j ^ч ^*33 ^ 
- 4.2 hours (see Table 1 and Fig. 2 and 3 ) . In exp. 2 no gamma phase was 
detectable, however the pattern of the renal excretion rate profile sugges­
ted its existence. This is the reason of the longer t 1/2f 0.6 hours (36 
minutes) found in this experiment. Dog nr 891 (exp. 3) died directly after 
termination of anaesthesia, probably due to depression of the respiratory 
center. Early death might be the reason for 10 - 20 % underestimation of the 
mean C L R E ( j S m and similar overestimation of С ^ п Е а З т ' 
itf-a-
3 4 5 
lime (hours) 
Fig. 2. Plasma and renal pharmacokinetics of ethyl-deshydroxy-Sm in exp.1 
administered as an i.v. bolus, 0.24 mg.kg 
excreted in the urine after 24 hours. The t 
t1/2Y w a s ^'^ hours. 
1/2 
59 % of the dose was 
was 0.3 hours and 
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Table 1. Pharmacokinetic parameters of ethyl-deshydroxy-Sm in beagle dogs. 
Exp. dog sex body dose type ti/2 ^ 
nr. nr. weight (mg.kg ) of exp. (h) 
(kg) 
1. 634 F 10.5 0.24 iv bolus 0.3 
2. 633 F 9.5 0.25 iv bolus 0.6 
3. 891 M 13.5 0.5 iv bolus 0.3 
t-» 
ы 
Φ 
4. 16 M 10.5 0.16 4 h. inf. 
5. 633 F 9.6 0.19 4 h. inf. 
6. 633 F 9.9 0.22 5 h. inf 
7. 15 F 8.9 0.4 4 h. inf. 
t1/2 Ύ A U C C LEdSm CREdSm C LCR CLNREdSm 
(h) (mg.h.l-1) 
ml.min .kg 
4.2 0.5 7.4 4.3 4.1 3.0 
0.6 7.0 3.4 4.1 3.6 
2.0 1.7 5.0 2.5 1.6 2.5 
1.3 0.4 6.4 4.5 2.6 1.9 
0.Θ 0.5 6.6 4.5 3.8 2.1 
0.6 0.6 5.9 4.1 3.4 1.8 
1.5 1.9 3.5 1.0 1.6 2.5 
In exp. 1 (Fig. 2) drug was first eliminated with a t^ /j β of 0.3 hours. In 
the second hour of the experiment EdSm plasma concentrations showed slight 
temporary increase of plasma levels that could not be explained by depres­
sion of the CLDj;
<
js
ra
· in this experiment initially, renal excretion rate was 
lower than R-- (Fig.4). When the plasma concentrations decreased to approxi­
mately 100 ng.ml" , EdSm was eliminated only by the Rcp- This coincided with 
the temporary increase of plasma concentrations (Fig. 2) which were probably 
of non-renal origin. At the end of experiment, again, renal excretion rate 
became lower than the Я~„ which produced a slow t^/2 У 0^ * · ^ hours. 
i o ! -
; 
. 
1 0 * -
. 
• 
1 0 s -
1 0 ! -
renal excr rate 
ng mm ' 
^Ч 
Ί 
^ ^ ^ ^ 
plasma cone L r ^ -
\ ng ml"1 
^ ^ - ^ 
^ ^ > - ^ _ Hog 891 
3 4 5 
time (hours) 
Fig. 3. Plasma and renal pharmacokinetics of EdSm in exp.3 administered as 
an i.v. bolus, 0.5 mg . kg" . The t. ,, 3 was 0.3 hour and t1 /2 γ
 w a s 
2.0 hours. 69% of the dose was excreted in urine until the dog died 
at t»10 hours. 
At higher dose, drug was eliminated exclusively by the Rçp and no tubular 
secretion or reabsorption were observed (Fig. 5). 
• 1 . 
Continuous infusions 
EdSm was infused at different doses (0.16 - 0.4 mg.kg-' ) for 4 to 5 hours. 
In all experiments a shortstanding steady state was observed within 1 hour 
after the start of infusion. This primary steady state lasted for only 20 
- Θ0 minutes. After this time plasma concentrations started to increase and 
if drug was infused long enough, new, secondary steady state was produced. 
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Fig. 4. Tubular titration curve in exp. 1 , i.v. bolus injection. This curve 
was constructed from the renal excretion rates of individual 10 
minutes urine samples and fitted plasma concentrations. The Rgp was 
calculated from the CL, CR 1.25. Renal excretion rates lower than 
Rç F suggest active tubular reabsorption. 
40-
30-
20-
10-
0-
renal excr rate 
(^jg mm"1) 
^ - - ' ' R G F 
, · ' ' 
,'
x 
·'' 
Л ' ' 
ψ' 
·*< y 
.'* 
^ 
400 Θ00 
plasma cone (ng ml"1) 
1200 
Fig. 5. Tubular titration curve in exp. 2 , i.v. bolus injection of 0.5 
mg EdSm.kg . EdSm was cleared exclusively by the IU_. Both tubular 
secretion and reabsorption mechanisms are saturated almost Immedi­
ately after drug administration. 
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After discontinuation of the infusions, plasma concentrations decayed 
rapidly with a t 1 ^ γ ranging from 0.6 to 1.5 hours. In exp. 5 plasma EdSm 
concentrations decayed rapidly for about 30 min and afterwards showed tem­
porary slowing of drug elimination that was restored again after another 30 
min. The terminal t ^ y ^ s 0·6 hour (36 minutes). 
Analysis of the tubular titration curves in exp.4 (Fig. 6) showed that at 
the low dose EdSm initially was actively reabsorbed by the renal tubuli, but 
when the infusion was continued, the drug was also actively secreted by the 
tubuli (Fig. 7). This process appears saturable at the higher plasma concen­
trations and the drug continues to be eliminated only by the Rcp· This 
saturation was accompanied by the formation of the secondary steady states. 
When the drug infusion was discontinued, drug was eliminated initially only 
by the Η ™ but later, active tubular reabsorption started to play a role. 
This was the cause of prolonged terminal t. /,Ύ observed in these cases. In 
exp.6 (Fig.8) the pattern was essentially the same (data not shown). After 
discontinuation of drug infusion, desaturation of the renal reabsorption 
mechanisms was observed what resulted in temporary increase of plasma con­
centrations. It is probable, that later, renal tubular secretion mechanisms 
recovered too and the drug was eliminated with a shorter terminal t^ ,^γ of 
0.6 hours (36 minutes). 
Dog nr 15, (exp. 4) which received 0.4 mg.kg" in 4 hours, died several 
hours after experiment due to cardiac arrhytmia and circulatory insuf­
ficiency. In this experiment too, a 10-20 % underestimation of the CL_ EJ S 
can be expected as the urine could not be collected for a period of 24 
hours. 
During the experiments a constant pattern of urine flow fluctuations was 
observed. After a very high urine flow (2-5 ml .min" ) observed in the first 
10 - 15 minutes of experiment, a urine flow depression was followed. The 
urine flow values frequently decreased to 0.3 - 0.5 ml.min" but restored to 
the average value of 0.75 ml.min" in the second and third hour. After 
termination of infusion, a small increase of urine flow was frequently 
observed. The pH values were initially 8.0-8.4 and decreased to the values 
of 7.0 - 7.6 later in the experiment. 
Dose / AUG relationship 
Analysis of the dose/AUC relationship showed that i.V. bolus and continuous 
infusions followed a different pattern (Fig. 9 ) . Continuous infusions, 
especially that of 5 hours (exp. 5, Fig. 8) showed steeper increase of the 
dose/AUC relation. 
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Fig. 6. Plasma and renal pharmacokinetics of EdSm in exp.4 administered as 
continuous infusion, 0.16 mg.kg" in 4 hours. 70% of the dose was 
recovered in urine after 24 hours. The terminal elimination t 
was 1.3 hours. 
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At higher doses, the mean СЬ__-_ tended to be lower than the mean CL_ R 
(Table 1 ) , while the CL, NREdSm remained constant (2.5 + 0.7 ml.min .kg ). 
The mean CL. REdSm decreased in a dose-dependent manner (r = - 0.96) with an 
exception of exp. 3 where immediate saturation of the tubular reabsorption 
resulted in relatively high C L ™ - - . 
Protein binding 
To determine protein binding, ten blood samples from different experiments 
with EdSm plasma concentrations varying from 54 to 6 0 ng.ml" were assayed. 
Protein binding appeared to be constant in this concentration range and was 
40.5 + 2.θ %. 
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Fig. 7. Tubular titration curve obtained in exp. 6 after administration of 
EdSm as continuous infusion. Drug is extensively secreted by the 
renal tubuli which can be concluded from the renal excr. rates 
higher than Rgp· Tubular secretion was saturated at the end of 
infusion and this was the reason for increase of plasma concen-
trations (see Fig. 6). After discontinuation of infusion EdSm was 
excreted initially only by the RQJ.· Lateron renal reabsorption 
mechanisms became desaturated and this was the cause of temprorary 
slowing of drug elimination from plasma. 
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Fig. 8. Plasma and renal pharmacokinetics of EdSm in exp. 6 administered as 
continuous infusion, 0.22 mg.kg" in 5 hours. 70% of the dose was 
recovered in urine after 24 hours. The primary steady state was 
established after 1.5 hours and in the 4th and 5th hours a new 
steady state was established. Terminal t1 ^Ч was 0.6 hours. 
DISCUSSION 
EdSm showed non-linear pharmacokinetics. At lower doses 50 - 70% of the 
drug dose was excreted in urine (CL---- ). During experiments a great varia­
bility of ^-^REdSm w a s observed which was the result of changes in tubular 
reabsorption and secretion. In low dose continuous infusion drug was elim­
inated predominantly by the Г(-„ and tubular secretion. When this process was 
saturated the CL^,,^ decreased because of domination of tubular re-
absorption. This was the reason of the dose-dependent decrease of CLiiE(jSm* 
However, when the tubular reabsorption mechanisms became saturated too, 
CLREdSm d e c r e a s e d to the value of Rcp· This was seen clearly in case of exp. 
3. Changes in <^LREdSm w e r e *-^е reason of non-linearity of the dose/AUC 
ratio. The dose/AUC ratio for infusions was steeper than that for i.v. bo­
lus. Because of the non-linear pharmacokinetics in cont. infusions and i.v. 
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Fig. 9. Relation between the dose and AUG was dependent by the mode of 
administration; i.v. bolus (·) or continuous infusion ( О ). The 
figure shows a dose-dependent increase of AUG due to accumulation of 
EdSm in plasma. 
bolus EdSm appeared to be more toxic in dogs than the two other Sm ana­
logues, which showed a linear pharmacokinetics (deshydroxy-Sm) or non-linear 
pharmacokinetics with a much less steep increase of the dose/AUC relation 
(n-pentyl-Sm, unpublished). 
These experiments showed clearly, that the changes of renal tubular 
secretion and reabsorption were due to saturation of the carrier proteins 
and not inhibition of their synthesis and decay of activity. In the latter 
case the changes would be time but not dose dependent. 
From the above experiments it may be concluded that EdSm is predominantly 
excreted by the С^дсщ an<î saturation and desaturation of tubular secretion 
and resorption mechanisms determines its complicated pharmacokinetics. EdSm 
which had the highest LD50 in mice among all Sm analogues and showed good 
antitumor activity, showed non-linear pharmacokinetics in the dog with a 
steep increase of the dose/AUC relation. Two dogs died because of drug 
toxicity at doses which were lower than non-toxic doses of the other ana-
logues. The mechanism of this non-linear pharmacokinetics might be related 
to the inhibition of the synthesis and/or saturation of enzymes involved in 
the tubular secretion of the drug. 
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SUMMARY 
N-pentyl-sparsomycin (PSm) is a lipophilic analogue of sparsomycin (Sm), 
which is a well known inhibitor of protein synthesis. This compound was 
selected for preclinical pharmacokinetic studies because of its high in 
vitro and in vivo antitumor activity. In this study in which the drug was 
evaluated m beagle dogs under anaesthesia, the drug concentrations in 
plasma, urine and bile samples were determined using high performance liquid 
chromatography (HPLC). Plasma protein binding was approximately 54%. The 
mean t1 ,2 ß w a s ".2 hours (12 minutes) and t1 /, γ was 0.75 +_ 0.1 hours (45 +6 
minutes). During continuous infusions up to 5.25 hours, the steady state was 
reached in 3 out of 6 experiments, suggesting that in some cases the real 
ь1/2У а з l o n 9 e r than measured. PSm was actively reabsorbed from the renal 
tubuli. This process was saturable at the higher doses. Tubular reabsorption 
played only a minor role in pharmacokinetics as most of the drug (67%) was 
eliminated by the non-renal clearance. The non-renal clearance was saturable 
at higher doses of PSm and was the reason for non-linearity of pharmaco­
kinetics. 
INTRODUCTION 
Sparsomycin (Sm, NSC-059729), an antibiotic isolated in 1962 from Strepto-
myces sparsogenes ( 1) is a well known ribosomal protein synthesis inhibitor 
(2). The drug showed a potent anticancer activity in KB cells in vitro and 
m some rodent tumors in vivo (2,3). In 1964 Sm was studied in a phase I 
clinical trial but its testing was discontinued because of unusual retinal 
toxicity (ring scotomas) seen in two out of the five patients (4). Due to 
the drug's poor availability from the natural sources and the expense, 
further research and use of this drug was delayed for two decades. 
Following the chemical synthesis of Sm in 1981 (5) and structure activity 
relationship (SAR) investigations (6,7), in vivo studies on the analogues 
were performed. Sm analogues are unique among protein synthesis inhibitors 
as several of them showed lower toxicity and higher activity in vivo than 
the parent drug ( ). 
During the SAR studies it was found, that analogues with a hydrophobe R2 
side chain (see Fig.1) shows higher affinity to the ribosomes and higher 
activity in cell free systems which synthesize proteins (9). Based on these 
findings, a hydrophobic pocket in the larger ribosomal subunit has been 
proposed (7). This place on the ribosomal acceptor site is probably desti-
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nated for binding with the more lipophilic aminoacids. Additional studies 
showed that the analogue with five carbon atoms in the R2 aliphatic side 
chain, n-pentyl-Sm (PSm), possessed the best in vitro activity (9). PSm 
showed high LD50 in mice (4.7 mg.kg" ) when administered daily for nine 
days. The comparable value for Sm is 0.26 mg.kg" (3). PSm was active on 
Ρ3Θ8 and L1210 leukemias in vivo (median T/C = 160% and 164%, respectively), 
RC renal cell carcinoma (T/C = 414%) and ВІ6 melanoma (T/C = 131%)(β). There 
was only minimal activity on C38 colon carcinoma (β). Based on these data, 
PSm has been considered as a candidate for clinical trial. 
The biologic effect of a protein synthesis inhibitor depends on the 
disappearance of the native proteins. The higher their turnover rate, the 
more rapid the biological effect. If PSm is excreted and/or metabolized by 
enzymes with a short life span, then inhibition of protein synthesis using 
this drug also inhibits its own elimination which would result in drug 
accumulation in plasma and in increased toxicity. If this effect were to 
occur, it would be most clearly seen during continuous infusion. 
0 0 R' 0;. 
Η 
Fig. 1. Structure of Sm : Hi -CHjOH , R2 -CH3 
and PSm : Ri -CHjOH, R2 -(CHj^CHj 
The purpose of this study is to describe the plasma pharmacokinetics of PSm 
and to assess whether accumulation in plasma occurs, which would increase 
toxicity during prolonged administration. 
MATERIALS AND METHODS 
Animals 
Four beagle dogs, one male (13-16 kg) and three females (8.7-10 kg), were 
obtained from the Central Animal Laboratory of the University of Nijmegen. 
The dogs were used several times in the pharmacokinetic experiments with at 
least a 3 month rest period between tests. Before the dogs were accepted 
for these experiments, their general condition, body weight, and kidney and 
liver functions were evaluated. The dogs were fed a standard granulated food 
(Hope Pharms BV, Woerden, The Netherlands) and had free access to the tap 
ч
СНз 
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water. The phamacokinetic experiments were performed under anaesthesia, 
after which the animals were housed in metabolic cages enabling urine col­
lection for a total of 24 hours. 
Drug and formulation 
PSm was synthesized following a modified method, originally described by 
Ottenheijm et al. (5, HCJ Ottenheijm, personal communication) and was ac­
quired in a freeze dried form. The injections were prepared aseptically by 
the hospital pharmacy. The drug was dissolved in 10% propylene glycol and 
0.03 M phosphate buffer (pH = 7) in a concentration of 0.5 mg/ml and 
filtered through a 0,2 urn filter (FP 030/2 Schleicher к Schnell, Dassel, 
F.R.G.). The dissolved drug was stored in dark flasks at 40C for up to 24 
hours. 
Stability of the drug in this formulation was tested at 4°, 20°, 40° and 
60oC for 12 weeks. Only at the highest temperature the drug concentration 
decreased by 13.5 % in 12 weeks. At the other temperatures PSm was stable. 
Pharmacokinetic experiments 
The dogs were deprived of food for the last 12 hours before each experiment. 
Experiments were performed under Ethrane (Enflurane, Abbot, Campoverde, 
Italy) and NjO anaesthesia with thiopental (Penthotal, Abbot, Campoverde, 
Italy) induction (15 mg/kg) . 
Each experiment lasted for 5-7 hours. The animals received intravenous 
fluid (0.9% NaCl and 2% mannitol) at a rate of 2.7 ml/min. The fluid infu­
sion rate was controlled by an infusion pump (IVAC, type 531, San Diego, CA, 
USA). Continuous infusions of PSm were administered using a 60 ml syringe 
driver (Infors HT, type 5003, Basel, Switzerland), delivering 10 ml per 
hour. The accuracy of infusion rate was controlled every hour. The remainder 
of the solution was routinely checked to determine the definitive drug 
concentration (see analysis). Rectal temperature and heart rate (ECG) were 
continuously surveyed. Blood samples (5 ml) were drawn in heparinized vacuum 
tubes through a central venous catheter. These samples were centrifuged 
within one hour of collection. Plasma was separated and frozen at -20oC 
pending analysis. 
During the whole experiment urine was collected through a urinary cathe­
ter every 10 min. At the end of each collection period, urinary bladder was 
flushed with 5 ml of 0.9% NaCl. Urine samples were made in duplicate for 
determination of the drug and the creatinine concentrations. Urine samples 
were kept in the dark at -20oc pending analysis. 
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After recovery from anaesthesia, the dogs were returned to a metabolic 
cage where urine collection and blood sampling were continued for 24 hours. 
Dog 7Θ5 (exp. nr 3) was subjected to perioperative bile drainage. Bile 
samples, about 2 ml every 20 min, were collected for determination of drug 
concentration. After this experiment, the dog was sacrificed by an overdosis 
of barbiturates. 
Drug analysis 
PSm concentrations in plasma, urine and bile were determined using the 
reversed phase HPLC method as previously described (10). Plasma samples were 
deproteinized with 7% perchloric acid (Aldrich, Brussels, Belgium). A 
semiautomated HPLC system from Kratos Analytical, (Ramsey, NJ, USA) was 
utilized. This system consists of two Spectroflow 400 pumps, a Multiport 
Streamswitch with two six way valves (Rheodyne, Cotati, CA, USA), a 757 UV-
Vis Detector and DS 610 Multirange strip chart recorder. The connection of 
the sampling valves for the reverse flushing method has been described 
elsewhere (10). The system was operated by means of an HPLC solvent program­
mer (type 9224, Kipp Analytical, Rotterdam, The Netherlands). The columns 
used were a concentration column (50 χ 3 mm id) filled with LiChrosorb RP-8 
(10 jum particle size) and an analytical column (100 χ 4.6 mm id) filled with 
CP Spher С (8 ¿im particle size); both packing materials were from Chrom-
pack BV (Middelburg, The Netherlands). Solvent A (flow 1.3 ml/min) for 
sample concentration and cleaning of the columns consisted of distilled 
water. Solvent В (flow 1.0 ml/min), to carry the sample from the concen­
tration column through the analytical column, consisted of 45% methanol 
(HPLC grade. Fisons, Loughborough, England) in water. Drug concentrations 
were determined by the comparison of the sample peak heights with standards 
made from untreated control plasma spiked with known concentrations of the 
drug and incubated for 1 hour at 370C. The accuracy of the calibration 
curves were estimated by comparing the concentration to peak heigth ratios 
for five different concentrations. The calibration curve was acceptable when 
the SD of the ratios was less than 5%. The detection limits for PSm were: in 
plasma 5 ng.ml and in urine 20 ng.ml 
Protein binding assays 
The protein binding of PSm was determined using an ultrafiltration method. 
Prior to these studies, no aspecific drug binding to the filters (EMIT free 
level TM, Syva, Palo Alto, CA, USA) was found. Heparinized plasma samples 
were centrifugea through the filters at 2500 g for 20 min. Drug recovery 
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after ultrafiltration was subtracted from the total drug concentration 
obtained from a deproteinized sample and expressed as the percentage of the 
total drug concentration. 
Fitting of the curves and expression of the results 
Curves were fitted by semi-log regression of the graphically identified 
elimination phases and by the usual stripping method. The area under the 
fitted concentration versus time curve (AUC, mg.h.l" ) was calculated using 
the trapezoidal rule. Other pharmacokinetic parameters were calculated from 
the following equations: 
CL p S m = D . AUC-1 (ml . min"1.kg"1) 
CL p S m . t 1 / 2 . 0 . 6 9 3 " 1 ( 1 . k g - 1 ) 
CLRpSra = CLpj^ . % of t h e dose r e c o v e r e d m u r i n e (ml . mm . k g )  
dose 
vd 
PSm 
beta = 
 % of 
CLNRPSm 
(mg. .kg"1) 
= 
I 
LPSm · 
 osi 
CLPSm -
1/2 ' '
  m 
CLRPSm ( ml . 
1
  .
 
min 
 "1) 
 
• kg"1) 
w h e r e : 
D 
t1 /2 - elimination half-life 
V, - volume of distribution (in the beta and gamma phases) 
CLpg - total body clearance of PSm 
CL_pSm - renal clearance of PSm 
CL N Rp S - non renal clearance of PSm 
AUC - area under the concentration versus time curve 
Tubular titration curves were obtained by plotting fitted plasma concen-
trations against renal excretion rate. RQ- was obtained from the mean CL-p . 
1.25. Curves were interpreted according to the method of Heekman and Van 
Ginneken (11). 
RESULTS 
PSm was administered either as an i.v. bolus (exp. 1, 0.07 mg PSm.kg" and 
exp. 2, 0.53 mg PSm.kg" ) or as a continuous infusion for 2 - 5.25 hours at 
the doses ranging from 0.08 to 1.1 mg PSm.kg (exp. 3-8). In total eight 
experiments were carried out on four dogs. The pharmacokinetic data are 
shown in Table 1 where the means +^  SD are presented. 
After administration of i.v. bolus (exp. 1 and 2) the curves showed one 
distribution and two elimination phases. The alpha distribution phase had an 
estimated t. ¡^
 α
 of approximately 0.03 hours (2 minutes) but could not be 
determined accurately. The drug was eliminated from plasma with the t./, bot 
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Table. 1. Pharmacokinetic parameters of n-pentyl-Sm in beagle dogs. 
Exp. 
nr. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
Means 
+^  SD 
dog 
nr. 
785 
634 
634 
16 
15 
785 
785 
16 
sex 
M 
F 
F 
F 
F 
M 
M 
F 
body 
weight 
(kg) 
12.6 
10.0 
9.8 
9.2 
8.4 
16.0 
16.0 
9.9 
dose 
(mg.kg" 
0.07 
0.53 
0.08 
0.21 
0.21 
0.24 
0.24 
1.1 
type 
) of exp. 
iv bolus 
iv bolus 
4 h inf. 
4 h inf. 
3.5 h inf. 
3.5 h inf. 
2 h inf. 
5.25 h inf. 
t1/2 e 
(h) 
0.2 
0.2 
-
-
-
-
-
-
0.2 
0.0 
ъ1/2^ 
(h) ( 
0.74 
0.76 
- * 
0.78 
0.62 
0.83 
0.90 
0.60 
0.75 
0.1 
C
ss 
ng.ml" ) 
38.5 
-
110.0 
-
-
580.0 
AUC 
(mg.h.l" 
0.11 
0.89 
0.15 
0.39 
0.43 
0.57 
0.46 
3.04 
V 
•') ß 
(l.k 
0.18 
0.18 
-
-
-
-
-
-
0.18 
0.0 
d 
Ύ 
g"1) 
0.65 
0.65 
-
0.63 
0.44 
0.50 
0.68 
0.28 
0.55 
0.15 
C LPSm 
10.1 
9.8 
9.0 
9.0 
8.2 
7.0 
8.8 
6.0 
8.5 
1.4 
CRPSm 
ml.min" 
3.8 
3.0 
5.2 
2.0 
3.0 
2.6 
3.3 
2.5 
3.2 
1.0 
C LCR 
•'.kg"1 
3.7 
3.5 
3.1 
2.5 
2.9 
4.5 
3.4 
2.9 
3.3 
0.6 
CLNRPSm 
6.3 
6.8 
3.8 
7.0 
5.2 
4.4 
5.5 
3.5 
5.3 
1.3 
* The part of the curve after discontinuation of the infusion was not évaluable. 
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Fig. 2. Plasma pharmacokinetics after bolus injections of 0.53 mg PSm.kg" , 
exp. 2 ( · ), and 0.07 mg PSm.kg" , exp. 8 ( B ) . The t 1 « ^ was 0.2 
hours (12 min) and ^ , , Ύ w a s 0.75 hours (45 min). 
0.2 hours (12 minutes) and t^^yof 0.75 (45 minutes) (Fig.2). When the drug 
was administered as continuous infusion (Fig.3) only terminal t^/jY 0^ 0.75 
+_ 0.1 hours (46 jf б minutes) could be indentified, equal to the t 1 ^Y seen 
in i.v. bolus experiments. In experiments 4, 6, and 7, steady state was not 
reached during 2 to 4 hours of infusion. In experiments 3, 5, and 8 the 
steady state was reached within 1-2 hours, and in these experiments, shorter 
terminal half-lives were observed then in exp. 4, б and 7 (0.6 versus 0.8 
hours). 
PSm was actively reabsorbed by the renal tubuli (Fig. 4-7) as the renal 
excretion rate was lower than the calculated RQF· At the lowest dose tested 
(exp.1 Fig.4) tubular reabsorption was dominant and only 3.75% of the dose 
was recovered in urine after 24 hours (CL Rp S m = 0.4 ml.min.kg" ). At the 
higher dose administered as a single i.V. bolus (exp.2, 0.53 mg.kg" ) PSm 
was eliminated exclusively by the Rçp (Fig.5). When the low PSm dose was 
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plasma 
concentration 
time (hours) 
Fig. 3. Plasma pharmacokinetics of PSm determined during and after conti­
nuous infusions, exp.3. ( φ ), 0.08 mg.kg- in 4 hours, exp.4. {~k) 
0.21 mg.kg in 4 hours, exp.5. ( • ), 0.21 mg.kg in 3.5 hours, 
exp.6. ( · ), 0.24 mg.kg-1 in 3.5 hours, exp.7. ( О ), 0.24 mg.kg 
in 2 hours, exp.β ( χ ) 1.1 mg.kg" in 5.25 hours. The terminal t./jY 
was 0.75 +^0.1 hours (45 +^  6 minutes). 
administered as continuous infusion for 4 hours, beyond tubular reabsorption 
also tubular secretion was seen (exp. 3, Fig. 6). At the higher doses, 
tubular secretion was saturated and tubular reabsorption was dominant (exp. 
6. Fig. 7 ) . At the end of the infusion tubular reabsorption was saturated 
and the drug was excreted exclusively by the RQI.· This pattern was seen 
also during exp. 8 (1.1 mg.kg in 5.25 hours infusion, data not shown). 
In the dose range between 0.07 and 0.53 mg PSm.kg" the relation between 
dose and AUG was linear with correlation coefficient r = 0.97 and the mean 
dose/AUC ratio was 0.53 +_ 0.07. At the highest dose tested, 1.1 mg PSm.kg 
there was a 30% decrease of the CLp- and the dose/AUC ratio decreased to 
0.36. This apparent non-linearity at the dose of 1.1 mg PSm.kg" (exp. 8) 
was due to decrease of сь»лі}рд
т
·
 The CL Rp S m was also lower than the mean of 
all experiments, but this was due to decrease of the renal function and low 
mean CL C R. 
The volume of distribution of the beta phase (i.v. bolus experiments) was 
— 1 — 1 
0.18 l.kg and for the gamma phase 0.55 +0.15 l.kg 
To determine the protein binding, nine blood samples from different 
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experiments with PSm concentrations varying from 63 to 774 ng.ml were 
assayed. A constant protein binding of 54 +^4.3% was found over this concen­
tration range. 
Fig. 4. 
plasma conc(ng ml"1) 
Tubular titration curve in exp. 1. The slope of R Q F curve was 
obtained from the mean CLpj, · 1.25· The renal excretion rate in this 
experiment was far below the R-,™ value due to extensive tubular re-
absorpt ion. 
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Fig. 5. Tubular titration curve in exp. 2 after administration of a high 
dose of PSm ( 0.53 mg.kg" ) as an i.v. bolus. Due to immediate 
saturation of the carrier PSm is eliminated exclusively by the R Q F · 
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renal excr. rate 
(jug-min"1) 
plasma cone, (ng-ml"1) 
Fig. 6. Tubular titration curve in exp. 3. During continuous infusion, 
initially drug was reabsorbed by the tubuli. When the plasma concen-
trations reached steady state, renal excretion rate was higher than 
the R-p suggesting tubular excretion. The bars show the SD of the 
plasma concentrations at the steady state (horizontal) and the renal 
excretion rate at the steady state (vertical). After discontinuation 
of infusion again, tubular reabsorption was observed. 
In exp. 7 no metabolites of PSm in 1:10 diluted bile were observed. Only 
trace amounts of unchanged PSm in the bile were noted. 
DISCUSSION 
PSm, an analogue of Sm, was selected from a dozen other analogues because of 
its good antitumor activity (8) and its optimal lipophilicity as determined 
by in vitro and in vivo studies (9). The drug is hardly water soluble, and 
while it is instable in several organic solvents it is stable in propylene 
glycol (D. Blok personal communication). 
Pharmacokinetic evaluation revealed that the drug is reabsorbed by the 
renal tubuli. In one experiment only at the lowest dose administered as 
continuous infusion (exp. 3) it was found that PSm might also be actively 
excreted by the renal tubuli. 
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Fig. 7. Tubular titration curve during exp. 7 (continuous infusion). 
Initially (·) only tubular reabsorption was observed. After dis­
continuation of infusion drug was eliminated exclusively by the IL,-
(о), probably due to saturation of the tubular reabsorption. 
The dominant tubular reabsorption was saturable either at the end of the 
infusion or immediately after administration of high PSm dose as an i.v. 
bolus. The CLNRpsm m a ^ a l s o be saturated at the higher doses and this is 
probably the reason why the pharmacokinetics is nonlinear. 
In a previous study (12), Sm was continuously administered by infusion to 
beagle dogs under anaesthesia. It then induced a considerable reduction in 
the renal clearance with a subsequent exponential increase in the Sm plasma 
concentration. In two experiments performed with different doses, such 
changes appeared at the same time suggesting the decay of a transport 
enzyme. The pattern of PSm and kidney interaction is quite different from 
that observed with Sm. The changes are dose but not time dependent, which 
suggests saturation and not decay of the enzyme activity. Inhibition of the 
de-novo synthesis of the carrier enzymes would induce time dependent events. 
It is difficult to explain why the plasma concentration versus time curve in 
3 out of 6 experiments steadily increases and does not show a definable 
steady state even during long (5 χ t^«Y) infusions. It could be possible 
that in some cases the real terminal half-life is greater than that calcu-
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lated from the data. 
Τη conclusion: the more lipophilic analogue of Sm, PSm shows a different 
pharmacokinetic behaviour than is seen with Sm. The CLp_ is two times 
higher than that for Sm (11), which would lower the chance of accumulation 
and toxicity. The dose-dependent pharmacokinetics of PSm is related to 
saturation of non renal mechanisms of drug elimination as well as disturb­
ance of the renal function. 
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SUMMARY 
Sparsomycin (Sm) is a potent inhibitor of protein synthesis with an anti-
cancer potential. Two years after its discovery m 1962 a phase I clinical 
trial revealed serious drug-induced retinotoxicity m two out of five 
patients. The mechanism of this toxicity still remains unresolved. The 
recent development of several promising analogues of Sm prompted us to re-
investigate the possible toxic action of Sm on ocular targets. The effect of 
a maximal tolerable treatment with Sm on ocular rhodopsin and opsin levels 
were studied in normal albino rats with or without permeabllization of the 
blood-retina barrier with sodium iodate, and in Royal College of Surgeons 
(RCS) rats. The RCS rats are known to have deficient degradation of visual 
pigment in retinal pigment epithelium (RPE) and develop a defective blood-
retina barrier. 
Treatment with subtoxic doses of Sm daily for 10 days causes accumulation 
of the drug m the plasma. However, Sm does not significantly reduce ocular 
rhodopsin content and no changes in ocular morphology were observed. A 
single injection of sodium iodate was found to reduce rhodopsin but not 
opsin levels. Sm administered after sodium iodate lowered opsin levels by 
27% suggesting only partial inhibition of biosynthesis even under these 
extreme conditions. In tumor bearing cachectic animals, Sm administration 
did not affect rhodopsin levels. Rhodopsin accumulation in RCS rats was only 
affected to a minor extent by treatment with Sm. These results strongly 
indicate that Sm might only become retinotoxic upon extensive degradation of 
the blood-retina barrier as in combination with strong metabolic poisons. 
INTRODUCTION 
Sparsomycin (Sm, NSC-059729) was discovered in 1962 as a metabolite of 
Streptomyces sparsogenes (1). The antibiotic was found to be active on KB 
human epidermoid carcinoma cells in vitro and several rodent tumors in vivo 
(1). The drug proceeded rapidly to a phase I study that started already in 
1964 (2). Five patients were treated with Sm that was administered daily in 
increasing doses. At day 13 and 15 of the treatment, respectively, two 
patients developed blurred vision and ring scotomas, later confirmed by 
histopathological examination as widespread degeneration of the RPE es-
pecially accentuated in the posterior temporal areas. The trial was dis-
continued and the drug was assumed retinotoxic. 
On assignment of the National Cancer Institute (Bethesda, MD) additional 
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toxicological studies in rats and monkeys were performed (3). Sm was admin-
istered in subtoxic doses daily for up to 28 days. Retinotoxicity was as-
sessed by electroretinography and eye histology. Abnormal electroretinograms 
were only observed in moribund rats, probably due to their poor general 
condition. No changes were seen in monkeys. Histopathological changes were 
not detected in any animal. After these studies were completed in 1967, most 
of the investigations on Sm were discontinued because of poor supply of the 
drug. 
In the late sixties it was discovered that Sm is a potent inhibitor of 
cellular protein biosynthesis (4). After its chemical structure was eluci-
dated in 1976 (5), synthetic Sm became available in 1981 (6). Thereupon a 
wide program of structure-activity relationship studies produced three de-
rivatives which were good candidates for a phase I study (7). These develop-
ments prompted us to investigate the alleged retinotoxic potential of Sm on 
a biochemical level. Since the photoreceptor cell maintains a high rate of 
biosynthesis of visual pigment protein (opsin), which is compensated by 
circadian phagocytotic action of the adjacent RPE (8), we investigated the 
effect of Sm treatment on the ocular rhodopsin and opsin levels m rat. In 
addition, possible synergistic effects of cachexia, and a metabolic poison -
sodium iodate-inducing breakdown of the retina-blood barrier, were studied. 
MATERIALS AND METHODS 
Drugs 
Sm was synthesized and purified as described before (6) and acquired in a 
freeze-dried form. The drug was dissolved in phosphate buffered saline (PBS, 
pH = 7.4) and kept at 40C in dark flasks for maximally 10 days. Sodium 
iodate (NaJO,) was from Merck, FUG, and was used as a 5% solution in PBS. 
Animals 
Male albino Wistar rats, 200-250 g, were supplied by the Central Animal 
Laboratory of the University of Nijmegen. The rats were adapted to a 12/12 
hour light/dark schedule for at least one week prior to experiment. Animals 
were always sacrificed after 24 hour of dark adaptation to ensure maximal 
regeneration of rod visual pigment (opsin to rhodopsin). Drugs were admin-
istered i.p. during the light phase except for the final doses 30 min prior 
to exsanguination (exp. 1) which were carried out in darkness. 
Pink-eyed RCS rats (males and females) were supplied by the same 
facility, at the age of 19 days and body weight of 30-40 g. Young animals 
were weaned up to a week before the experiments started and then adapted to 
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standard rat granulated food (RMH, Hope Farms, Woerden, The Netherlands) and 
tap water. At day 20 the animals were placed in a dark cabinet and remained 
there for the rest of the study so that all visual pigment remains in the 
rhodopsin state. All procedures were carried out in dim red light (λ > 610 
nm) . 
Treatment protocol 
Exp. 1. Sm administration at maximal tolerable dose daily for 10 days. 
Fourty healthy Wistar rats were randomized to control (n=10) or treatment 
groups (n=5). Five control animals were sacrificed on day 0, and single 
controls were sacrificed simultaneously with the treatment groups. Animals 
were exsanguinated under pentobarbital anaesthesia by a cardiac puncture 3 0 
minutes after respectively 1,2,3,4,6 and 10 daily doses of 0.5 mg Sm/kg ι.p. 
This dose was found the maximally tolerable one in a previous pilot study. 
After exsanguination the eyes were extirpated for rhodopsin analysis. Plasma 
was isolated from the collected blood by centrifugation and stored at -20oC 
pending analysis. Plasma Sm concentrations were determined by quantitative 
high performance liquid chromatography (9). For histologic examination two 
randomly selected eyes, from two different animals, were fixed in Bouin 
solution. 
Exp.2. As exp.1 but following pretreatment with sodium iodate 0.05 mg/kg 
(10) on day 0. Animals were treated on days 1-5 with 0.5 mg Sm/kg i.p. and 
were sacrificed 24 hours after the last infection. Eyes were analysed for 
rhodopsin and opsin content. 
Exp.3. Effect of cancer cachexia. 15 Wistar rats were inoculated s.c. in 
the right flank with 10 viable Walker 256 carcinosarcoma cells. The tumors 
became palpable in 7 days and the animals were then randomized in three 
groups (n=5). Tumor bearing rats without further treatment served as 
control. The other groups were treated with daily doses of either 0.15 mg 
Sm/kg i.p. or with 0.30 mg Sm/kg ι.p. for 5 days. Additionally, 5 healthy 
rats served as "normal" control at day 0. All eyes were analysed for rhod­
opsin content. 
Exp.4. Sm administration to RCS rats. The animals were supplied in nests 
of 5-6 animals, at 2-3 nests per time and the experiments had to be per­
formed in several phases. The animals were housed m darkness, and were 
treated on postnatal days 20-24 with a daily dose of 0.5 mg Sm/kg i.p. They 
were sacrificed either on day 25 or 31 and the eyes were assayed for rhod­
opsin. 
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Rhodopsin determination 
Eyes were extirpated in darkness under pentobarbital anaesthesia with or 
without previous exsanguination. The animals were sacrificed afterwards by 
cervical dislocation. Extirpated eyes were placed in light-tight aluminium 
containers and quick-frozen at -80oc. For rhodopsin assay the eyes were 
thawn in darkness in plastic Eppendorf tubes containing 0.25 ml of PIPES 
buffer (pH 6.5) and cut in fine pieces with sharp scissors. The PIPES buffer 
contained 20 ^ M PIPES (Sigma, St. Louis, USA), 120 mM NaCl, 5 mM KCl, 1 mM 
MgCL2, 1 mM CaCl2, 0.5 mM EDTA, 1 mM DTE, titrated to pH 6.5 by 1 M NaOH. 
Thereafter the scissors were rinsed three times with 0.25 ml PIPES buffer 
containing 1% Ammonyx LO (Fluka, Buchs, Switzerland). Each rinse was added 
to the corresponding tissue homogenate. Rhodopsin was then extracted from 
the tissue homogenate by gentle rotation for 1 hour at ^C, whereupon 
samples were centnfuged at 15000 g at 40C for 30 minutes. The clear super­
natant was assayed for rhodopsin by differential spectroscopy under standard 
conditions as described elsewhere in details (11) employing a PU 8 00 
spectrophotometer. The rhodopsin concentration was calculated from the dif­
ference in A500 before and after illumination, using a molar absorbance 
coefficient of 40300. In exp. 2 the illuminated samples were frozen again at 
- 80 for opsin determinations using ELISA. 
Opsin assay 
The enzyme-linked immunosorbent assay (ELISA) for quantitative determination 
of opsin using anti-bovme rhodopsin antisera (12) as applied to mice (13) 
was adapted for rats. The rat opsin standards required to construct ELISA 
calibration curves were prepared by illumination of pooled rhodopsin 
extracts of six rat eyes (Fisher χ Copenhagen: Fl) of which the rhodopsin 
content was determined by spectroscopy. Polystyrene 96 well flat-bottom 
microtiter plates were obtained from Greiner (Frickenhausen, FRG). The 
plates were coated with rat opsin by incubation of 1:6400 diluted opsin 
extract for 16 hours at 40C (final detergent concentration 0.00065%). After 
coating, the wells were washed three times with PBS (0.02 M phosphate 
buffered saline, pH 7.4). The inhibition assay was carried out in the pre­
incubation mode essentially according to Schalken et al. (13) using serially 
diluted antiserum CERNJS843 elicited against purified bovine rhodopsin 
(12,14). Calibration curves were constructed by semi-log plots of the re­
sulting absorbance at 492 nm versus the amount of opsin added (0.001 - 5 
pmol opsin per well). The opsin contents of the rat eye extracts were as­
sayed in the same way using triplicate samples at various dilutions, and 
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calculated from the resulting absorption at 492 nm using the linear part of 
the sigmoidal calibration curve (15 - 85% of maximal absorption). 
Statistics 
The duplicate standard deviation was used as a quality control. The mean 
rhodopsin content of both eyes of an animal was used to calculate the mean 
of the group. Because the duplicate SD value was very small (3.2% for 
rhodopsin), occasionally one eye value, due to submission of the second eye 
to histopathologic examination, were accepted as means of two eyes (exp.1 
only). The means of Sm plasma concentrations after different number of 
administrations were compared to the values obtained after the 1st admin­
istration. The data were analysed using the Kruskall-Wallis test for paral­
lel independent groups. The same test was used to compare rhodopsin and 
opsin concentrations. The accepted level of significance was p<0.05. 
RESULTS 
General technical aspects 
The overall SD for duplicate samples for rhodopsin in controls was 0.06 
nmol/eye (2-4% of the measured values). For opsin this value was 0.09 
nmol/eye (3-5% of the measured values). 
Exp. 1. Dose and plasma concentrations 
The dose of Sm administered to healthy Mistar rats (0.5 mg Sm/kg ι.p. 
daily, during 10 days) was the maximal tolerable dose and it was derived 
from a pilot study on 20 rats. At day 10 m exp.1 the animals had lost 21 +_ 
8% of body weight and were moribund. Plasma Sm concentrations were measured 
30 min after the daily drug injection and were significantly elevated in all 
cases m relation to day 1 values (see Fig. 1). Although no definite pattern 
could be discerned, the levels seem to plateau after 4 days at 600 - 800 ng 
Sm/ml. 
Effect of Sm administration of rhodopsin levels 
The ocular rhodopsin content showed a small (7%) but not significant drop 
(see Fig. 2) already after a single dose, 30 min after Sm administration. No 
real progression of this effect during further treatment, nor any correla­
tion with the plasma Sm concentrations was observed. Instead, after 10 days 
of treatment, the ocular rhodopsin levels had recovered to the control 
values. To eliminate this possible acute effect of Sm in subsequent exper­
iments the animals were sacrificed 24 hours after the last injection, under 
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the assumption that this time interval should allow full recovery from any 
acute effect. Histologic examinations of the eyes did not show any morpho­
logical abnormalities at any time. 
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Fig. 1. Sm plasma concentrations in Wistar rats 30 min after respectively 
1,2,3,4/6 and 10 daily Sm doses of 0.5 mg/kg. * p<0.05 
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Fig. 2. Mean rhodopsin concentrations in eyes of Wistar rats treated with 
0.5 mg Sm/kg for respectively 1,2,3,4,6 and 10 days. The differences 
between the means were not significant. 
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The controls sacrificed at the same time as treated animals produced con­
stant and normal rhodopsin levels, indicative for adequate dark adaptation 
and constant experimental conditions. 
Exp. 2. Combined treatment with sodium iodate and Sm 
In this experiment (Fig. 3) rats were pretreated with sodium iodate in order 
to destabilize the RPE and permeabilize the blood-retina barrier. Control 
animals only treated with sodium iodate showed a tenfold decrease in rhod­
opsin content which dropped from 1.76 +_ 0.3 nmol/eye in untreated controls 
to 0.17 +^0.02 nmol/eye for animals treated with sodium iodate (p<0.03). 
Treatment with Sm did not significantly affect the rhodopsin levels in 
normal (1.53 +_ 0.16 nmol/eye) or iodate pretreated animals (0.14 +_ 0.1 
nmol/eye). To differentiate this phenomenon somewhat further, the ocular 
extracts were also assayed for total visual pigment protein (opsin) using 
the ELISA method on illuminated samples. Combination of sodium iodate with 
Sm led to a decrease of opsin levels from 1.93 ^0.25 nmol/eye in untreated 
controls and 1.62 +^  0.36 nmol/eye m animals treated with sodium iodate 
alone to 1.2 + 0.3 nmol/eye in animals treated with sodium iodate and Sm 
(p<0.003 and n.s., respectively). 
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Fig. 3. Mean rhodopsin ( · ) and opsin ( о ) concentrations in both eyes of 
Wlstar rats treated for 5 days with 0.5 mg Sm/kg with or without 
sodium iodate (NaJO,) pretreatment. Control values as well as ef­
fects of sodium iodate and Sm alone are also shown. Significance: A-
C p<0.03, A-Ε n.s., Α-G p<0.003, B-D n.s., B-F n.s., B-Η p<0.03, D-H 
n.s., F-H p<0.03. 
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As expected, the total opsin content of normal animals is slightly, but not 
significantly higher than the rhodopsin content (1.93 +_ 0.25 versus 1.76 
nraol/eye). Remarkably, the total opsin content is slightly but not signifi­
cantly lowered upon treatment with sodium iodate (1.62 +_ 0.36 nmol/eye) in 
contrast to the rhodopsin levels (0.17 +_ 0.02 nmol/eye). Sm alone did change 
neither the rhodopsin (1.53 +_ 0.16 nmol/eye) nor the opsin content (1.95 +_ 
0.24 nmol/eye). However, the opsin/rhodopsin ratios change from 1.1 +_ 0.13 
for the controls to 1.26 +_ 0.08 for animals treated with Sm alone (p<0.04). 
Exp. 3. Effect of cancer cachexia 
In this experiment (Pig. 4) Walker 256 carcinosarcoma bearing rats were 
treated for 5 consecutive days with Sm at a daily dose of 0.15 or 0.3 mg/kg. 
The dose of Sm was reduced because of the increased toxicity of the drug in 
these tumor-bearing animals. Two animals did not survive the treatment with 
0.15 mg Sm/kg, while one animal did not survive the 0.3 mg Sm/kg dosage. All 
animals, including controls were emaciated and lost 12+^9 % of their body 
weight at randomization (tumor included). Tumor growth by itself did not 
influence the rhodopsin levels (1.79 +_ 0.2 versus 1.75 н^  0.07 nmol/eye in 
the untreated controls). Treatment with Sm produced the normal pattern: 
slight decrease in rhodopsin content (0.15 mg/kg - 1.65 +_ 0.1 nmol/eye; 0.30 
mg/kg - 1.7 + 0.2 nmol/eye ). The differences were not significant. 
rhodopsin 
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А В Sm Sm 
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Fig. 4. Mean rhodopsin concentrations in eyes of Wlstar rats bearing Walker 
256 carcinosarcoma s.c. and treated for 5 days with Sm either 0.15 
mg/kg or 0.3 mg/kg. Control values of tumor free (A) and untreated 
tumor bearing animals (B) are also included. 
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Exp. 4. Influence of Sm treatment on RCS rats 
In this experiment 20 days old RCS rats were treated with four doses of 0.5 
mg Sm/kg/day (Fig. 5). Animals were sacrificed on days 25 and 31. Rhodopsin 
concentrations in untreated rats increased linearly from 1.5 +_ 0.2 nmol/eye 
on day 21 to 2.8 +_ 0.1 nmol/eye on day 31. The Sm treatment produced only a 
small (7.7%) decrease of rhodopsin concentration on day 25 (1.93 +^  0.2 
nmol/eye versus 2.09 + 0.14 nmol/eye in the controls), consistent with the 
previous results. The differences were not significant. 
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Fig. 5. Mean rhodopsin concentrations in eyes of RCS rats treated on days 
20-24 with 0.5 mg Sm/kg (В). Untreated controls on day 21 as well as 
on day 25 and 31 (A) are presented for comparison. 
DISCUSSION 
Before entering clinical study with one of the new Sm analogues, several 
important questions should be addressed. 
1. Are the retinotoxic effects observed really due to Sm ? 
2. If yes, can retinotoxicity be reproducibly induced by Sm in animal models 
and is the retinotoxicity of Sm the consequence of inhibition of protein 
biosynthesis? 
3. Does Sm or its analogues penetrate the blood-retina barrier ? 
Ad.1. Other factors than Sm may be responsible for retinotoxicity. 
The "natural" Sm originally used in the phase I study might not be pure. 
Contaminants may have been responsible for enhancement of its toxicity and 
172 
retinotoxic potential. The "natural" Sm showed a LD50 in mice of 4.32 m^kg 
(National Cancer Institute, 1964) compared to 11.3 mg/kg for synthetic, 
highly purified Sm (7). However, the only contamination of a Sm sample 
isolated from natural sources and generously supplied by the National Cancer 
Institute, Bethesda, MD, was a considerable percentage of isosparsomycin as 
revealed by HPLC analysis (unpublished). Isosparsomycin is a stereoisomer of 
Sm formed under the influence of light, and might have accumulated during 
the 20 years of storage. Isomerization of Sm to isosparsomycin would in­
crease rather than decrease the LD50 as isosparsomycin is not active as 
inhibitor of protein biosynthesis (15). 
It can, however, not be excluded that the retinotoxicity is due to iso­
sparsomycin by a mechanism different from inhibition of protein bio­
synthesis. Isosparsomycin bears some structural similarities to 11-cis-
retinal (Fig.6), the chromophore of the rod and cone visual pigments: rhod-
opsin, iodopsin etc. Therefore, possible competitive inhibition of regener­
ation of opsin by Sm or isosparsomycin was investigated in vitro. Even at a 
1000-fold molar excess to opsin both compounds only slightly inhibited the 
regeneration of opsin with 11-cis-retinal to rhodopsin (De Grip, personal 
communication). 
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Fig. 6. Structure of ( a ) 11-cis-retinal and ( b ) sparsomycin 
Another possibility is that synergistic toxicity of Sm occurs with other 
drugs administered to the patients in the phase I clinical trial. One of the 
patients that developed retinal damage received, concomitantly with Sm, 
thioridazine (2). This drug has a recognized retinotoxic potential, similar 
to that produced by chloroquin (16). Thioridazine is a lipophilic drug 
accumulating in RPE and is responsible for disruption of membranes. Both 
chloroquin and thioridazine inhibit the appearance of newly synthesized 
proteins in the rod outer segment in vitro (16). However, some authors 
suggest that chloropromazine (similar to thioridazine) may be toxic to the 
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retina by inducing fotosensitization (17). The possibility of synergistic 
action between Sm and thioridazine can not be excluded and should be 
investigated m the future. 
Ad.2. Sm itself has little effect on rhodopsin levels. 
Finally it should be considered that upon penetration into the RPE and the 
retina, Sm may inhibit biosynthesis of opsin or of other short living pro-
tein(s) involved in degradation of rhodopsin or in retinol transport and/or 
metabolism. As a result of this, levels of (rhod)opsin in the eye should 
change upon administration of Sm, and these levels should be indicative for 
the ocular toxicity of Sm. Complete inhibition of rhodopsin biosynthesis in 
bovine retinas in vitro by puromycin has been demonstrated by O'Brien (18). 
The present study was designed to investigate whether Sm could provoke 
similar effects in vivo. Hydrophilic drugs, like Sm (octanol/water partition 
coefficient log Ρ = - 1.7 (19) is unlikely to be able to penetrate an 
undamaged blood-retina barrier, and it is improbable that it would reach 
sufficient intraocular concentrations to inhibit opsin biosynthesis for a 
prolonged time (20). Hence it is not surprising that administration of Sm 
daily for 10 days at the maximally tolerable dose did not significantly 
change the ocular rhodopsin content. 
In all experiments reported here Sm produced a small but not significant 
decrease m rhodopsin content. Interestingly this decrease was acute and 
also appeared already 30 minutes after the first injection in dark adapted 
animals. Hence this probably is not an effect on biosynthesis of opsin or 
regeneration of rhodospin, but should reflect preturbation of the shedding 
and phagocytose of the outer segment tops. 
Ad.3. Blood-retina barrier. 
Another factor that may increase intraocular Sm concentrations is accumu­
lation in plasma. Data on plasma Sm concentrations in humans are not avail­
able but we have found indications for accumulation in mice (7), beagle dogs 
(21) and now in rats (see Fig. 2), We considered the possibility that combi­
nation of blood-retina barrier leakiness and increased plasma Sm concen­
trations may be responsible for the Sm-induced retinal toxicity. However, 
our results do not indicate any correlation between an increase in plasma 
concentrations and ocular rhodopsin levels. To test this hypothesis further, 
we needed to study the effect of a defective blood-retina barrier. 
The blood-retina barrier may be disrupted by different pathological 
conditions (22-24). Artificially, the blood-retina barrier may be disrupted 
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by application of strongly oxidizing metabolic poisons like sodium iodate 
(25). Our experiments with this compound showed that the artificial increase 
of blood-retina barrier leakiness is accompanied by serious changes in 
retinal metabolism. A dramatic loss of rhodopsin is observed, in agreement 
with earlier findings (26), but the opsin levels are barely affected. This 
indicates that due to the toxic effects of sodium iodate on the RPE (25) the 
regeneration of rhodopsin from opsin is blocked, probably by interference 
somwehere in the visual cycle (reformation of 11-cis-retinal by RPE). The 
fact that the opsin levels are almost maintained may be due to (A) mainten­
ance of opsin biosynthesis (photoreceptors) and degradation (RPE) at nearly 
similar rates or (B) complete block of both processes. If the alternative 
(B) would be correct, treatment with Sm could not produce a reduction in 
opsin level as we observed. Hence, we conclude that in the early stage of 
iodate poisoning, opsin biosynthesis and degradation still proceed and that 
under those conditions (defective blood-retina barrier, severe metabolic 
stress) Sm is able to exert an inhibitory action on protein biosynthesis, 
thereby much less affecting phagocytosis and degradation by RPE. It is 
difficult to assess from the present data whether this inhibition by Sm is 
complete or only partial. If biological turnover of opsin in mammals is Θ-10 
days (8), complete inhibition of biosynthesis for 5 days should decrease the 
opsin level by 50-60% while we observed a decrease of only 27%. Since the 
catabolie potential of the RPE may also be affected by sodium iodate (25) 
this means that rod protein biosynthesis is inhibited under these conditions 
by Sm, somewhere between 50 and 100%. Alternatively, development of the 
blood-retina barrier leakiness may be delayed by 2-3 days. Flage et al. (25) 
reported the first gross morphological changes in the rabbit retina 4 days 
after sodium iodate treatment. 
The RCS rat differs from the normal animal by a genetic deficiency in 
outer segment phagocytosis in RPE (27). In these animals the continuous 
biosynthesis of opsin by the rod cell results in a linear increase of 
rhodopsin concentrations up to the fifth week of life, providing rats are 
kept in the dark (28). After this time the retinas become dystrophic and 
animals turn blind. Caldwell and Laughlin (29) showed that the blood-retina 
barrier of RCS rats is leaky from about the 3rd week of life. This leakiness 
is probably due to the relaxation of the tight junctions. In this system, 
treatment with Sm had no significant effect on rhodopsin levels. Hence, 
defective blood-retina barrier is not per se sufficient to produce a retino-
toxic action of Sm. 
Two patients that developed retinopathy after treatment with Sm weighed 
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both only 50 kg and suffered from a far advanced stage of cancer. It is thus 
possible that both of them were cachectic and in poor general condition. 
Another patient treated for 17 days with a dose similar to that administered 
to the above two patienta did not develop retinopathy but his initial body 
weight was 92 kg. Thus it may be speculated that poor general condition may 
be a risk factor for Sm-induced retmotoxicity. However, experiments with 
tumor bearing rats failed to show cachexia as a factor responsible for Sm-
induced retmotoxicity. The constant rhodopsin values seen in these animals 
suggest a high priority for opsin biosynthesis and activation even during 
cachexia. 
Conclusion 
Our experiments failed to identify a possible mechanism for the alleged 
retinal toxicity of Sm. Increase of blood-retina barrier permeability by 
sodium iodate possibly allows Sm to penetrate the retina and inhibit opsin 
biosynthesis, but these circumstances were extreme in that a strong metab-
olic poison was required, which was not likely to resemble any condition in 
vivo. Vision in these rats was already severely affected due to rhodopsin 
deficiency afore Sm was administered. 
Our general conclusion is that the hydrophilic Sm is unlikely to be able 
to diffuse through the undamaged blood-retina barrier but even a defective 
barrier is not sufficient to promote Sm retmotoxicity. Only in synergism 
with secondary factors like strong metabolic poisons, or pathological con-
ditions like retinitis pigmentosa or diabetes mellitus Sm may show retino-
toxic action. Whereas, general cancer cachexia seems to have no synergistic 
effect. While we fail to observe strong retinotoxic action of Sm under 
conditions which do not deviate from normal, we still feel that Sm analogues 
which are more lipophilic than the parent drug and show higher antitumor 
activity produce a higher risk of retmotoxicity and should be investigated 
for their potential ocular toxicity in the same animal models. 
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CHAPTER 14 
GENERAL DISCUSSION AND PROSPECTS 
The preclinical investigations carried out and reported in this thesis were 
done in order to select the best analogue for clinical studies. The results 
indicate that some Sparsomycin (Sm) analogues are less toxic and more active 
than the parent drug. The three analogues with the most promising activity 
are deshydroxy-Sm, ethyl-deshydroxy-Sm and n-pentyl-Sm. They showed high 
activity on three ascitic murine tumor models but were not active on four 
solid tumors. When the ascitic tumor sensitive to Sm analogues (L1210 leuke-
mia) was inoculated s.c. and the drugs were administered i.V., only ethyl-
deshydroxy-Sm showed some activity. On another tumor (RC renal cell 
carcinoma) s.c. all three analogues were equally active. No activity was 
found on four human tumor xenografts (.gastric, mammary, colon and ovary 
cancers) in nude mice (Fiebig, personal communication). 
However, Sm showed interesting anticancer potential when combined with 
other cytotoxic agents. Used together with cisplatin, Sm showed significant 
potentiation of cisplatin antitumor activity in vitro and in vivo without 
increasing its toxicity. Ethyl-deshydroxy-Sm in combination with cisplatin 
is the only analogue that shows high activity on L1210 leukemia growing s.c. 
This striking synergy opens new possibilities in cancer chemotherapy. 
Cisplatin is not the only drug that can be potentiated by Sm. Several 
other compounds, i.e. 5-fluorouracil, methotrexate, cytosine arabinoside, 
vincristine and bleomycin, also show promising synergy with Sm in vitro. In 
all experiments performed by us on Sm and by others on different PSI, the 
sequence of drug administration was critical for the cytotoxic effect. These 
observations should play a key role in further clinical and in studies 
concerning the mechanism of action. 
Sm and its analogues do not induce bone marrow toxicity. This increases 
their attractiveness in combination with other anticancer drugs· 
Our data indicate that Sm-induced inhibition of protein synthesis may act 
as a specific modifier of the cytotoxicity of different anticancer agents. 
Studies should be performed in order to elucidate the mechanisms of the 
synergy and its potential to kill malignant cells selectively without in-
creasing toxicity to the normal cells. 
Further research on Sm analogues should confirm potentiation of cisplatin 
activity on different murine tumors as well as in human tumor xenografts in 
nude mice. Potentiation of activity of other anticancer drugs should also be 
studied in the same way. 
The data obtained until now seems to indicate that ethyl-deshydroxy-Sm 
will be probably the drug of choice for further preclinical studies. The 
relatively higher toxicity of ethyl-deshydroxy-Sm found in beagle dogs 
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should not interfere with the choice of this compound for clinical studie·; 
if the compound will prove to be active on other tumors. Non-linear pharma-
cokinetics found in dog, would be dangerous if the drug would be admin-
istered daily for a longer time. Synergy between Sm and cisplatin was found 
when Sm and cisplatin were applied every 4 days. Moreover, the doses neces-
sary to induce optimal effect were lower than the LD10 for Sm. 
The drug of choice should be subjected to detailed toxicological evalua-
tion m animals before its use in humans. These studies should be performed 
with this compound alone and in combinations with other cytostatics. If this 
drug will not increase toxicity of the second anticancer drug, then the 
phase I study in man should be also performed with combinations of drugs, 
for example with cisplatin and increasing dose of ethyl-deshydroxy-Sm. 
During toxicological evaluation special attention should be paid to the 
potential retinotoxicity of the compound. Although extensive investigations 
were performed on rats xn order to study the possxble mechanisms of Sm 
retinotoxicity, no effect of Sm on the retina was found. It is probable, 
that Sm does not penetrate the blood-retina barrier because it is too hydro-
philic. Future studies should test whether more lipophilic analogues, which 
seem to be more active, do penetrate the blood-retina barrier and induce 
retinotoxicity. 
In conclusion: The use of Sm analogues is an exciting new perspective in 
cancer chemotherapy. These protein synthesis inhibitors seems to be 
especially promxsxng in combination with other cytotoxic compounds and not 
as single drug. Ethyl-deshydroxy-Sm is probably the drug of choice for 
further preclinical and clinical studies. Future investigations directed to 
the mechanisms of action and proper scheduling of the drugs are necessary 
prior to the clinical application of this approach. 
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SUMMARY 
Sparsomycin (Sm) is a well known inhibitor of protein synthesis with an 
anticancer potential. The first clinical trial with this drug derived orig-
inally from natural sources, in 1964, was unsuccessful. In 1981 Ottenheijm 
and co-workers succeeded in the chemical synthesis of Sm. Since this time 
their main goal was development of less toxic and more active analogues. 
More than fifty compounds were prepared and studied m vitro for their 
inhibitory activity. These studies, as well as history, chemistry and bio-
logical activity of selected Sm analogues, are reviewed in Chapter 2. 
Newly synthesized analogues were tested for their inhibitory activity in 
vitro on cell free E. coll ribosomes and in L1210 leukemia clonogenic assay. 
The relation between structural modifications, physicochemical properties, 
and biological activity is described in Chapter 3. 
Two types of structural modification appeared to be important for ac-
tivity. First, the introduction of a more lipophilic side chain replacing 
the methyl group caused higher affinity for the nbosomal binding site. 
Compounds with 5-6 carbon atoms in the aliphatic side chain showed an opti-
mal affinity. These compounds too, showed the highest activity on L1210 
leukemia in vitro. Second, removal of the hydroxyl group proved to be criti-
cal for the activity in vivo as well as for the physicochemical properties 
of these deshydroxy compounds. Deshydroxylated analogues vrere slightly more 
lipophilic than their hydroxylated counterparts but were significantly 
better water soluble and showed a favourable LD50 in mice. These compounds 
too, had distinctive high antitumor activity. The above mentioned two modi-
fications i.e. introduction of a more lipophilic side chain and removal of 
the hydroxyl group, were combined in the compound ethyl-deshydroxy-Sm. This 
compound showed a high LDSO and good antitumor activity in several murine 
tumor models. 
Chapter 4 presents a detailed antitumor activity study in eight murine 
tumor models. Compounds with high in vitro activity showed the increased 
LDSO m mice. This increase was directly proportional to the lipophilicity 
of the drug. Three Sm analogues, i.e. n-pentyl-Sm, deshydroxy-Sm and ethyl-
deshydroxy-Sm, were found to be the most active analogues. However, ac-
tivity was manifested only in rapidly growing ascitic tumors, i.e. P388 and 
L1210 leukemias and RC renal cell carcinoma (T/C = 150 - 600%). When the 
sensitive tumors (L1210 or RC) were inoculated s.c. and the drug was ad-
ministered i.V., there was loss of activity for all compounds. On L1210 
leukemia s.c. only ethyl-deshydroxy-Sm showed some activity (T/C = 139%). On 
RC tumor s.c. all three analogues were equally moderately active (T/C= 138 -
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150%). There was only slight activity on B16 melanotia and no activity on 
four solid tumors: C22LR osteosarcoma, C38 colon carcinoma, LL - Lewis lung 
carcinoma and M5076 sarcoma. 
Stimulated by data from the literature on modification of cytotoxicity of 
some anticancer drugs by protein synthesis inhibitors, the m vitro modu-
lation of cisplatin cytotoxicity by inhibition of protein synthesis with Sm 
was studied (Chapter 5) . These investigations were done with CHO cells. Low 
Sm concentrations, inhibiting protein synthesis by 20%, protected cells from 
cisplatin-induced cytotoxicity. Higher Sm concentrations enhanced cisplatin 
cytotoxicity. Both effects were highly significant. These results were 
independent of the inhibition of the cell cycle. Data obtained from these 
studies formed an important cornerstone for further investigations on the 
synergistic activity of Sm analogues with other cytotoxic drugs. 
The same principle of synergism was investigated in L1210 bearing mice 
(Chapter 6.1). Sm administered 3-6 hours prior to the administration of 
cisplatin, potentiated significantly the antitumor activity of the latter 
drug. In the optimal combination, 66% of the animals were cured from leu-
kemia, while cisplatin alone could not produce any cure. In this study, host 
protection against cisplatin-induced toxicity was also observed. Mice pre-
treated with Sm lost significantly less weight due to cisplatin. Addition-
ally, the only drug that was active on L1210 leukemia s.c, ethyl-
deshydroxy-Sm, was found to have a significant potentiating effect on cis-
platin activity (Chapter 6.2). Cisplatin alone as well as ethyl-deshydroxy-
Sm alone did not show any significant activity. Combination of the two drugs 
resulted in a T/C of 313% and a single cure. Deshydroxy-Sm administered in 
combination with cisplatin in the same tumor model showed only weak and 
insignificant potentiation of the cisplatin effect. 
In a subsequent in vitro study, Sm was found not only to influence the 
activity of cisplatin (Chapter 7) . The combination of Sm with seven classi-
cal anticancer agents was tested on CHO cells. Preincubations with Sm an-
tagonized the activity of the following S-phase specific agents: metho-
trexate, 5-fluorouracil, cytosine arabinoside and vincristine. Postincu-
bation with Sm instead, potentiated their effect. A similar, but less signi-
ficant effect, was observed with doxorubicin. In contrast, preincubation 
with Sm enhanced the activity of non-S-phase specific compounds, namely 
cisplatin and bleomycin, but not of melphalan. Postincubations were ineffec-
tive or less effective. The results of this study indicate some potentially 
useful combinations of Sm with other cytotoxic drugs to be investigated in 
vivo. 
184 
Somewhat disappointing results of antitumor activity testing with Sm 
analogues prompted us to study the relationship between pharmacokinetics, 
activity and toxicity in mice (Chapter 8). In this study the area under the 
curve (AUC) at the LDIO was determined for Sm and its three promising ana-
logues. Increase of the lipophilicity of the drug increased its total body 
clearance. Lipophilic compounds were also more extensively bound to plasma 
proteins. Deshydroxy-Sm (VI) was twice as rapidly cleared from the plasma as 
Sm, but its AUC at the LD10 was lower than that of Sm. Ethyl-deshydroxy-Sm 
was the only drug that showed a 2.5 fold increase of the AUC at the LDIO in 
comparison to Sm. Significant increase of the LDIO for this compound is 
probably related to the fact that ethyl-deshydroxy-Sm has a different dose-
limiting toxicity in mice than hydroxylated compounds. Ethyl-deshydroxy-Sm 
induced no haemorrhages in mice, which were observed after treatment with 
toxic doses of all hydroxylated analogues. 
The pharmacokinetic studies were later extended to beagle dogs (Chapter 
9). In these investigations, pharmacokinetic studies were correlated with 
toxicity. Beside the determination of Sm pharmacokinetics for a single dose, 
it was found that Sm tends to accumulate in plasma when administered in 
sequential daily doses. This may explain the toxicity seen after several 
days of treatment. All the plasma proteins which were studied upon treatment 
with Sm disappeared from the plasma proportionally to their biological half-
life. Thus, if Sm acts only through inhibition of protein synthesis, than 
the toxicity should be due to disappearance of critical proteins. In 
beagles, disappearance of plasma fibrinogen was found critical for develop-
ment of haemorrhagic diathesis seen in 2 out of 5 dogs treated with Sm for 9 
days. 
Pharmacokinetic studies in beagle dogs were performed also with three 
promising analogues. In Chapter 10 the plasma and renal pharmacokinetics of 
deshydroxy-Sm are presented. Chapter 11 describes the pharmacokinetics of 
ethyl-deshydroxy-Sm and Chapter 12 describes the pharmacokinetics of n-
pentyl-Sm. All three compounds, as well as the parent drug Sm, behaved 
somewhat differently in dogs than in mice. In mice, linear pharmacokinetics 
up to the LDIO were seen in all cases. In dogs, non-linear pharmacokinetics 
were found for ethyl-deshydroxy-Sm and n-pentyl-Sm. Ethyl-deshydroxy-Sm was 
found to be relatively more toxic in comparison to the other analogues, 
while n-pentyl-Sm produced the highest non-lethal AUCs. Non-linearity of 
ethyl-deshydroxy-Sm pharmacokinetics was related to extensive, active re-
absorption of the drug from the renal tubuli. The same process was observed 
in case of n-pentyl-Sm but due to its high lipophilicity this compound was, 
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extensively eliminated by non-renal clearance and active tubular re-
absorption played only a relatively minor role. 
In the last chapter (Chapter 13) the results of several experiments on 
Sm-induced eye toxicity in rats are presented. No indication of Sm pen-
etration through the blood-retina barrier was found in healthy animals and 
therefore it can be concluded that the risk of retinotoxicity should be very 
low. However, when the blood-retina barrier is disrupted, for example by 
sodium iodate, Sm partially inhibits opsin biosynthesis. The histopatholo-
gical appearance of Sm-induced retinotoxicity could not be reproduced in 
these studies. 
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SAMENVATTING 
SPARSOMYCINE EN ZIJN ANALOGA 
een preklinisch onderzoek naar nieuwe geneesmiddelen tegen kanker 
Sparsomycine (Sm) is een bekende eiwitsyntheseremmer met mogelijke anti­
kanker activiteit. Het eerste klinische onderzoek met Sm, verkregen door 
isolatie uit bacteriestammen, bij mensen in 1964 is mislukt. In 1981 
slaagde Ottenheijm en medewerkers erin Sm synthetisch te maken. Sindsdien 
heeft deze groep in samenwerking met onze afdeling zich gericht op het ont­
wikkelen van minder toxische en meer actieve analoga. Meer dan 50 derivaten 
zijn gesynthetiseerd en in vitro bestudeerd. De resultaten hiervan, evenals 
de geschiedenis, chemie en biologische activiteit zijn beschreven in 
Hoofdstuk 2. 
Nieuw gesynthetiseerde analoga zijn getest op hun remmende activiteit van 
de eiwit synthese in een celvrij systeem (dat gebruik maakt van ribosomen 
van E. coli) en op LI 210 leukemie cellen in de donogene assay. Het onder­
zoek naar de relatie tussen structuurmodificaties, fysicochemische eigen­
schappen en biologische activiteit is weergegeven in Hoofdstuk 3. Twee 
modificaties blijken voor de activiteit met name belangrijk te zijn. Op de 
eerste plaats, het invoeren van alkyl groepen op het bivalente zwawel atoom 
waardoor een hogere lipofiliteit ontstaat en daardoor een hogere affini­
teit tot de ribosomale bindingsplaats optreed. Een optimale affiniteit wordt 
bereikt met stoffen die 5 tot б koolstofatomen in de alifatische zijketen 
hebben. Deze stoffen laten de hoogste activiteit op L1210 leukemie cellen in 
vitro zien. Op de tweede plaats blijkt dat verwijdering van de hydroxyl 
groep van belang is voor de biologische activiteit en de fysicochemische 
eigenschappen. Gedeshydroxyleerde analoga zijn iets meer lipofiel dan hun 
gehydroxyleerde equivalenten, maar ze zijn significant beter wateroplosbaar 
en vertonen een gunstige LD50 bij muizen. Gedeshydroxyleerde verbindingen 
onderscheiden zich door een hoge antitumoractiviteit. Deze twee modifica­
ties: hogere lipofiliteit en deshydroxylering zijn aangebracht in de stof 
ethyl-deshydroxy-Sm. Deze stof vertoont een hoge LD50 en een goede antitumor 
activiteit bij de verschillende muizentumoren. 
Hoofdstuk 4 geeft een gedetailleerd overzicht van de onderzoeksresultaten 
betreffende antitumoractiviteit van Sm-analoga bij 8 muizentumoren. Sm-
derivaten, die in vitro een hoge remmende aktiviteit vertonen, laten een 
toename van de LD50 bij muizen zien. Deze toename is evenredig met de 
lipofiliciteit. Drie analoga: n-pentyl-Sm, deshydroxy-Sm en ethyl-
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deshydroxy-Sm blijken de meest actieve analoga te zijn. Deze aktiviteit 
manifesteert zich alleen bij de snel groeiende ascitesvormende tumoren te 
weten Ρ3Θ8 en L1210 leukemieën en RC renal cellcarcinoma (T/C = 150 - 600%). 
Wanneer de gevoelige tumoren (L1210 en RC) s.c. geinoculeerd worden en de 
stoffen i.v. toegediend worden, blijkt er een verlies van activiteit voor 
alle derivaten op te treden. Voor 1,1210 leukemie s.c. vertoont alleen ethyl-
deshydroxy-Sm enige activiteit (T/C = 139%). Voor de RC tumor s.c. zijn alle 
drie analoga even actief (T/C = 13Θ - 150%). Er wordt een geringe activiteit 
voor B16 melanoom en geen activiteit voor de volgende 4 solide tumoren C22LR 
osteosarcoom, LL Lewis longcarcinoom, M5076 sarcoom en C38 coloncarcinoom 
waargenomen. 
Op grond van gegevens uit de literatuur over de modificatie van de cyto-
toxiciteit van sommige antikankemiddelen door remming van de eiwitaynthese, 
werd Sm in combinatie met andere cytostatica getest (Hoofdstuk 5). Dit 
onderzoek is verricht op CHO cellen. Het bleek dat lage Sm-concentraties, 
die 20% van de eiwitsynthese remmen, de cellen beschermen tegen de cyto-
toxiciteit van cisplatinura. Hogere Sm-concentraties daarentegen, potentiSren 
de activiteit van cisplatinura. Beide effecten zijn statistisch significant. 
Deze effecten zijn onafhankelijk van de remming van de celcyclus. De re­
sultaten verkregen tijdens dit onderzoek, vormen de hoeksteen voor verdere 
onderzoeken betreffende het synergisme tussen Sm en analoga en andere cyto-
toxische middelen. 
Een soortgelijk synergisme is onderzocht in muizen met L1210 leukemie 
(Hoofdstuk 6.1). Indien Sm 3 - б uur voor cisplatinura wordt toegediend, 
wordt de antitumoractiviteit van laatstgenoemde verbinding, significant 
gepotentieerd. In een optimale combinatie kon 66% van de dieren van leuke­
mie worden genezen, terwijl cisplatinura alleen geen genezing tot stand kon 
brengen. In dit onderzoek werd ook bescherming tegen cisplatinum-
geinduceerde toxiciteit geconstateerd. Muizen voorbehandeld met Sm, blijken 
significant minder gewicht te verliezen als gevolg van cisplatinum-behande-
ling. 
Ethyl-deshydroxy-Sm, het enige middel dat actief is tegen L1210 leukemie 
cellen s.c, blijkt ook een significant versterkend effect op de cisplatinura 
activiteit te hebben (Hoofdstuk 6.2). Zowel cisplatinura alleen als ethyl-
deshydroxy-Sm alleen, toonden geen significante activiteit. Een combinatie 
van beide middelen resulteerde m een T/C van 313 % en in een langdurige 
overleving bij een van de zes muizen. In hetzelfde tumormodel vertoont des­
hydroxy-Sm in combinatie met cisplatinura, een zwak en met-significant 
effect. 
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In het in vitro onderzoek dat volgde, blijkt Sm ook de activiteit van 
andere cytostatica te beïnvloeden (Hoofdstuk 7). Een combinatie van Sm met 
een van 7 klassieke antikankermiddelen is op CHO cellen getest. Voor-
behandeling met Sm antagoniseert de activiteit van de volgende S-fase speci-
fieke middelen: methotrexaat, 5-fluorouracil, cytosine arabinoside en vin-
cristine. Nabehandeling met Sm daarentegen, versterkt hun effect. Eenzelfde, 
hoewel minder significant effect, wordt gezien met doxorubicine. Voor-
behandeling met Sm verhoogt de activiteit van de niet S-phase specifieke 
stoffen: cisplatinum en bleomycin, maar niet de activiteit van melfalan. 
Deze resultaten geven aan dat het zinvol is om bepaalde combinaties van Sm 
met andere cytotoxische middelen in vivo nader te bestuderen. 
De tegenvallende resultaten van de antitumor activiteit van Sm-analoga 
heeft ertoe geleid, de relatie tussen farmacokinetiek, activiteit en toxi-
citeit in muizen verder te onderzoeken (Hoofdstuk 8) . Daartoe werd de opper-
vlakte-onder-de-curve (AUC) bij LD10 bepaald voor Sm en 3 veel belovende 
analoga. Een hogere lipofiliteit van Sm-derivaten veroorzaakt een hogere 
totale lichaamsklaring en meer binding aan plasma-eiwitten. Deshydroxy-Sm 
wordt tweemaal zo snel uit het plasma verwijderd dan Sm, hoewel zijn AUC bij 
LD10 lager is dan die van Sm. Ethyl-deshydroxy-Sm is het enige analogon 
welke een verhoging van de AUC bij LD10 te zien geeft t.o.v. Sm. De signifi-
cante toename van de LD10 en LD50, waargenomen voor deze stof, is waar-
schijnlijk gerelateerd aan het feit dat ethyl-deshydroxy-Sm een andere 
dosisbeperkende toxiciteit vertoont dan de gehydroxyleerde analoga. Ethyl-
deshydroxy-Sm induceert geen bloedingen bij muizen, wat wel het geval is met 
de gehydroxyleerde derivaten. 
De farmacokinetische onderzoeken zijn later uitgebreid naar beagle honden 
(Hoofdstuk 9 ) . In dit onderzoek wordt farmacokinetiek gecorreleerd aan 
toxiciteit. Naast een eenmalige dosis, werd Sm ook meerdere dagen achtereen 
toegediend. Er werden bij de langdurige toedieningsvorm aanwijzingen gevon-
den voor cumulatie van Sm in het plasma. Dit zou de toxiciteit kunnen 
verklaren die na enkele dagen optreedt. Het bleek dat alle bestudeerde 
plasma-eiwitten tijdens de behandeling met Sm, uit het plasma verdwijnen met 
een snelheid evenredig aan hun biologische halfwaarde-tijd. Hieruit kan 
worden geconcludeerd dat, indien Sm uitsluitend werkt als eiwit-synthese 
remmer, de toxiciteit moet worden toegeschreven aan het verdwijnen van 
bepaalde kritieke eiwitten. Bij beagle honden blijkt het verdwijnen van het 
fibrinogeen verantwoordelijk te zijn voor het optreden van de haemorhagische 
diathese, welke bij 2 van de 5 behandelde honden na 9 dagen Sm-behandeling 
is waargenomen. 
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Farmacokinetische onderzoeken in beagle honden zíjn ook uitgevoerd met de 
drie meest belovende analoga. Hoofdstuk 10 gaat In op de farmacokinetiek 
van deshydroxy-Sm in plasma en urine. Hoofdstuk 11 en 12 beschrijven de 
farmacokinetiek van respectivelijk ethyl-deshydroxy-Sm en n-pentyl-Sm. Alle 
drie genoemde derivaten, evenals de moederverbinding Sm, geven een verschil-
lend gedrag te zien in honden en in muizen. Muizen vertonen voor alle 
derivaten een lineaire farmacokinetiek tot aan de LD10. Honden vertonen voor 
ethyl-deshydroxy-Sm en n-pentyl-Sm een niet lineaire kinetiek. Ethyl-
deshydroxy-Sm is relatief de meest toxische stof van de bestudeerde analoga, 
terwi]! n-pentyl-Sm de hoogste met-lethale AUC geeft. Het feit dat de 
farmacokinetiek van ethyl-deshydroxy-Sm niet lineair verloopt, wordt ver-
klaard door een sterkere, actieve reabsorptie m de renale tubuli. Dit geldt 
ook voor n-pentyl-Sm, maar deze stof is veel lipofxeler, waardoor eliminatie 
via andere wegen dan de nieren veel belangrijker wordt en dus ook de actieve 
tubulaire reabsorptie relatief veel minder belangrijk is. 
In het laatste hoofdstuk (Hoofdstuk 13) wordt aandacht besteed aan de Sm-
gemduceerde oogtoxiciteit bij ratten. Er zijn geen aanwijzingen gevonden 
dat Sm in gezonde dieren de bloed-retina barriere zou kunnen passeren. Het 
risico van retinotoxicitelt zal daarom uitermate klein zijn. Is echter de 
bloed-retina barriere beschadigd (bv. door natriumiodaat, een sterk oxi-
derend toxisch middel), dan is Sm in staat de biosynthese van opsine gedeel-
telijk te remmen. De bij de Sm-geïnduceerde retinotoxiciteit optredende 
histopathologische verschijnselen konden in dit onderzoek niet worden gere-
produceerd. 
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Stellingen behorende bij het proefschrift: 
SPARSOMYCIN AND ITS ANALOGUES 
A preclinical study on novel anticancer drugs 
Z. Zylicz 
De antitumoractiviteit van sparsomycine en zijn analoga kan 
niet alleen verklaard worden door remming van de eiwitsyn-
these. Enkele structuuranaloga vertonen in vitro en in vivo 
een grotere antitumoractiviteit dan sparsomycine terwijl het 
slechte remmers van de eiwitsynthese zijn. 
(dit proefschrift) 
Bij de beoordeling van de toxiciteit van een reeks van ana-
loga, is het zinvol om bij de bepaling van de lethale dosis 
(LD10) ook de oppervlakte onder de concentratie-curve (bij de 
LD10) te betrekken. 
(dit proefschrift) 
Het is niet de loutere aanwezigheid van een polaire groep, die 
de wateroplosbaarheid van een molecuul waarborgt. 
(dit proefschrift) 
De kracht van sparsomycine-analoga ligt niet in de eigen 
antitumoractiviteit, maar in de modulatie van de activiteit 
van andere cytotoxische middelen. 
(dit proefschrift) 
De waarheid dient als een mantel te worden aangereikt, en niet 
als een natte doek die om de oren wordt geslagen. 
(M. Frisch) 
The dissatisfied dead cannot noise abroad the negligence they 
have experienced. 
(A. Hinton) 
Het gebruik van superabsorberende papieren luiers bij de ver-
zorging van zuigelingen, vertraagt de ontwikkeling van de 
fysiologische reflex "nat-vies-huilen" en het optreden van 
zindelijkheid. 
(eigen waarneming gemaakt tijdens het 
promotie-onderzoek, doch buiten de gewone 
werkuren) 
You can never judge another man until you will walk in his 
moccasins. 
(oud Indiaans gezegde) 



